
<html lang="en"     class="pb-page"  data-request-id="2826275c-1e01-4a7c-87db-dfc738ac1f71"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm1004286;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2010.53.issue-24"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection" /></meta><meta name="dc.Creator" content="Mark E.  Flanagan" /></meta><meta name="dc.Creator" content="Todd A.  Blumenkopf" /></meta><meta name="dc.Creator" content="William H.  Brissette" /></meta><meta name="dc.Creator" content="Matthew F.  Brown" /></meta><meta name="dc.Creator" content="Jeffrey M.  Casavant" /></meta><meta name="dc.Creator" content="Chang  Shang-Poa" /></meta><meta name="dc.Creator" content="Jonathan L.  Doty" /></meta><meta name="dc.Creator" content="Eileen A.  Elliott" /></meta><meta name="dc.Creator" content="Michael B.  Fisher" /></meta><meta name="dc.Creator" content="Michael  Hines" /></meta><meta name="dc.Creator" content="Craig  Kent" /></meta><meta name="dc.Creator" content="Elizabeth M.  Kudlacz" /></meta><meta name="dc.Creator" content="Brett M.  Lillie" /></meta><meta name="dc.Creator" content="Kelly S.  Magnuson" /></meta><meta name="dc.Creator" content="Sandra P.  McCurdy" /></meta><meta name="dc.Creator" content="Michael J.  Munchhof" /></meta><meta name="dc.Creator" content="Bret D.  Perry" /></meta><meta name="dc.Creator" content="Perry S.  Sawyer" /></meta><meta name="dc.Creator" content="Timothy J.  Strelevitz" /></meta><meta name="dc.Creator" content="Chakrapani  Subramanyam" /></meta><meta name="dc.Creator" content="Jianmin  Sun" /></meta><meta name="dc.Creator" content="David A.  Whipple" /></meta><meta name="dc.Creator" content="Paul S.  Changelian" /></meta><meta name="dc.Description" content="There is a critical need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis. Janus tyrosine kinases (JAK1, JAK3) are expre..." /></meta><meta name="Description" content="There is a critical need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis. Janus tyrosine kinases (JAK1, JAK3) are expre..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 24, 2010" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm1004286" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm1004286" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm1004286" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm1004286" /></link>
        
    
    

<title>Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm1004286" /></meta><meta property="og:title" content="Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0009.jpeg" /></meta><meta property="og:description" content="There is a critical need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis. Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions. Blockade of the JAK1/JAK3-STAT pathway with a small molecule was anticipated to provide therapeutic immunosuppression/immunomodulation. The Pfizer compound library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by CP-352,664 (2a). Synthetic analogues of 2a were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay. Select compounds were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis. Optimization within this chemical series led to identification of CP-690,550 1, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="There is a critical need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis. Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions. Blockade of the JAK1/JAK3-STAT pathway with a small molecule was anticipated to provide therapeutic immunosuppression/immunomodulation. The Pfizer compound library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by CP-352,664 (2a). Synthetic analogues of 2a were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay. Select compounds were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis. Optimization within this chemical series led to identification of CP-690,550 1, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0009.jpeg" /></meta><meta name="twitter:title" content="Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm1004286"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm1004286">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm1004286&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm1004286&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm1004286&amp;href=/doi/10.1021/jm1004286" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 8468-8484</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm101020z" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm100597c" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+E.++Flanagan">Mark E. Flanagan</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Todd+A.++Blumenkopf">Todd A. Blumenkopf</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+H.++Brissette">William H. Brissette</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+F.++Brown">Matthew F. Brown</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+M.++Casavant">Jeffrey M. Casavant</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chang++Shang-Poa">Chang Shang-Poa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan+L.++Doty">Jonathan L. Doty</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eileen+A.++Elliott">Eileen A. Elliott</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+B.++Fisher">Michael B. Fisher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Hines">Michael Hines</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Craig++Kent">Craig Kent</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth+M.++Kudlacz">Elizabeth M. Kudlacz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brett+M.++Lillie">Brett M. Lillie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kelly+S.++Magnuson">Kelly S. Magnuson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandra+P.++McCurdy">Sandra P. McCurdy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Munchhof">Michael J. Munchhof</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bret+D.++Perry">Bret D. Perry</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Perry+S.++Sawyer">Perry S. Sawyer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+J.++Strelevitz">Timothy J. Strelevitz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chakrapani++Subramanyam">Chakrapani Subramanyam</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianmin++Sun">Jianmin Sun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+A.++Whipple">David A. Whipple</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â³</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+S.++Changelian">Paul S. Changelian</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Pfizer Global Research & Development, 50 Pequot Avenue, New London, Connecticut 06320, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">Â§</span> <span class="aff-text">Yale University, New Haven, Connecticut 06520, United States</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">â¥</span> <span class="aff-text">Department of Statistics, University of Connecticut, 215 Glenbrook Road U-4120, Storrs, Connecticut 06269, United States</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">â¥</span> <span class="aff-text">Hill Road, East Lyme, Connecticut 06333, United States</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">#</span> <span class="aff-text">Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877, United States</span></div><div class="aff-info" id="aff7"><span class="aff-symbol">â³</span> <span class="aff-text">Del Shankel Structural Biology Center, University of Kansas, 2034 Becker Drive, Lawrence, Kansas 66047, United States</span></div><div class="aff-info" id="aff8"><span class="aff-symbol">â</span> <span class="aff-text">Lycera Corporation, 46701 North Commerce Center Drive, Plymouth, Michigan 48170, United States</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Telephone: 860-441-0205. Fax: 860-715-4693. E-mail: <a href="/cdn-cgi/l/email-protection#cca1adbea7e2a9e2aaa0ada2adabada28cbcaaa5b6a9bee2afa3a1"><span class="__cf_email__" data-cfemail="c7aaa6b5ace9a2e9a1aba6a9a6a0a6a987b7a1aebda2b5e9a4a8aa">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm1004286&amp;href=/doi/10.1021%2Fjm1004286" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 8468â8484</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 24, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 April 2010</li><li><span class="item_label"><b>Published</b> online</span>24 November 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 December 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm1004286" title="DOI URL">https://doi.org/10.1021/jm1004286</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8468%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMark%2BE.%2BFlanagan%252C%2BTodd%2BA.%2BBlumenkopf%252C%2BWilliam%2BH.%2BBrissette%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D24%26contentID%3Djm1004286%26title%3DDiscovery%2Bof%2BCP-690%252C550%253A%2BA%2BPotent%2Band%2BSelective%2BJanus%2BKinase%2B%2528JAK%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%2Band%2BOrgan%2BTransplant%2BRejection%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8484%26publicationDate%3DDecember%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm1004286"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">12171</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">211</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm1004286" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;E. Flanagan&quot;},{&quot;first_name&quot;:&quot;Todd&quot;,&quot;last_name&quot;:&quot;A. Blumenkopf&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;H. Brissette&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;F. Brown&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;M. Casavant&quot;},{&quot;first_name&quot;:&quot;Chang&quot;,&quot;last_name&quot;:&quot;Shang-Poa&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;L. Doty&quot;},{&quot;first_name&quot;:&quot;Eileen&quot;,&quot;last_name&quot;:&quot;A. Elliott&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;B. Fisher&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Hines&quot;},{&quot;first_name&quot;:&quot;Craig&quot;,&quot;last_name&quot;:&quot;Kent&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;M. Kudlacz&quot;},{&quot;first_name&quot;:&quot;Brett&quot;,&quot;last_name&quot;:&quot;M. Lillie&quot;},{&quot;first_name&quot;:&quot;Kelly&quot;,&quot;last_name&quot;:&quot;S. Magnuson&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;P. McCurdy&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Munchhof&quot;},{&quot;first_name&quot;:&quot;Bret&quot;,&quot;last_name&quot;:&quot;D. Perry&quot;},{&quot;first_name&quot;:&quot;Perry&quot;,&quot;last_name&quot;:&quot;S. Sawyer&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;J. Strelevitz&quot;},{&quot;first_name&quot;:&quot;Chakrapani&quot;,&quot;last_name&quot;:&quot;Subramanyam&quot;},{&quot;first_name&quot;:&quot;Jianmin&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;A. Whipple&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;S. Changelian&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;8468-8484&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm1004286&quot;},&quot;abstract&quot;:&quot;There is a critical need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis. Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions. Blockade of the JAK1/JAK3-STAT pathway with a small molecule was anticipated to provide therapeutic immunosuppression/immunomodulation. The Pfizer compound library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by CP-352,664 (2a). Synthetic analogues of 2a were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay. Select compounds were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis. Optimization within this chemical series led to identification of CP-690,550 1, a potential first-in-class JAK inhibitor for tre&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm1004286&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm1004286" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm1004286&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm1004286" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm1004286&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm1004286" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm1004286&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm1004286&amp;href=/doi/10.1021/jm1004286" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm1004286" /></input><a href="/doi/pdf/10.1021/jm1004286" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26pmid%3D21105711%26genre%3Darticle%26aulast%3DFlanagan%26date%3D2010%26atitle%3DDiscovery%2Bof%2BCP-690%252C550%253A%2BA%2BPotent%2Band%2BSelective%2BJanus%2BKinase%2B%2528JAK%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%2Band%2BOrgan%2BTransplant%2BRejection%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D24%26spage%3D8468%26epage%3D8484%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/24" title="Go to Volume 53, Issue 24"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jmcmar.2010.53.issue-24/production/jmcmar.2010.53.issue-24.largecover.jpg" alt="Go to Volume 53, Issue 24"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">There is a critical need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis. Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions. Blockade of the JAK1/JAK3-STAT pathway with a small molecule was anticipated to provide therapeutic immunosuppression/immunomodulation. The Pfizer compound library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by CP-352,664 (<b>2a</b>). Synthetic analogues of <b>2a</b> were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay. Select compounds were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis. Optimization within this chemical series led to identification of CP-690,550 <b>1</b>, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14046" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14046" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Modulation of immune function has been a successful strategy for treating transplant rejection and autoimmune diseases.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, current therapies also possess significant side effects resulting from the ubiquitous expression of their targets of action.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Consequently, researchers continue to search for new biological targets, such as cytokine signaling pathways (one such pathway is shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) that may offer more selective immunosuppressive therapies to treat these conditions.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Overview of cytokine signaling through the JAK/STAT pathway. Reprinted by permission from Macmillan Publishers Ltd.: <i>Nat. Rev. Immunol</i>. <b>2003</b>, <i>3</i>, 900â911, copyright 2003.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The Janus tyrosine kinases (JAKs)<a class="ref internalNav" href="#fn1" aria-label="a">a</a> have generated great interest in recent years as therapeutic targets due to the unique role that these enzymes play as gatekeepers in the signal transduction process.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3-5)</a> Named after the Roman god of gates and doors (âJanusâ), these four enzymes (JAK1, JAK2, JAK3, and Tyk2) control signaling of numerous cytokines and therefore play a central role in acquired and innate immunity and hematopoiesis.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> JAK3 expression is limited to lymphoid cells where it associates with the common Î³ chain (Î³<sub>c</sub>) of the IL-2 family of receptors (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> JAK1 is broadly expressed, including expression in lymphoid cells as well as the nervous system, where it associates with Î²-chains of the IL-2 family of receptors, as well as numerous other cytokine receptors. Upon cytokine binding, receptor assembly brings JAK1 and JAK3 in close proximity such that they undergo autophosphorylation and phosphorylation of the Î²-chain C-terminus. Ultimately, this leads to the activation of signal transducers and activators of transcription (STAT) proteins, a critical step in the relay of messages to the nucleus.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Through this process JAK1 and JAK3 control the signaling pathways of multiple cytokines (IL-2, -4, -7, -9, -15, and -21) important for various T cell functions including development, activation, and homeostasis.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The criticality of these cytokines and the subsequent transduction of their signals for proper T cell function are evident from mutations of JAK3 or Î³<sub>c</sub>, both of which disrupt cytokine signaling and lead to a virtually identical immunodeficient phenotype [severe combined immunodeficiency (SCID)].<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> Up to two-thirds of all hereditary cases of SCID are believed to occur as a result of mutations in one of these two proteins;<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> up to 14% of all hereditary cases of SCID are estimated to be due to JAK3 mutations.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a><div class="NLM_fn" id="fn1">a<p class="last">Abbreviations: Î³<sub>c</sub>, Î³ common chain; ACR, American College of Rheumatology; ADME, absorption, distribution, metabolism, and excretion; 9-BBN, 9-borabicyclo(3.3.1)nonane; BBO, broad band observe; BID, twice daily; CL<sub>R</sub>, renal clearance; COSY, correlation spectroscopy; CYP, cytochrome P<sub>450</sub>; DMF, dimethylformamide; DMSO, dimethyl sulfoxide; Fu, fraction unbound; GM-CSF, granulocyte macrophage-colony stimulating factor; GST, glutathione <i>S</i>-transferase; HSA, high-speed analoging; HFF, human foreskin fibroblast; HHT, heterotopic cardiac transplant; HLM, human liver microsome; HMBC, heteronuclear multiple bond coherence; HPLC, high-performance liquid chromatography; HRMS, high-resolution mass spectrometry; HU03, human erythroleukemia cells; iv, intravenous; JAKs, Janus tyrosine kinases; LC/MS/MS, liquid chromatography/tandem mass spectrometry; LRMS, low-resolution mass spectrometry; MMF, mycophenolate mofetil; NADPH, nicotinamide adenine dinucleotide phosphate; NOESY, nuclear Overhauser enhancement spectroscopy; po, orally; RA, rheumatoid arthritis; SAR, structureâactivity relationships; SCID, severe combined immunodeficiency; SCX, strong cation exchange; STAT, signal transducers and activators of transcription; THF, tetrahydrofuran; Vd, volume of distribution.</p></div></div><div class="NLM_p">We recognized the potential utility for blockade of this pathway in order to achieve therapeutically desirable immunosuppression/immunomodulation and initiated a program to identify a selective small molecule inhibitor of JAK3. This led to the identification of the development compound CP-690,550 1 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), which has demonstrated efficacy in preclinical and clinical studies of autoimmune diseases, including rheumatoid arthritis (RA) and chronic plaque psoriasis, and renal allograft rejection.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17">(14-17)</a> We describe herein the medicinal chemistry strategy that led to the discovery of this chemical entity.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of <b>1</b> and HTS lead <b>2a</b> (CP-352,664).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our initial efforts were focused on JAK3 as a target for immunosuppression because its expression is limited to lymphoid cells. To identify lead matter, the Pfizer compound library (â¼400000 compounds, ca. 1996) was screened against the JAK3 catalytic domain as a recombinant glutathione <i>S</i>-transferase (GST) fusion protein, resulting in the identification of a pyrrolo[2,3-<i>d</i>]pyrimidine-containing lead series represented by <b>2a</b> (CP-352,664) (210 nM vs JAK3 kinase). Follow-on analogues of <b>2a</b> were initially screened against the JAK1, JAK2, and JAK3 enzymes. Inhibition of JAK2 was assessed early in the screening cascade because of its essential role in hematopoiesis, including <i>epo</i> receptor signaling and red blood cell homeostasis,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> which it was believed could lead to untoward effects such as anemia. Compounds were also evaluated in an IL-2 induced T cell blast proliferation assay, which provides a functional measure of the ability of compounds to inhibit JAK1 and/or JAK3 activities. Additionally, since the lead compound (<b>2a</b>) had a short human liver microsome (HLM) half-life (14 min), new analogues were routinely screened for metabolic stability using human liver microsomes for half-life determination.</div><div class="NLM_p">Cellular specificity assays were also employed for compounds of interest. A human foreskin fibroblast (HFF) assay was used to determine nonspecific inhibition of cellular proliferation outside of the hematopoietic compartment, and a granulocyte macrophage-colony stimulating factor (GM-CSF) induced JAK2 cellular proliferation assay (HU03 cell line) was used to evaluate compounds for JAK2 functional activity. Consequently, a ratio of HU03/IL2-blast activity for a given analogue provided a measure of JAK2 activity relative to JAK1/3. Finally, the most significant <i>in vivo</i> hurdle for an experimental immunosuppressive drug was to prolong survival of a transplanted allogeneic organ in a preclinical species. Therefore, select compounds were evaluated in a murine vascularized heterotopic cardiac transplant (HTT) model<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and a neovascularized transplant model.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p last">At the outset of the program the goal was to identify a prototype molecule that had a potency of â¤10 nM against the JAK3 kinase and â¤100 nM in the IL-2 blast cellular assay, greater than 100-fold selectivity as measured by a comparison of enzyme or cellular data for JAK3 relative to JAK2, HLM half-life nominally of â¥60 min, and improved overall physicochemical characteristics relative to <b>2a</b>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57121" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57121" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Improved Cellular Potency and the Likely Role of JAK1</h3><div class="NLM_p">Early structureâactivity relationships (SAR) revealed that compounds possessing cyclic, lipophilic, amino headgroups provided the best JAK3 enzyme potency (e.g., <b>2a</b>â<b>i</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Consequently, efforts were focused on optimization of this group from the pyrrolopyrimidine heterocycle in order to achieve the program objectives.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Headgroup Structure and JAK Enzyme Potencies of Compounds <b>2a</b>â<b>2i</b><a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div><p class="last"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0001.gif" alt="" id="fx1" /></img></p></div></div><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0002.gif" alt="" id="fx2" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">Cell potencies were determined using an IL-2 induced T cell blast proliferation assay. Metabolic stabilities of <b>2a</b>â<b>2i</b> were determined by incubations with human liver microsomes (HLMs) and reported by half-life.</p></div></div></div><div class="NLM_p">It was anticipated that inhibition of JAK1 could play a role in cellular potency either additively or synergistically with JAK3, due to the manner by which these enzymes operate together at the IL-2 receptor. The first indication of this came from an empirical observation relating amino headgroup structure to IL-2 blast (cell) potency. As illustrated in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, it was observed that compounds possessing an <i>N</i>-methyl-cycloalkyl headgroup motif exhibited an improvement in cell potency. This was unexpected based solely on consideration of JAK3 potency, which remained approximately the same as compared with earlier compounds (e.g., <b>2a</b>â<b>c</b>). However, the <i>N</i>-methyl-cycloalkyl analogues demonstrated greater potency against JAK1 (e.g., <b>2e</b>â<b>i</b>), suggesting that the combination of JAK1 and JAK3 (or JAK1 alone) may be key to realizing the improved cellular potencies observed. The physical property (clogP) distribution across these compounds (<b>2</b>) and the fact that none were crystalline when initially tested make other explanations for these cellular potency differences, such as solubility or plasma protein binding, less likely. The role of JAK1 is further supported by the fact that <b>1</b> in a solution phase kinase assay was more potent against JAK1 than measured in the ELISA assay (IC<sub>50</sub> = 3.2, 4.1, and 1.6 for JAK1, JAK2, and JAK3, respectively).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> This latter point will be explored in more detail in the <a class="ref internalNav" href="#sec3" aria-label="Discussion and Conclusions">Discussion and Conclusions</a>.</div><div class="NLM_p">While the <i>N</i>-methyl-cycloalkyl analogues (<b>2e</b>â<b>i</b>) demonstrated improved whole-cell activity compared with the lead (<b>2a</b>), the JAK2/JAK3 selectivity did not improve. Furthermore, these analogues showed no improvement in metabolic stability as indicated by their HLM half-lives. Therefore, many issues remained, but further investigation was warranted based on the association of this SAR with improved cellular potency. We expanded on this SAR through the use of high-speed analoging (HSA) as illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Expansion of structureâactivity relationships using high-speed analoging around the <i>N</i>-methyl-cycloalkyl headgroup motif leading to compounds <b>6a</b>â<b>h</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Reductive aminations with methylamine were conducted with cyclic ketones containing various functionalities. The resulting cyclic amines (<b>4</b>) were then coupled to the 4-chloropyrrolopyrimidine (<b>5</b>), purified, and tested. In all, approximately 100 compounds (<b>6</b>) were targeted in this manner. Polar features were included in this array in an effort to improve metabolic stability and physical properties. Unfortunately, the randomized placement of these polar groups in this experiment resulted only in compounds exhibiting reduced kinase activity (see also <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> Table 1). Although a breakthrough in combining metabolic stability with improved cellular potency was not realized, other important SAR features were revealed from this HSA study. Compounds <b>6a</b>â<b>c</b> indicated a potency advantage for methyl substitutions at the C2â² and/or C5â² positions of a cyclohexane ring; the most potent compound identified was <b>6c</b>, which exhibited a 2â²,5â²-dimethyl substitution pattern on the cyclohexyl ring. At 20 nM potency against JAK3, even as a mixture of at least three isomers (prepared from the racemic ketone), this material represented an 8-fold improvement in JAK3 inhibition compared with <b>2f</b> (unsubstituted cyclohexyl). Although the cellular potency for these did not reflect this 8-fold difference, JAK1 enzyme data were not determined for these HSA compounds, which may have helped to explain this discrepancy. As shown for the other compounds in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, a small substituent at C2â² (methyl or ethyl) provided the most significant potency boost. Although a small substituent at this position was clearly advantageous, larger groups were not well tolerated (e.g., <b>6e</b>â<b>h</b>). While SAR at the C2â² position appeared to be restricted to smaller groups, HSA follow-up compounds derived from the natural product carvone (described in the next section) indicated that the C5â² position would accommodate larger groups (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. HSA Follow-Up Compounds Derived from Carvone Analogue <b>12</b></div><p class="last"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0003.gif" alt="" id="fx3" /></img></p></div></div><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0004.gif" alt="" id="fx4" /></img></td></tr></tbody></table></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Optimizing Interactions through the Use of Natural Products</h3><div class="NLM_p">One follow-up strategy employed to capitalize on learnings from the HSA work and potentially to simplify the stereochemical issues associated with the <b>6c</b> mixture was to take advantage of natural products that offered access to similarly substituted ring systems as exhibited by <b>6c</b>. One such natural product was carvone (<b>7</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Carvone is a member of the terpenoid family, and in addition to possessing the desired substitution around the cyclohexane ring, it also offered the advantage of being commercially available in both the <i>R</i>-(â) and <i>S</i>-(+) stereochemical configurations.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Therefore, as illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, reduction of the carvone double bond with L-selectride, followed by reductive amination with methylamine, generated a mixture of the amine isomers <b>9</b>. Reacting mixture <b>9</b> with <b>5</b> resulted in new mixtures that were approximately 1:1 consisting of the all-<i>cis</i> and all-equatorial products. Remarkably, the mixture derived from <i>S</i>-(+)-carvone (<b>11</b>) was approximately 300 times more potent against JAK3 kinase than the corresponding mixture derived from <i>R</i>-(â)-carvone (<b>10</b>). Separation and analysis of the components of <b>11</b> revealed that the all-<i>cis</i> compound <b>12</b> was the most potent isomer (JAK3 IC<sub>50</sub> = 2 nM; IL-2 blast IC<sub>50</sub> = 50 nM), therefore establishing the optimal relative and absolute stereochemistry around the cyclohexane ring to be the all-<i>cis</i> configuration derived from <i>S</i>-(+)-carvone. Importantly, <b>12</b> represented a milestone for the program, as it was the first analogue tested that possessed both JAK3 kinase and cellular potencies consistent with program objectives. With greater hydrophobicity (a higher clogP) than <b>6c</b>, it was not surprising that microsomal stability for <b>12</b> was poor (HLM <i>t</i><sub>1/2</sub> = 14 min). Furthermore, aqueous solubility (1.3 Î¼g/mL) and rat bioavailability (% <i>F</i> â¼ 7) were less than desirable.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0013.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Generation of carvone-derived analogues resulting in the identification of milestone compound <b>12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Attempts to address these issues from this carvone scaffold resulted in some potent analogues (e.g., Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>); however, it was ultimately determined that the lipophilicity of the core cyclohexane ring of this series made it difficult to address pharmacokinetic issues while maintaining other desirable attributes. Furthermore, many of the synthetic manipulations from the isopropenyl group of <b>12</b> resulted in a new stereocenter, which complicated analogue generation and scale-up. Consequently, our strategy shifted toward identifying more polar headgroups capable of providing analogues in more drug-like space (clogP â¤ 3).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Improved Properties: The âPiperidine Seriesâ and <b>1</b></h3><div class="NLM_p">To address issues with the carvone analogues, we moved to a piperidine headgroup scaffold as illustrated in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. The advantages of adding a heteroatom into the cyclohexane ring were several. First, this change lowered the clogP of the target compounds compared with similar carvone-derived analogues (generally greater than one logP unit). Second, incorporating a nucleophilic nitrogen at this position in the ring (at what would be the C5â² position of a cyclohexyl) greatly facilitated analogue generation by allowing attachment of groups through a variety of linkages. Finally, by preparing compounds in this manner, it was possible to avoid the introduction of the additional stereocenters generated through modification of the carvone isopropenyl group. Although the piperidine had two stereocenters that required being appropriately defined and set, this was eventually accomplished very efficiently by classical resolution (patent WO 096909, 2002).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Moving from the Carvone Analogues to a Piperidine-Containing Headgroup Scaffold<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div><p class="last"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0005.gif" alt="" id="fx5" /></img></p></div></div><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0006.gif" alt="" id="fx6" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">The main subseries investigated were sulfonamides, ureas, amines, and amides (representative examples).</p></div></div></div><div class="NLM_p">Given the tight SAR observed for the carvone-derived analogues, the fundamental question at the outset of the piperidine approach was whether it would be possible to introduce a heteroatom into this ring and still maintain desirable enzyme and cellular potency. To address this question, a variety of groups were appended to the piperidine. The main subseries investigated were sulfonamides, ureas, amines (reductive amination products), and amides (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Although the SAR varied across these subseries, the important general finding was that good JAK3 enzyme potency was achievable from this scaffold. Sulfonamides provided good JAK3 inhibition and encouraging selectivity relative to JAK2, but cell potency was found to be very difficult to achieve. Several urea analogues exhibited very good potency (both enzyme and cell); however, finding the right balance of other properties proved difficult. Several analogues with alkyl group substitutions on the piperidine nitrogen provided excellent enzyme potency but required electron-withdrawing groups (benzylic) in order to reduce the p<i>K</i><sub>a</sub> of the piperidine nitrogen (ionization in the headgroup typically resulted in significant loss of activity). These lipophilic amines generally exhibited high plasma protein binding and significant HLM metabolism.</div><div class="NLM_p">The amide subseries was ultimately successful (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). One early trend observed with these amide-containing compounds was that smaller substituents generally conferred better enzyme potency; furthermore, the cell potency tracked with an amalgamation of JAK3 and JAK1 enzymatic inhibitions. Importantly, these compounds also followed a trend for lower clogPs (â¤2) translating to improved metabolic stability. As a consequence, the cyanoacetamide compound <b>18m</b> was prepared, as it was anticipated that the small, polar nature of this side chain would intersect both of these SAR patterns and impart improved potency and metabolic stability. This is precisely what was observed, and with <b>18m</b>, for the first time, all <i>in vitro</i> program objectives had been met, with the exception of selectivity for JAK3 over JAK2, which was still measured to be only 20-fold.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. StructureâActivity Relationships for the Amide Subseries of Piperidine-Containing Compounds</div><p class="last"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0007.gif" alt="" id="fx7" /></img></p></div></div><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0008.gif" alt="" id="fx8" /></img></td></tr></tbody></table></div></div><div class="NLM_p">Separation of the enantiomers of <b>18m</b> was not successful by chiral high-performance liquid chromatography (HPLC); however, the benzyl-protected precursor of this material (<b>19</b>) was separable by this method (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). The two purified components <b>19a</b> and <b>19b</b> were therefore carried forward separately producing <b>1</b> and its enantiomer <b>1a</b>. Evaluation of these two compounds revealed that <b>1</b> had an IC<sub>50</sub> of 1 nM against JAK3, which was approximately 40 times more potent than <b>1a</b>. Eventually all four stereoisomers of <b>18m</b> were prepared and studied in our laboratories and other laboratories.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> With compound <b>1</b> being the most potent isomer it was anticipated that its absolute stereochemical configuration would reflect that of the most potent carvone-derived analogue <b>12</b>. Final stereochemical confirmation for <b>1</b> came from the evaluation of a related urea analogue <b>20</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Compound <b>20</b> was crystalline as the free base, and since the stereochemical configuration of the pyrrolidinol moiety was known (derived from (<i>S</i>)-3-hydroxypyrrolidine), the corresponding single crystal X-ray structure of <b>20</b> provided unambiguous assignment of the 3<i>R</i>,4<i>R</i> stereochemical configuration for <b>1</b>. Corroboration of this stereochemical assignment has come from published cocrystal structures of <b>1</b> with JAK family members.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0014.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Preparation of both enantiomers of <b>1</b> from intermediates <b>19a</b> and <b>19b</b>, separated by chiral HPLC. Single crystal X-ray structure of urea analogue <b>20</b>, prepared from <b>19a</b>, provided unambiguous confirmation of the 3<i>R</i>,4<i>R</i> stereochemical configuration for <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In order to proceed to development studies, a suitable solid form of <b>1</b> needed to be identified. To do this, the free base of <b>1</b> was screened against a panel of acids, resulting in the identification of the crystalline citrate salt. This material (citrate salt) was ultimately selected for development based on its desirable characteristics of good solubility (>4 mg/mL in water), high melting point onset (>200 Â°C), lack of hygroscopicity, and high degree of crystallinity (patent WO 048162, 2003).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Preclinical Pharmacokinetics</h3><div class="NLM_p"><b>1</b> is being developed as the crystalline citrate salt. In rats and dogs, intravenous (iv) dosing of <b>1</b> resulted in moderate to high plasma clearances, which were predicted from microsome incubations (<i>t</i><sub>1/2</sub> = 68 and 30, respectively). In monkeys, plasma clearances were low to moderate, consistent with the half-life observed in monkey liver microsomal incubations (>100 min). Low to moderate volumes of distribution were also observed, resulting in half-lives of 0.6â2.1 h (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Oral dosing of the crystalline citrate salt resulted in oral bioavailabilities that were consistent with the expected magnitude in first-pass hepatic metabolism, estimated from the iv clearances. Plasma protein binding for <b>1</b> was very similar in rats, dogs, monkeys, and humans [human fraction unbound (Fu) = 24%]. Preliminary <i>in vitro</i> studies predicted minimal risk with respect to unwanted drugâdrug interactions for multiple cytochrome P<sub>450</sub> (CYP) isoforms (IC<sub>50</sub><i>s</i> > 52 Î¼M for CYPs 1A2, 2C19, 2D6, and 3A4). Studies performed in Caco-2 cell monolayers predicted that <b>1</b> (at 10 Î¼Î) should not be a substrate for efflux transporters and should be absorbed transcellularly by passive diffusion with a predicted human absorption of >70%.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Preclinical Pharmacokinetic (PK) Summary for <b>1</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left">Â </th><th class="colsep0 rowsep0" colspan="5" align="center" char=".">iv PK summary</th><th class="colsep0 rowsep0" colspan="3" align="center" char=".">po PK summary</th></tr><tr valign="bottom" class="colsep0"><th class="colsep0 rowsep0" align="center" valign="bottom">species</th><th class="colsep0 rowsep0" align="center" valign="bottom" char=".">CL (mL min<sup>â1</sup> kg<sup>â1</sup>)</th><th class="colsep0 rowsep0" align="center" valign="bottom" char=".">CL<sub>R</sub> (mL min<sup>â1</sup> kg<sup>â1</sup>)</th><th class="colsep0 rowsep0" align="center" valign="bottom" char=".">Vdss (L/kg)</th><th class="colsep0 rowsep0" align="center" valign="bottom" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" valign="bottom" char=".">Fu (%)</th><th class="colsep0 rowsep0" align="center" valign="bottom" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" valign="bottom" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" valign="bottom" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">442</td><td class="colsep0 rowsep0" align="char" char=".">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">1020</td><td class="colsep0 rowsep0" align="char" char=".">78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">790</td><td class="colsep0 rowsep0" align="char" char=".">48</td></tr></tbody></table></div></div><div class="NLM_p last">In contrast to the moderate to high clearances observed in preclinical species, human hepatic metabolism of <b>1</b> was predicted to be low based on studies conducted in human liver microsomes and hepatocytes (<i>t</i><sub>1/2</sub> > 120 min). Consequently, the low clearance of the citrate salt in humans was predicted to occur via a combination of renal excretion of unchanged drug and low hepatic metabolic clearance. Allometric scaling of the renal clearance (CL<sub>R</sub>) in animals (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>) yielded a predicted human CL<sub>R</sub> of 1.2 mL min<sup>â1</sup> kg<sup>â1</sup>, which was then incorporated with an estimate of low metabolic clearance (â¤2.5 mL min<sup>â1</sup> kg<sup>â1</sup>). Volume of distribution predictions yielded an average Vdss in human of 1.9 L/kg. Based on the Vdss and CL predictions, the predicted terminal elimination half-life in human was â¼7 h. Therefore, although <b>1</b> was metabolized in preclinical species, the low metabolic turnover observed with human liver microsomes and hepatocytes provided confidence that clearance would occur predominantly via a combination of renal excretion of unchanged drug and low hepatic metabolic clearance, and pharmacokinetics sufficient to support qd or bid dosing of <b>1</b> would be observed in humans. This prediction has largely held true in the clinic (oral <i>t</i><sub>1/2</sub> = 2â5 h) with the exception that some hepatic metabolism of <b>1</b> was in fact observed via CYPs 3A4/5 and 2C19.<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26-28)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60574" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60574" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Following its identification as a lead molecule, the <i>in vitro</i> pharmacology of <b>1</b> has been studied extensively. The results of these studies show <b>1</b> to be a potent inhibitor of the JAK kinase family, with a high degree of selectivity within the human kinome.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Structural and thermodynamic characterization of <b>1</b> complexed with JAK family members provides insights into this high degree of kinome selectivity.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">Previous reports of kinase activity describe <b>1</b> as being 20-fold selective relative to JAK2 and 112-fold selective relative to JAK1.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> More recently, in solution-phase caliper assays <b>1</b> exhibited low nanomolar âPANâ inhibitory potency against JAK1, JAK2, and JAK3 and to a lesser extent Tyk2 (IC<sub>50</sub> = 3.2, 4.1, 1.6, and 34.0 for JAK1, JAK2, JAK3, and Tyk2, respectively).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p">In cellular assays <b>1</b> exhibited 11 nM potency in the IL-2 blast proliferation assay (JAK1 and JAK3), 324 nM potency in the HU03 cellular specificity assay (JAK2), and >10000 nM activity in the HFF assay (nonspecific effects on cellular proliferation).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> While the JAK kinase activities for <b>1</b> changed with assay conditions, the cellular potencies measured are consistent with recent results of a human whole blood assay indicating that Î³<sub>c</sub> cytokine-dependent activation (driven by JAK1 and JAK3) was potently inhibited by <b>1</b>, exhibiting functional selectivity over GM-CSF-dependent (JAK2-driven) activation of the pathway.<a onclick="showRef(event, 'ref19 ref30'); return false;" href="javascript:void(0);" class="ref ref19 ref30">(19, 30)</a></div><div class="NLM_p">These data confirm that the desired 100-fold selectivity for JAK3 relative to the other JAKs was ultimately not accomplished with <b>1</b>; however, inhibition of JAK1 and JAK2 may actually enhance the efficacy of <b>1</b> for certain indications, such as RA, by impeding the signaling of proinflammatory cytokines, such as IL-6 (IL-6 signals through JAK1/JAK2). It is therefore possible that a near-optimal balance of JAK kinase inhibitions may have fortuitously been achieved with <b>1</b>, benefiting efficacy across multiple therapeutic indications while maintaining clinically manageable functional selectivity for JAK2.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Clinical Development</h3><div class="NLM_p"><b>1</b> is currently in clinical development for RA (phase III), prevention of acute (renal) allograft rejection (phase II), psoriasis (oral and topical; phase II), Crohnâs disease (phase II), ulcerative colitis (phase II), and dry eye disease (topical; phase I/II).</div><div class="NLM_p">In preclinical studies of inhibition of allograft rejection <b>1</b>, dosed as monotherapy or in combination with mycophenolate mofetil (MMF), demonstrated efficacy in rodents and in nonhuman primates; prolonged survival was observed in a dose-responsive fashion.<a onclick="showRef(event, 'ref14 ref31'); return false;" href="javascript:void(0);" class="ref ref14 ref31">(14, 31)</a> Prevention of allograft rejection has also been demonstrated in a rat model of aorta transplantation<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and in various other murine models.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Following the encouraging findings in preclinical transplant models, <b>1</b> was evaluated in renal allograft recipients. The tolerability profile of <b>1</b> coadministered with MMF was evaluated in a phase I dose-escalation study.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In a pilot, phase IIa multicenter study, <b>1</b> dosed at 15 and 30 mg bid was compared with tacrolimus in 61 patients receiving <i>de novo</i> kidney transplants.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In the latter study, immune suppression in the <b>1</b> treatment groups was supported by prevention of rejection and by evidence of infection. The effects of JAK2 may have manifested in the <b>1</b> groups as a trend toward more frequent anemia and neutropenia. This study suggests that relatively low rates of acute rejection are achievable with <b>1</b>-based regimens and that JAK inhibition provides a novel, potentially viable means to prevent allogeneic response in allograft recipients.</div><div class="NLM_p"><b>1</b> has also demonstrated efficacy in therapeutic models of destructive, inflammatory arthritis in rodents.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Encouraged by these data, <b>1</b> entered development as a disease-modifying antirheumatic drug (DMARD) for the treatment of RA. A 6-week proof-of-concept study in 264 adult patients with active RA, who had an inadequate response to methotrexate, etanercept, infliximab, or adalimumab, compared <b>1</b> (5, 15, and 30 mg bid) with placebo. All three doses resulted in significant improvement versus placebo (<i>p</i> < 0.0001) in the primary end point, American College of Rheumatology (ACR)20.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In this study, the most common adverse events reported were headache and nausea. The risk of infection over 6 weeks appeared to be slightly higher for <b>1</b> 15 and 30 mg bid than placebo or <b>1</b> 5 mg bid. Dose-dependent decreases in absolute neutrophil count and a dose response in mean change (decrease) from baseline in hemoglobin were observed. Small increases (0.004â0.06 mg/dL mean) in mean serum creatinine compared with baseline and with placebo and dose-dependent increases in total, high-density lipoproteinâ and low-density lipoproteinâcholesterol were observed in all <b>1</b> dose groups.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p">This study was followed by two large phase IIb placebo-controlled, dose-ranging studies, one in 509 RA patients with an inadequate response to stable background methotrexate (study A3921025; NCT00413660<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a>) and one in 384 patients with an inadequate response to prior DMARDs, who had discontinued all traditional and biologic DMARDs other than antimalarials (study A3921035; NCT00550446<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a>). Study A3921035 also included adalimumab dosed 40 mg subcutaneously every other week for six injections, followed by <b>1</b> 5 mg bid for another 12 weeks.</div><div class="NLM_p">In the analysis of the primary end points in studies A3921025 and A3921035, <b>1</b> [3â15 mg bid; 20 mg qd (A3921025 only)] was significantly effective for the primary end point, ACR20 response at 12 weeks compared with placebo. Adverse events in both studies were similar to those observed in other phase II studies; in addition, a slight increase in the rate of alanine aminotransferase increases >3 times the upper limit of normal was observed in patients dosed with <b>1</b> 15 mg bid in study A3921025.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">Phase III studies of <b>1</b> (5 and 10 mg bid) for the treatment of RA, a phase II study (2, 5, and 15 mg bid) for psoriasis, and a phase I/II study (topical solution) are currently ongoing.</div><div class="NLM_p">In conclusion, the JAK1/3-STAT signaling pathway has proven to be a highly potent and productive target for selective immunosuppression/immunomodulation. The utility of exploiting this mechanism is evident from the preclinical and clinical efficacy observed with <b>1</b>. JAK3 was the original target due to its expression being limited to lymphoid cells and the immunosuppressed phenotype of patients possessing mutations in this protein. While the targeted 100-fold selectivity for JAK3 relative to JAK2 was ultimately not achieved, <b>1</b> is highly selective for the JAK family of kinases. Furthermore, in cellular assays, <b>1</b> has demonstrated functional selectivity for JAK1/3 versus JAK2, which importantly has proven to be manageable clinically in terms of unwanted JAK2 effects, such as anemia, aided by the favorable pharmacokinetics of this compound.</div><div class="NLM_p last">To find this chemical entity, a standard high-throughput screening protocol was initiated, which resulted in the identification of <b>2a</b>. With this lead, a strategy was pursued in which the basic medicinal chemistry principles of low molecular weight and logP were observed, eventually leading to a highly soluble, highly ligand and lipid efficient inhibitor in <b>1</b>. From the outset of the program the issues of potency (both enzyme and cell), metabolic stability, and selectivity were engaged simultaneously. High-speed analoging was performed to screen chemical space quickly, resulting in new substitution patterns associated with potency improvements. Natural products were also used as chemical building blocks to understand target binding better and to optimize interactions. Finally, a scaffold shift to a piperidine-containing headgroup resulted in an improvement in drug-like properties. Ultimately, however, it was the introduction of the cyanoacetamide side chain that brought the optimal balance of potency, chemical properties, and pharmacokinetic attributes that has positioned <b>1</b> to become a novel, first-in-chemotype, and potential first-in-class JAK inhibitor for the treatment of autoimmune diseases and organ transplant rejection.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43541" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43541" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Enzyme Assays</h3><div class="NLM_p last">The JAK1, JAK2, and JAK3 kinase assays utilize a protein expressed in baculovirus-infected SF9 cells (a fusion protein of GST and the catalytic domain of human JAK enzyme) purified by affinity chromatography on glutathioneâSepharose. The substrate for the reaction was polyglutamic acid-tyrosine [PGT (4:1), Sigma catalog no. P0275], coated onto Nunc Maxi Sorp plates at 100 Î¼g/mL overnight at 37 Â°C. The plates were washed three times, and JAK enzyme was added to the wells, which contained 100 Î¼L of kinase buffer (50 mM HEPES, pH 7.3, 125 mM NaCl, 24 mM MgCl<sub>2</sub>) + ATP + 1 mM sodium orthovanadate). After incubation at room temperature for 30 min, the plates were washed three times. The level of phosphorylated tyrosine in a given well was determined by standard ELISA assay utilizing an anti-phosphotyrosine antibody.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Cell Assays</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Inhibition of Human IL-2 Dependent T Cell Blast Proliferation (IL-2 Blast Assay)</h4><div class="NLM_p">This screen measures the inhibitory effect of compounds on IL-2 dependent T cell blast proliferation <i>in vitro</i>. Since signaling through the IL-2 receptor requires JAK3, cell active inhibitors of JAK3 should inhibit IL-2 dependent T cell blast proliferation. The cells for this assay are isolated from fresh human blood. After separation of the mononuclear cells using Accuspin System-Histopaque-1077 (Sigma catalog no. A7054), primary human T cells are isolated by negative selection using Lympho-Kwik T (One Lambda, Inc., catalog no. LK-50T). T cells are cultured at (1â2) Ã 10<sup>6</sup>/mL in media [RPMI + 10% heat-inactivated fetal calf serum (Hyclone catalog no. A-1111-L) + 1% penicillin/streptomycin (P/S; Gibco)] and induced to proliferate by the addition of 10 Î¼g/mL PHA (Murex Diagnostics, catalog no. HA 16). After 3 days at 37 Â°C in 5% CO<sub>2</sub>, cells are washed three times in media and resuspended to a density of (1â2) Ã 10<sup>6</sup> cells/mL in media plus 100 units/mL human recombinant IL-2 (R&D Systems, catalog no. 202-IL). After 1 week the cells are IL-2 dependent and can be maintained for up to 3 weeks by feeding twice weekly with equal volumes of media plus 100 units/mL IL-2.</div><div class="NLM_p last">To assay for a test compoundâs ability to inhibit IL-2 dependent T cell proliferation, IL-2 dependent cells are washed three times, resuspended in media, and then plated (50000 cells per well/0.1 mL) in a flat-bottom 96-well microtiter plate (Falcon catalog no. 353075). From a 10 mM stock of test compound in dimethyl sulfoxide (DMSO), serial 2-fold dilutions of compound are added in triplicate wells starting at 10 Î¼M. One row serves as 100% proliferation control and is incubated with DMSO alone. After 1 h, 10 units/mL IL-2 is added to each test well, and plates are then incubated at 37 Â°C and 5% CO<sub>2</sub> for 72 h. Plates are then pulsed with [<sup>3</sup>H]thymidine (0.5 Î¼Ci/well; NEN catalog no. NET-027A) and incubated for an additional 18 h. Culture plates are harvested with a 96-well plate harvester, and the amount of [<sup>3</sup>H]thymidine incorporated into proliferating cells is determined by counting on a Packard Top Count scintillation counter. Data are analyzed by plotting the percent inhibition of proliferation versus the concentration of test compound. An IC<sub>50</sub> value (micromolar) is determined from this plot.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Inhibition of Human Erythroleukemia Cells (HU03 Assay)</h4><div class="NLM_p last">This screen is designed to assess the ability of compounds to inhibit GM-CSF-driven proliferation of the human erythroleukemia cell line HU03. GM-CSF receptor is dependent upon the protein tyrosine kinase JAK2 for signaling. This screen assesses the cellular activity of compounds that inhibit this kinase. HU03 are maintained [RPMI + 10% FCS + P/S + 25 ng/mL GM-CSF (Sargramostim Leukine, 250 Î¼g; Immunex Corp.)] at 3.5 Ã 10<sup>5</sup>â1.0 Ã 10<sup>6</sup>cells/mL. The cells are fed three times per week depending upon the cell count. To assay for a test compoundâs ability to inhibit GM-CSF-dependent HU03 cell proliferation, cells are washed three times, resuspended in media, and then plated (2500 cells per well/0.1 mL) in a flat-bottom 96-well microtiter plate (Falcon catalog no. 353075). From a 10 mM stock of test compound in DMSO, serial 2-fold dilutions of compound are added in triplicate wells starting at 10 Î¼M. One row serves as 100% proliferation control and is incubated with DMSO alone. After 1 h, 50 Î¼L of 10 units/mL GM-CSF (final) in media is added to all wells. Plates are then incubated at 37 Â°C and 5% CO<sub>2</sub> for 72 h. Cells are pulsed with [<sup>3</sup>H]thymidine and harvested, and percent inhibition is determined in the same fashion as the IL-2 dependent T cell proliferation assay.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Inhibition of Human Foreskin Fibroblast Proliferation (HFF Assay)</h4><div class="NLM_p last">This screen measures nonspecific inhibition of cellular proliferation. HFFs are obtained from explants of neonatal human foreskin tissue and cultured in media (DMEM with 10% heat-inactivated fetal bovine serum and 1% P/S). Primary cultures are grown in media in tissue culture flasks and split prior to confluency using trypsinâEDTA (Gibco). Fibroblasts are grown in T-175 tissue culture flasks and split 1:5 every 3â4 days. HFFs are used in this assay from passage 5 to 16. To assay for a test compoundâs ability to inhibit HFF proliferation, cells are trypsinized and washed three times, resuspended in media, and then plated (2500 cells per well/0.15 mL) in a flat-bottom 96-well tissue culture plate (Falcon catalog no. 353075). From a 10 mM stock of test compound in DMSO, serial 2-fold dilutions of compound are added in triplicate wells starting at 10 Î¼M. One row is plated with DMSO only and serves as the 100% proliferation control. Cells are pulsed with [<sup>3</sup>H]thymidine and harvested, and percent inhibition is determined in the same fashion as the IL-2 dependent T cell proliferation assay.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>In Vitro</i> Pharmacokinetic Assays</h3><div class="NLM_p"><i>In vitro</i> absorption, distribution, metabolism, and excretion (ADME) and <i>in vivo</i> studies were carried out in accordance with previously published methods.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Microsome Incubations</h4><div class="NLM_p last">Incubations of <b>1</b> (1 Î¼M) were carried out in replicate with microsomes (CYP concentration = 0.25 Î¼M) in 0.1 M potassium phosphate buffer (pH = 7.4) at 37 Â°C. The reaction mixture was prewarmed at 37 Â°C for 2 min before adding nicotinamide adenine dinucleotide phosphate (NADPH) (1.2 mM). The final incubation volume was 600 mL. Aliquots (75 mL) of the reaction mixture at <i>t</i> = 0, 2, 5, 15, and 30 min were added to acetonitrile (200 mL) containing indomethacin as internal standard (50 ng/mL), and the samples were centrifuged at 2500<i>g</i> for 5 min before liquid chromatography/tandem mass spectrometry (LC/MS/MS) analysis. For control experiments, NADPH was omitted from these incubations.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Hepatocyte Incubations</h4><div class="NLM_p last">Stability of <b>1</b> in hepatocytes was examined as follows. Cryopreserved hepatocytes from preclinical species and human were thawed and suspended in Williamsâ E media supplemented with 24 mM sodium bicarbonate and 10% fetal bovine serum at 0.5 Ã 10<sup>6</sup> viable cells/mL for clearance prediction. <b>1</b> (1 Î¼M) for clearance predictions was incubated with hepatocytes at 37 Â°C for 4 h with gentle agitation. A gas mixture of oxygen/carbon dioxide (95:5) maintained at about 2.5 kPa for about 5 s was passed through this mixture at every 1 h of incubation. Flasks were corked immediately after gassing. Freezing the incubation aliquots in liquid nitrogen terminated the reactions. Following extraction, the samples were then analyzed by LC/MS/MS.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Plasma Protein Binding</h4><div class="NLM_p last">The binding of <b>1</b> to rat, dog, monkey, and human plasma proteins was determined using the equilibrium dialysis method. <b>1</b> was added to fresh plasma from animals or human. <b>1</b> concentrations examined are pharmacologically relevant based on <i>in vivo</i> efficacy studies in animals. The plasma samples (1 mL) were subjected to equilibrium dialysis (<i>n</i> = 6 or 8) using Spectra Por dialysis membranes (VWR, West Chester, PA, USA) with a molecular mass cutoff of 12.4 kDa. The resulting plasma samples were subjected to dialysis against isotonic phosphate buffer (pH 7.4) for 6 h. Following equilibration, the volume of the plasma and buffer samples removed from each equilibration cell was noted. Aliquots of dialyzed plasma (100 mL) and buffer (100 mL) were transferred to 96-well blocks, and acetonitrile (200 mL) containing indomethacin as internal standard (50 ng mL<sup>â1</sup>) was added to each well. Each matrix was normalized to the other by the addition of equal volumes of the opposite matrix (i.e., plasma to buffer and buffer to plasma). Following extraction, the samples were then analyzed by LC/MS/MS.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> DrugâDrug Interactions</h4><div class="NLM_p last">The ability of a compound to act as a competitive inhibitor of the five major CYPs, namely, CYP1A2, 2C9, 2C19, 2D6, and 3A4, was examined as follows. Phenacetin (50 mM) (a probe substrate for CYP1A2), diclofenac (10 mM) (a probe substrate for CYP2C9), <i>S</i>-mephenytoin (50 mM) (a probe substrate for CYP2C19), bufuralol (10 mM) (a probe substrate for CYP2D6), testosterone (50 mM), or midazolam (5 mM) (probe substrates for CYP3A4) was incubated with human liver microsomes (CYP concentration = 0.25 mM), 3.3 mM MgCl<sub>2</sub>, and 1.3 mM NADPH in a total volume of 0.6 mL of 100 mM phosphate buffer, pH 7.4, in the presence and absence of test compound at a concentration range of 0â50 mM. The reactions were initiated by the addition of NADPH, and incubations were conducted in a shaking water bath at 37 Â°C for 10 min, in the case of diclofenac, bufuralol, testosterone, and midazolam, or at 30 min, in the case of phenacetin and <i>S</i>-mephenytoin. All reactions were terminated by the addition of acetonitrile (200 mL), and the samples were centrifuged at 2500<i>g</i> for 5 min before LC/MS/MS analysis. Procedures for the quantitation of metabolites of probe P450 substrates used in the present study have been described in detail by Obach.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Specific CYP enzyme inhibitors, ketoconazole (CYP3A4), quinidine (CYP2D6), sulfaphenazole (CYP2C9), (+)-<i>N</i>-3-benzylnirvanol (CYP2C19), and furafylline (CYP1A2), were used as positive controls in the competitive inhibition studies.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Caco-2 Cell Permeability<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></h4><div class="NLM_p last">Caco-2 cells, obtained from the American Type Culture Collection (Rockville, MD), were seeded in 24-well Falcon multiwell plates (polyethylene terephthalate membranes, pore size 1.0 mm) at 4.0 Ã 10<sup>4</sup> cells per well. The cells were grown on filter supports for 3 weeks. Permeability studies were performed after 15â17 days of culture. Cells were used between passages 34 and 41. Complete culture medium was removed from both the apical and basolateral compartments, and the monolayer was preincubated with prewarmed apical (0.5 mL) or basolateral (1.5 mL) buffer for 0.5 h at 37 Â°C in a shaking water bath. The apical buffer consisted of Hank's balanced salt solution, 25 mM <i>d</i>-glucose monohydrate, 20 mM 2-(<i>N</i>-morpholino)ethanesulfonic acid, 1.25 mM CaCl<sub>2</sub>, and 0.5 mM MgCl<sub>2</sub> (pH = 6.5). The basolateral buffer consisted of Hank's balanced salt solution, 25 mM <i>d</i>-glucose monohydrate, 20 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>â²-2-ethanesulfonic acid, 1.25 mM CaCl<sub>2</sub>, and 0.5 mM MgCl<sub>2</sub> (pH = 7.4). At the end of the preincubation, the media were removed and one (at concentrations of 1, 10, and 50 mM) or blank buffer was added. The effects of P-glycoprotein inhibitors on transport of <b>1</b> (1 mM) in both apical to basolateral (A to B) and basolateral to apical (B to A) directions were assessed by inclusion of verapamil (100 mM) or CP-100,356 (10 mM) in both donor and acceptor well solutions. To assess the integrity of the monolayer, the flux of [<sup>14</sup>C]mannitol from apical to basolateral was determined following incubation with <b>1</b>. Inserts with a flux greater than 2%/h were excluded from the study. Flux rate (<i>F</i>, mass/time) was calculated from the slope of the appearance of <b>1</b> on the receiver side, and the apparent permeability (<i>P</i><sub>app</sub>) was calculated from the equation <i>P</i><sub>app</sub> (cm/s) = (<i>FV</i><sub>D</sub>)/(<i>SC</i><sub>0</sub>), where <i>S</i> is surface area of the monolayer (0.83 cm<sup>2</sup>), <i>V</i><sub>D</sub> is the donor volume, and <i>C</i><sub>0</sub> is the initial concentration in the donor compartment. Incubations were conducted in duplicate. Following extraction, the samples were then analyzed by LC/MS/MS.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>In Vivo</i> Pharmacokinetic Studies</h3><div class="NLM_p last">The Pfizer Institutional Animal Care and Use Committee approved all procedures. Male and female Sprague-Dawley rats (220â250 g), beagle dogs (9â13 kg), and cynomolgus monkeys (4â6 kg) were used for these studies. All animals were fasted overnight before dosing. <b>1</b> was administered via the jugular vein (rats) or via the brachial vein (dogs and monkeys). <b>1</b> was administered iv at 3 mg/kg and orally (po) at 10, 30, and 100 mg/kg in rats (administered in 20% cremophor/10% ethanol/70% water), 3 mg/kg iv and 5 mg/kg po in monkeys (administered in glycerol formal), and 3 mg/kg iv and 5 mg/kg po in dogs (administered in glycerol formal). For all po studies, <b>1</b> was given as a suspension in 0.5% methylcellulose. Blood samples were taken, via the jugular vein (rats and dogs) or femoral vein (monkeys), in series at appropriate time intervals, and urine samples were also collected from rats for the length of the entire study (0â24 h). All samples were kept frozen until analysis. Following extraction, the samples were then analyzed by LC/MS/MS.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Compound Preparation and Characterization</h3><div class="NLM_p last">Routine <sup>1</sup>H nuclear magnetic resonance (NMR) and <sup>13</sup>C NMR spectra were recorded on a Varian Inova 400 MHz spectrometer unless otherwise specified. NMR structure elucidation experiments were collected using a Bruker DMX-500 spectrometer equipped with a Bruker 5 mm broad-band observe (BBO) probe at 300 K. Standard pulse sequences and phase cycling were used for all correlation spectroscopy (COSY), heteronuclear single-quantum coherence (HSQC), heteronuclear multiple bond coherence (HMBC), and nuclear Overhauser enhancement spectroscopy (NOESY) spectra. Low-resolution mass spectral data were collected using a Waters Micromass ZMD (electrospray ionization, chromatography on a Varian Polaris 5 C-18 column with acetonitrile and 0.1% formic acid aqueous gradient eluant). Compounds were determined to be â¥95% pure by HPLC [C18, 0% acetonitrile in water (0.1% trifluoroacetic acid) to 60% acetonitrile, UV 220 nm]. Reagents and solvents were obtained from commercial sources unless otherwise noted. All reactions were run under nitrogen unless otherwise noted. Chiral separations were conducted using a Voyager instrument with a Chiralpak AD column and a mobile phase of ethanol/hexane or isopropanol/hexane. X-ray data were collected at 1 Ã (maximum sin Î/Î» = 0.5) on a Siemens R4RA/v diffractometer at room temperature.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Compound Synthesis</h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3-((3<i>R</i>,4<i>R</i>)-4-Methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (<b>1</b>) Monocitrate</h4><div class="NLM_p">A mixture of 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>5</b>) (2.4 g, 15.9 mmol), prepared by the method of Davoll,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (3<i>R</i>,4<i>R</i>)-1-benzyl-<i>N</i>,4-dimethylpiperidin-3-amine (1.7 g, 7.95 mmol), prepared by the method of Brown Ripin<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and resolved as described in WO 02/096909, and 10 mL of triethylamine was heated in a sealed tube at 100 Â°C for 4 days. After cooling to room temperature and concentration under reduced pressure, the residue was purified by flash chromatography (silica; 3% methanol in dichloromethane) affording 1.0 g (38%) of (3<i>R</i>,4<i>R</i>)-1-benzyl-4-methylpiperidin-3-yl)methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl-amine (<b>19a</b>) as a colorless oil. Alternative coupling conditions can be found in WO 02/096909. Low-resolution mass spectrometry (LMRS): <i>m</i>/<i>z</i> 336.1 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.95 (3 H, d, <i>J =</i> 6.8 Hz), 1.61â1.75 (1 H, m), 1.81 (1 H, br s), 2.37 (2 H, br s), 2.82â2.95 (1 H, m), 3.54 (2 H, s), 3.61 (3 H, s), 5.21 (1 H, br s), 6.58 (1 H, d, <i>J =</i> 4.0 Hz), 7.18â7.40 (5 H, m), 8.25 (1 H, s). Alternatively, compound <b>19</b> was prepared by coupling racemic 1-benzyl-<i>N</i>,4-dimethylpiperidin-3-amine with <b>5</b>. Compound <b>19</b> was then separated by chiral HPLC (Chiralpak AD; 85:15 hexanes/ethanol); <b>19a</b> had a retention time of 7.43 min, and <b>19b</b> had a retention time of 6.90 min. Compound <b>1</b> was then prepared from <b>19a</b>, and compound <b>1a</b> was prepared from <b>19b</b> as described below.</div><div class="NLM_p last">To a solution of 79 g of (3<i>R</i>,4<i>R</i>)-1-benzyl-4-methylpiperidin-3-yl)methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amine dissolved in 2 L of ethanol was added 79 g of 20% palladium hydroxide on carbon (50% water by weight), and the mixture was agitated under an atmospheric pressure of 50 psi hydrogen for 3 days [conducting the hydrogenolysis at elevated temperature (50â70 Â°C) significantly decreases reaction times]. After the catalyst was removed by filtration through Celite, 51 g of cyanoacetic acid 2,5-dioxopyrrolidin-1-yl ester was added to the ethanolic solution, and the resulting mixture was stirred at room temperature for 1 h, at which time the ethanol was removed under reduced pressure. The residue was redissolved in 1.0 L of dichloromethane, and the solution was sequentially washed with 0.6 L of saturated aqueous sodium bicarbonate and 0.4 L of saturated sodium bicarbonate. The combined aqueous layers were back-washed with 0.4 L of 30 dichloromethane, and the dichloromethane layers were combined, dried over magnesium sulfate, filtered, and concentrated <i>in vacuo</i> affording 61 g of amber oil. This material was then redissolved in 2.1 L of acetone, and the solution was heated to 40 Â°C. Finely ground citric acid (37 g) was added slowly (as a solid) to the solution. The mixture continued stirring at 40 Â°C for 2 h (granulation was complete). After being cooled to room temperature, the solids were collected by filtration, washed with acetone, and dried <i>in vacuo</i> affording 78.5 g of 3-(3<i>R</i>,4<i>R</i>)-4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile monocitrate (<b>1</b> monocitrate) (66% from ((3<i>R</i>,4<i>R</i>)-1-benzyl-4-methylpiperidin-3-yl)methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amine) as a slightly off-white crystalline solid. This material was then combined with 750 mL of 1:1 v/v ethanol/water, and the slurry was agitated overnight. The solids were filtered and dried to afford 69 g of <b>1</b> monocitrate as a white crystalline solid (mp = 201 dec). LRMS: <i>m</i>/<i>z</i> 313.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (D<sub>2</sub>O) Î´ HOD: 0.92 (2 H, d, <i>J =</i> 7.2 Hz), 0.96 (1 H, d, <i>J =</i> 7.6 Hz), 1.66 (1 H, m), 1.80 (1 H, m), 2.37 (1 H, m), 2.58 (2 H, 1/2 ABq, <i>J =</i> 15.4 Hz), 2.70 (2 H, 1/2 ABq, <i>J =</i> 15.4 Hz), 3.23 (2 H, s), 3.25 (1 H, s), 3.33 (1 H, m), 3.46 (1 H, m), 3.81 (4 H, m), 4.55 (1 H, m), 6.65 (1 H, d, <i>J =</i> 3.2 Hz), 7.20 (1 H, t, <i>J =</i> 3.2 Hz), 8.09 (1 H, m). Anal. Calcd for C<sub>22</sub>H<sub>28</sub>N<sub>6</sub>O<sub>8</sub>: C, 52.38; H, 5.59; N, 16.66. Found: C, 52.32; H, 5.83; N, 16.30. For additional characterization of the monocitrate salt of <b>1</b> see WO 03/048162.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 9-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-2,3,4,4a,9,9a-hexahydro-1<i>H</i>-carbazole (<b>2a</b>)</h4><div class="NLM_p last">To a stirred solution of <b>5</b> (2 g/0.013 mol) in 100 mL of dimethylformamide was added 3.3 g (0.013 mol) of 2,3,4,4a,9,9a-hexahydro-1<i>H</i>-carbazole hydrobromide followed by 2.1 mL of pyridine, and the resulting mixture was stirred at reflux for 16 h. After being cooled to room temperature the reaction mixture was washed with 10% CuSO<sub>4</sub> and saturated brine and dried over MgSO<sub>4</sub>. Following filtration and concentration under reduced pressure the crude product (3.42 g) was purified by column chromatography (silica gel; 1:1 ethyl acetate/hexanes) affording 1.06 g (28%) of <b>2a</b> as an off-white solid. LRMS: <i>m</i>/<i>z</i> 291 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.21â1.45 (3 H, m), 1.67 (4 H, br s), 1.81â1.99 (1 H, m), 2.33 (2 H, dd, <i>J =</i> 32.0 Hz, <i>J =</i> 11.6 Hz), 3.62 (1 H, s), 4.86 (1 H, br s), 7.00â7.18 (2 H, m), 7.19â7.35 (3 H, m), 8.35 (1 H, d, <i>J =</i> 6.8 Hz). High-resolution mass spectrometry (HRMS): calcd for C<sub>18</sub>H<sub>18</sub>N<sub>4</sub> (MH<sup>+</sup>) 291.1604, found 291.1613.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-(Piperidin-1-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>2b</b>)</h4><div class="NLM_p">To a stirred solution of <b>5</b> (0.5 g/3.3 mmol) dissolved in 5 mL of <i>tert</i>-butanol was added 1.1 g (13 mmol) of piperidine, and the resulting mixture was heated to 85 Â°C for 3 h. After being cooled to room temperature the pH of the reaction mixture was adjusted to â¼1 with 1 N HCl (aqueous) and washed 2 Ã 20 mL with ether. The aqueous layer was then basified with 1 N NaOH precipitating the product, which was collected by filtration and dried in a desiccator affording 395 mg (60%) of <b>2b</b> as a white solid. LRMS: <i>m</i>/<i>z</i> 203.1. <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.69 (6 H, s), 3.88 (4 H, s), 6.47 (1 H, d, <i>J</i> = 3.2 Hz), 7.06 (1 H, d, <i>J</i> = 3.2 Hz), 8.32 (1 H, s), 11.65 (1 H, br s). <sup>13</sup>C NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 24.8, 25.9, 47.3, 101.5, 102.9, 120.3, 150.9, 152.2, 157.3. HRMS: calcd for C<sub>11</sub>H<sub>15</sub>N<sub>4</sub> (MH<sup>+</sup>) 203.1291, found 203.1296.</div><div class="NLM_p last">Compounds <b>2c</b> through <b>2i</b> were prepared in an analogous manner to that described for <b>2b</b>.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-(2,5-Dimethylpyrrolidin-1-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>2c</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 217.3 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 1.43 (6 H, d, <i>J</i> = 6.3 Hz), 1.82â1.87 (2 H, m), 2.14â2.17 (2 H, m), 4.50â4.53 (2 H, m), 6.55 (1 H, d, <i>J</i> = 3.5 Hz), 7.07 (1 H, d, <i>J</i> = 3.5 Hz), 8.07 (1 H, s). <sup>13</sup>C NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 21.2, 31.4, 55.1, 101.7, 102.5, 120.5, 150.2, 150.7, 155.0.</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-(Octahydro-1<i>H</i>-indol-1-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>2d</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 243.3 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.18â1.43 (3 H, m), 1.55 (1 H, d, <i>J</i> = 10.8 Hz), 1.62â1.95 (4 H, m), 2.16 (1 H, s), 2.26 (1 H, br s), 2.40 (1 H, br s), 3.82 (1 H, d, <i>J</i> = 7.6 Hz), 3.95 (1 H, d, <i>J</i> = 8.8 Hz), 4.38 (1 H, br s), 6.50 (1 H, s), 7.04 (1 H, s), 8.30 (1 H, s).</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-Cyclopentyl-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>2e</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 217.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.58â2.05 (9 H, m), 3.22 (3 H, s), 5.31 (1 H, t, <i>J =</i> 7.6 Hz), 6.56 (1 H, d, <i>J =</i> 3.6 Hz), 7.02 (1 H, d, <i>J =</i> 3.6 Hz), 8.29 (1 H, s).</div></div><div id="sec4_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-Cyclohexyl-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>2f</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 231.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.07â1.28 (2 H, m), 1.39â1.62 (3 H, m), 1.73 (2 H, d, <i>J =</i> 13.6 Hz), 1.78â1.95 (4 H, m), 3.22 (3 H, s), 4.68 (1 H, br s), 6.53 (1 H, d, <i>J =</i> 3.2 Hz), 7.02 (1 H, d, <i>J =</i> 3.6 Hz), 8.30 (1 H, s). <sup>13</sup>C NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 25.7, 25.9, 29.7, 30.4, 30.9, 55.4, 102.0, 102.8, 119.8, 150.9, 151.8, 157.5. HRMS: calcd for C<sub>13</sub>H<sub>19</sub>N<sub>4</sub> (MH<sup>+</sup>) 231.1604, found 231.1603.</div></div><div id="sec4_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-Methyl-<i>N</i>-(4-methylcyclohexyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>2g</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 245.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.91 (1.5 H, d, <i>J</i> = 6.4 Hz), 1.02 (1.5 H, d, <i>J</i> = 7.2 Hz), 1.17 (2 H, q, <i>J</i> = 10.0 Hz), 1.38 (2 H, br s), 1.60 (3 H, t, <i>J</i> = 14.0 Hz), 1.70â2.03 (3 H, m), 3.20 (1.5 H, s), 3.24 (1.5 H, s), 4.64 (1 H, br s), 6.51 (1 H, t, <i>J</i> = 3.2 Hz), 7.03 (1 H, d, <i>J</i> = 3.2 Hz), 8.27 (1 H, s).</div></div><div id="sec4_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-Cycloheptyl-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>2h</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 245.5 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 1.40â1.83 (12 H, m), 3.09 (3 H, s), 3.21 (1 H, s), 6.50 (1 H, d, <i>J =</i> 3.6 Hz), 6.96 (1 H, d, <i>J =</i> 3.2 Hz), 7.97 (1 H, s). <sup>13</sup>C NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 26.4, 28.8, 32.1, 33.4, 58.8, 103.3, 104.0, 121.5, 151.7, 151.9, 158.2. HRMS: calcd for C<sub>14</sub>H<sub>21</sub>N<sub>4</sub> (MH<sup>+</sup>) 245.1761, found 245.1759.</div></div><div id="sec4_6_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-Cyclooctyl-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>2i</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 259.3 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.46â1.85 (14 H, m), 3.19 (3 H, s), 5.03 (1 H, br s), 6.56 (1 H, d, <i>J</i> = 3.2 Hz), 7.00 (1 H, d, <i>J</i> = 3.2 Hz), 8.29 (1 H, s), 9.79 (1 H, br s).</div></div><div id="sec4_6_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> HSA Protocol</h4><div class="NLM_p">Ketones (<b>3</b>) (1 mmol) were added to tarred 4 mL vials and dissolved in 2 mL of methanol containing 4 mmol of methylamine. Acetic acid (120 mg/2 mmol as a 4 M solution in dichloroethane) was added followed by 1 g of borohydride polymer support (Amberlite IRA-400, 2.5 mmol BH<sub>4</sub>/g resin), and the capped vials were agitated for 18 h at room temperature. The reaction mixtures were then transferred to filters to remove the resin, the resin was washed 2 Ã 3 mL with methanol, and the samples were concentrated affording crude amines <b>4</b>, which were carried on without additional purification. To these vials was added <b>5</b> (0.5 mmol) as a 0.5 M solution in tetrahydrofuran (THF) followed by 3 mL of a 10% solution of dichloroethane in <i>tert</i>-butanol and 1 M in diisopropylethylamine. The resulting capped mixtures were agitated at 80 Â°C for 40 h and then concentrated in a vacuum oven at 35 Â°C. The crude products were dissolved in 3 mL of 10% methanol in dichloromethane and transferred to 6 cm<sup>3</sup> strong cation-exchange (SCX) columns that had been preconditioned with 3 column volumes of methanol. The columns were then washed 3 Ã 5 mL with methanol, and the product was eluted with 5 mL of 0.1 N ammonia affording test compounds <b>6</b> after drying in a vacuum oven at 35 Â°C. QC was performed on all final compounds by LRMS and HPLC [C18, 5 Î¼m, 19 Ã 100 mm; solvent A, 0.1% trifluoroacetic acid in water (v/v); solvent B, 0.1% trifluoroacetic acid in acetonitrile (v/v)].</div><div class="NLM_p last">Preparation of <b>4a</b> through <b>4h</b> was conducted in an analogous manner to that described in the <a class="ref internalNav" href="#sec4_6_11" aria-label="HSA Protocol">HSA Protocol</a> starting with ketones <b>3a</b> through <b>3h</b>. Some amine intermediates (<b>4</b>) were carried on without characterization.</div></div><div id="sec4_6_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>,3-Dimethylcyclohexanamine (<b>4a</b>) (Formate)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.97 (3 H, d, <i>J</i> = 7.2 Hz), 1.23 (1 H, dd, <i>J =</i> 116 Hz, <i>J =</i> 12.4 Hz), 1.25 (1 H, br s), 1.52â1.73 (4 H, m), 1.78â1.91 (2 H, m), 1.98â2.15 (1 H, m), 2.59 (3 H, s), 3.12 (1 H, q, <i>J =</i> 3.6 Hz), 8.61 (1 H, br s). HRMS: calcd for C<sub>8</sub>H<sub>17</sub>N (MH<sup>+</sup>) 128.1434, found 128.1433.</div></div><div id="sec4_6_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>,2-Dimethylcyclohexanamine (<b>4b</b>) (Formate)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.89â1.08 (3 H, m), 1.22 (2 H, br s), 1.28â1.81 (5 H, m), 2.01 (1 H, br s), 2.23 (1 H, br s), 2.68 (3 H, s), 2.91 (1 H, d, <i>J =</i> 9.2 Hz), 8.47 (1 H, s). HRMS: calcd for C<sub>8</sub>H<sub>17</sub>N (MH<sup>+</sup>) 128.1434, found 128.1432.</div></div><div id="sec4_6_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>,2,5-Trimethylcyclohexanamine (<b>4c</b>) (Formate)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´ TMS: 0.89 (3 H, d, <i>J =</i> 6.0 Hz), 0.94 (3 H, d, <i>J =</i> 7.4 Hz), 0.95â1.12 (2 H, m), 1.21â1.63 (3 H, m), 1.75 (1 H, dd, <i>J =</i> 28.0 Hz, <i>J =</i> 12.4 Hz), 2.74 (1 H, br s), 2.81 (3 H, s), 2.92 (1 H, d, <i>J =</i> 10.8 Hz), 8.46 (1 H, br s). HRMS: calcd for C<sub>9</sub>H<sub>19</sub>N (MH<sup>+</sup>) 142.1590, found 142.1590.</div></div><div id="sec4_6_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-Isopropyl-<i>N</i>,5-dimethylcyclohexanamine (<b>4f</b>) (Formate)</h4><div class="NLM_p last"><sup>1</sup> H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.61â0.78 (9 H, m), 0.82 (1 H, d, <i>J =</i> 6.4 Hz), 0.91 (1 H, t, <i>J =</i> 12.8 Hz), 1.08â1.32 (1 H, m), 1.43â1.65 (2 H, m), 1.84 (1 H, d, <i>J =</i> 14.8 Hz), 2.41 (3 H, s), 3.14 (1 H, s), 8.32 (1 H, s). HRMS: calcd for C<sub>11</sub>H<sub>23</sub>N (MH<sup>+</sup>) 170.1903, found 170.1902.</div></div><div id="sec4_6_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-Methyl-<i>N</i>-(3-methylcyclohexyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>6a</b>)</h4><div class="NLM_p">To a slurry of <b>5</b> (50 mg/0.32 mmol) in 1 mL of <i>tert</i>-butanol was added 45 mg (0.35 mmol) of <b>4a</b> followed by 84 mg (0.65 mmol) of diisopropylethylamine, and the resulting mixture was heated to 80 Â°C for 24 h. The reaction mixture was then cooled to room temperature and diluted with 25 mL of dichloromethane. The solution was washed with 1 N HCl and then with saturated NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to dryness <i>in vacuo</i>. The crude product was then purified by preparative thin-layer chromatography (TLC) (silica gel; 2:1 hexanes/ethyl acetate) affording 20 mg of <b>6a</b> (25%) as an â¼2:1 mixture of diastereomers. LRMS: <i>m</i>/<i>z</i> 245.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 0.68â0.80 (1 H, m), 0.84 (1 H, d, <i>J =</i> 7.2 Hz), 1.03 (2 H, d, <i>J =</i> 6.8 Hz), 1.18 (1 H, q, <i>J =</i> 12.2 Hz), 1.31â1.68 (5 H, m), 1.69â1.82 (1 H, m), 2.08 (1 H, br s), 3.06 (2 H, s), 3.09 (1 H, s), 3.21 (1 H, s), 4.55 (1 H, br s), 6.46 (0.3 H, d, <i>J =</i> 3.6 Hz), 6.48 (0.7 H, d, <i>J =</i> 2.0 Hz), 6.97 (1 H, t, <i>J =</i> 2.0 Hz), 7.98 (0.3 H, s), 7.99 (0.7 H, s). <sup>13</sup>C NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 21.1, 23.7, 25.5, 28.8, 32.2, 33.0, 33.9, 33.9, 34.2, 34.4, 36.2, 37.9, 42.3, 54.3, 59.2, 105.7, 105.8, 106.7, 124.1, 154.2, 154.2, 154.4, 161.2, 161.4. HRMS: calcd for C<sub>14</sub>H<sub>21</sub>N<sub>4</sub> (MH<sup>+</sup>) 245.1761, found 245.1756.</div><div class="NLM_p last">Compounds <b>6b</b> through <b>6h</b> were prepared in an analogous manner to that described for <b>6a</b>. Compounds <b>6d</b>, <b>6e</b>, <b>6g</b>, and <b>6h</b> were characterized by LRMS and HPLC purity as described above.</div></div><div id="sec4_6_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-Methyl-<i>N</i>-(2-methylcyclohexyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>6b</b>) (â¼3:1 Mixture of Diastereomers)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 245.5 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 0.66 (0.75 H, d, <i>J =</i> 7.0 Hz), 0.92 (2.25 H, d, <i>J =</i> 7.0 Hz), 0.98â1.24 (1 H, m), 1.25â1.42 (2 H, m), 1.43â1.55 (2 H, m), 1.56â1.82 (2 H, m), 1.90 (1 H, sp q, 2.29 (1 H, br s), 3.15 (2.25 H, s), 3.21 (0.75 H, s), 4.52â4.60 (1 H, m), 6.48 (1 H, d, <i>J =</i> 3.6 Hz), 6.97 (1 H, d, <i>J =</i> 3.2 Hz), 7.98 (0.25 H, s), 8.00 (0.75 H, s). <sup>13</sup>C NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 13.5, 19.4, 20.9, 26.3, 26.9, 27.0, 27.9, 33.5, 34.0, 34.1, 36.0, 36.4, 59.7, 103.4, 104.0, 121.6, 151.4, 151.7, 158.6, 159.4. HRMS: calcd for C<sub>14</sub>H<sub>21</sub>N<sub>4</sub> (MH<sup>+</sup>) 245.1761, found 245.1754.</div></div><div id="sec4_6_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-(2,5-Dimethylcyclohexyl)-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>6c</b>) (Mixture of Diastereomers)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 259.1 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 0.68 (1 H, d, <i>J =</i> 6.8 Hz), 0.82 (1 H, d, <i>J =</i> 7.0 Hz), 0.84 (2 H, d, <i>J =</i> 6.0 Hz), 0.88 (1 H, d, <i>J =</i> 7.2 Hz), 1.01â1.22 (1 H, m), 1.22â1.41 (1 H, m), 1.42â1.62 (2 H, m), 1.63â1.76 (1 H, m), 1.77â1.89 (0.5 H, m), 2.05 (0.5 H, d, <i>J =</i> 12.2), 2.15 (0.5 H, br s), 2.26 (0.5 H, br s), 3.02 (0.5 H, s), 3.08 (0.5 H, s), 3.14 (1.5 H, s), 3.18 (1.5 H, s), 4.55â4.62 (1 H, m), 6.42â6.54 (1 H, m), 6.92â6.99 (1 H, m), 7.96â8.07 (1 H, m). <sup>13</sup>C NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 22.7, 23.0, 28.4, 29.0, 29.7, 29.8, 30.2, 31.1, 32.3, 33.0, 33.2, 33.6, 33.9, 34.0, 34.7, 34.8, 34.8, 35.4, 35.7, 35.8, 36.2, 36.9, 39.3, 48.4, 48.6, 48.8, 49.0, 49.2, 49.5, 49.7, 54.1, 59.4, 103.4, 104.1, 104.1, 121.5, 121.5, 151.6, 151.7, 151.8, 151.9, 152.0, 158.7, 159.2, 159.4. HRMS: calcd for C<sub>15</sub>H<sub>23</sub>N<sub>4</sub> (MH<sup>+</sup>) 259.1917, found 259.1917.</div></div><div id="sec4_6_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-(2-Isopropyl-5-methylcyclohexyl)-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>6f</b>) (â¼3:1 Mixture of Diastereomers)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 287.4 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 0.55 (1 H, br s), 0.71 (3 H, d, <i>J =</i> 7.0 Hz), 0.79 (1 H, d, <i>J =</i> 7.0 Hz), 0.91 (3 H, d, <i>J =</i> 6.4 Hz), 0.97 (3 H, d, <i>J =</i> 4.0 Hz), 1.38â1.60 (3 H, m), 1.61â1.73 (2 H, m), 1.82â2.00 (2 H, m), 3.21 (1 H, s), 3.21 (3 H, s), 4.62 (1 H, br s), 6.49 (0.75 H, d, <i>J =</i> 2.8 Hz), 6.55 (0.25 H, s), 6.99 (1 H, s), 7.99 (0.25 H, s), 8.01 (0.75 H, s). <sup>13</sup>C NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 16.5, 21.5, 21.9, 22.7, 23.0, 24.9, 26.0, 28.1, 28.4, 31.8, 33.4, 34.1, 34.6, 35.6, 36.6, 39.4, 43.3, 46.1, 48.4, 48.6, 48.8, 49.0, 49.3, 49.7, 49.7, 60.9, 103.7, 104.0, 122.0, 150.4, 150.6, 150.9, 158.0. HRMS: calcd for C<sub>17</sub>H<sub>27</sub>N<sub>4</sub> (MH<sup>+</sup>) 287.2230, found 287.2231.</div></div><div id="sec4_6_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (5<i>S</i>)-2-Methyl-5-(prop-1-en-2-yl)cyclohexanone (<b>8</b>)</h4><div class="NLM_p last">A solution of <i>S</i>-(+)-carvone (<b>7</b>) (2.05 g/13.6 mmol) dissolved in 14 mL of dry THF was cooled to â70 Â°C, and to this mixture was added dropwise 14 mL of a 1.0 M solution of L-selectride in THF. Once the addition was complete, the reaction mixture stirred at â70 Â°C for 2 h, at which time the reaction was warmed to 0 Â°C and 40 mL of a 10% solution of sodium hydroxide was added dropwise with stirring over a 10 min period. Hydrogen peroxide (30%, 28 mL) was then added dropwise over a 10 min period, and the mixture was warmed to room temperature, transferred to a separatory funnel, and extracted 3 Ã 100 mL with hexanes. The organic extracts were washed 2 Ã 100 mL with water, 2 Ã 100 mL with 1.5 M sodium bisulfite, and 50 mL with saturated brine. The organic layer was then dried over MgSO<sub>4</sub>, filtered through Celite, and concentrated to dryness <i>in vacuo</i>. The crude product was then purified by flash chromatography (silica gel; 95:5 hexanes/ethyl acetate) affording 1.08 g (52%) of compound <b>8</b> as a colorless oil. LRMS: <i>m</i>/<i>z</i> 153.4 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.00 (2.5 H, d, <i>J =</i> 6.4 Hz), 1.03 (0.5 H, d, <i>J =</i> 6.8 Hz), 1.30â1.38 (1 H, m), 1.60 (1 H, d, <i>J =</i> 9.2 Hz), 1.69 (3 H, s), 1.84 (1 H, d, <i>J =</i> 25.6 Hz), 2.05â2.12 (1 H, m), 2.98â2.43 (4 H, m), 4.69 (2 H, d, <i>J =</i> 10.4 Hz).</div></div><div id="sec4_6_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (5<i>S</i>)-<i>N</i>,2-Dimethyl-5-(prop-1-en-2-yl)cyclohexanamine (<b>9</b>)</h4><div class="NLM_p last">To a 250 mL round-bottom flask was charged 3.21 g (15.1 mmol) of sodium triacetoxyborohydride and 1.08 g (7.1 mmol) of <b>8</b> dissolved in 70 mL of THF, to this mixture was added 3.6 mL of 2.0 M solution of methylamine in THF, and the resulting mixture was stirred at room temperature for 16 h, at which time the reaction was quenched upon addition of 75 mL of water. The resulting mixture was extracted 3 Ã 100 mL with chloroform, and the combined organic extracts were dried over MgSO<sub>4</sub>, filtered through Celite, and concentrated to dryness <i>in vacuo</i>. The crude product was then purified by flash chromatography (silica gel; 6:4 dichloromethane/hexanes to 9:1 dichloromethane/methanol) affording <b>9</b> as a colorless oil. LRMS: <i>m</i>/<i>z</i> 168.5 (MH <sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.79 (2 H, d, <i>J =</i> 7.2 Hz), 0.87 (1 H, d, <i>J =</i> 6.8 Hz), 1.14 (1 H, t, <i>J =</i> 4.8 Hz), 1.21â1.55 (3 H, m), 1.56â1.73 (2 H, m), 1.65 (3 H, s), 1.80â2.20 (2 H, m), 2.34 (1 H, s), 2.35 (2 H, s), 2.47 (0.6 H, d, <i>J =</i> 12 Hz), 2.57 (0.3 H, d, <i>J =</i> 3.2 Hz), 4.61 (2 H, d, <i>J =</i> 3.6 Hz).</div></div><div id="sec4_6_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-Methyl-<i>N</i>-((5<i>S</i>)-2-methyl-5-(prop-1-en-2-yl)cyclohexyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (Diastereomeric Mixture <b>11</b>)</h4><div class="NLM_p">A sealed tube was charged with 119 mg (0.78 mmol) of <b>5</b>, 233 mg (1.02 mmol) of <b>9</b>, 320 mg (3.16 mmol) of triethylamine, and 3 mL of <i>tert</i>-butanol, and the capped mixture was stirred at 100 Â°C for 48 h. After being cooled to room temperature the mixture was diluted with 30 mL of ether, transferred to a separatory funnel, and washed 2 Ã 20 mL with 1 N HCl, and the aqueous layers were combined and adjusted to pH 12 with 2 N KOH. The resulting basic layer was extracted 3 Ã 100 mL with dichloromethane, and the combined dichloromethane extracts were dried over MgSO<sub>4</sub>, filtered through Celite, and concentrated under reduced pressure affording a yellow oil. The crude product was then purified by flash chromatography (silica gel; 7:3 ethyl acetate/hexanes), and the fraction with an <i>R</i><sub><i>f</i></sub> = 0.16 was collected and concentrated to dryness <i>in vacuo</i> affording 10.4 mg of compound <b>11</b> as a white solid. LRMS: <i>m</i>/<i>z</i> 285.3 (MH <sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.82 (1.5 H, d, <i>J =</i> 6.4 Hz), 1.00 (1.5 H, d, <i>J =</i> 7.2 Hz), 1.40â1.48 (1 H, m), 0.65 (0.5 H, d, <i>J =</i> 13.2 Hz), 0.70 (0.5 H, d, <i>J =</i> 13.6 Hz), 1.69â1.95 (4 H, m), 1.72 (1.5 H, s), 1.75 (1.5 H, s), 2.05â2.22 (1 H, m), 2.45 (1 H, br s), 3.21 (1 H, s), 3.28 (3 H, s), 4.70 (1 H, d, <i>J =</i> 12.4 Hz), 4.73 (1 H, d, t, <i>J =</i> 2.8 Hz), 4.77 (1 H, br s), 6.51 (0.5 H, d, <i>J =</i> 3.2 Hz), 6.55 (0.5 H, s), 7.02 (0.5 H, d, <i>J =</i> 3.6 Hz), 7.03 (0.5 H, d, <i>J =</i> 3.6 Hz), 8.26 (0.5 H, s), 8.28 (0.5 H, s).</div><div class="NLM_p last">Diastereomeric mixture <b>10</b> was prepared in an analogous manner to that described for <b>11</b> beginning with <i>R</i>-(â)-carvone.</div></div><div id="sec4_6_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-Methyl-<i>N</i>-((1<i>S</i>,2<i>R</i>,5<i>S</i>)-2-methyl-5-(prop-1-en-2-yl)cyclohexyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>12</b>)</h4><div class="NLM_p last">Compound <b>12</b> was isolated from diastereomeric mixture <b>11</b> by chiral HPLC (Chiralpak AD; 9:1 hexanes/isopropanol + 0.1% DEA modifier). The retention time for <b>12</b> was 8.26 min; its diastereomer came off at 13.26 min. The peaks were collected and concentrated to dryness <i>in vacuo</i>. Physical data for <b>12</b>: LRMS: <i>m</i>/<i>z</i> 285.5 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.01 (3 H, d, <i>J</i> = 6.8 Hz), 1.42 (sp t, <i>J</i> = 9.2 Hz), 1.58 (1 H, br d, <i>J</i> = 12.8 Hz), 1.63â1.94 (4 H, m), 1.75 (3 H, s), 2.11 (1 H, t, <i>J</i> = 11.6 Hz), 2.45 (1 H, br s), 3.30 (3 H, s), 4.73 (2 H, s), 4.77 (1 H, br s), 6.53 (1 H, d, <i>J</i> = 3.6 Hz), 7.04 (1 H, d, <i>J</i> = 3.6 Hz), 8.27 (1 H, s). 1D and 2D NMR structural assignments for <b>12</b> were consistent with the all-<i>cis</i> relative stereochemistry around the cyclohexane ring.</div></div><div id="sec4_6_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-Methyl-<i>N</i>-((1<i>S</i>,2<i>R</i>,5<i>S</i>)-2-methyl-5-(prop-1-en-2-yl)cyclohexyl)-7-(phenylsulfonyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>13</b>)</h4><div class="NLM_p last">To 5 mL of dimethylformamide (DMF) was added 217 mg (5.43 mmol) of sodium hydride and after cooling to 0 Â°C was added 1.02 g (3.59 mmol) of <b>12</b> dissolved in 5 mL of DMF dropwise over a 10-min period. After bubbling ceased, 685 Î¼L of phenylsulfonyl chloride was added, and the mixture was brought to room temperature and stirred for 1.5 h, at which time the reaction was quenched upon addition of 10 mL of water. The resulting mixture was then extracted 3 Ã 10 mL with dichloromethane, and the combined extracts were washed 2 Ã with water and 2 Ã with saturated brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure producing 1.1 g of a yellow oil. The oil was purified by flash chromatography (silica gel; 9:1 hexanes/ethyl acetate) affording 748 mg (50%) of <b>13</b> as a white solid. LRMS: <i>m</i>/<i>z</i> 425.3 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.94 (3 H, d, <i>J</i> = 7.2 Hz), 1.39 (1 H, dd, <i>J</i> = 13.2 Hz, <i>J</i> = 3.6 Hz), 1.49â1.65 (2 H, m), 1.72 (3 H, s), 1.75â1.86 (2 H, m), 2.06 (1 H, t, <i>J</i> = 12.0 Hz), 2.33 (1 H, br s), 3.18 (3 H, s), 4.64 (1 H, br s), 4.71 (2 H, s), 6.58 (1 H, d, <i>J</i> = 3.6 Hz), 7.42 (1 H, d, <i>J</i> = 4.4 Hz), 7.47 (2 H, d, <i>J</i> = 8.0 Hz), 7.56 (1 H, t, <i>J</i> = 2.0 Hz), 8.15 (2 H, d, <i>J</i> = 8.8 Hz), 8.37 (1 H, s).</div></div><div id="sec4_6_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (<i>R</i>)-2-((1<i>S</i>,3<i>S</i>,4<i>R</i>)-4-Methyl-3-(methyl(7-(phenylsulfonyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)propan-1-ol (<b>14</b>)</h4><div class="NLM_p last">To a stirred solution of <b>13</b> (745 mg/1.76 mmol) in 5 mL of THF was added 7.0 mL (3.50 mmol) of 9-borabicyclo(3.3.1)nonane (9-BBN) (0.5 M in THF; Aldrich), and the resulting solution was heated to reflux for 18 h (reaction incomplete by TLC). Additional 9-BBN (7.0 mL) was added with continued refluxing for 2 h, at which time the reaction was cooled to room temperature, and water (10 mL) slowly added. The reaction mixture was partitioned between saturated NaHCO<sub>3</sub> and dichloromethane, and the organic layer was washed 2 Ã with water and with saturated brine, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The resulting crude oil was then purified by flash chromatography (silica gel; 1:1 hexanes/ethyl acetate) affording 428 mg (55%) of <b>14</b> as a white solid. LRMS: <i>m</i>/<i>z</i> 443.1 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.85â0.97 (6 H, m), 1.20â1.29 (1 H, m), 1.47 (1 H, d, <i>J</i> = 16.4 Hz), 1.55â1.64 (4 H, m), 1.65â1.80 (1 H, m), 2.33 (1 H, br s), 3.19 (3 H, s), 3.44â3.56 (1 H, m), 3.58â3.63 (1 H, m), 4.59 (1 H, br s), 6.58 (1 H, d, <i>J</i> = 3.6 Hz), 7.43 (1 H, d, <i>J</i> = 4.0 Hz), 7.49 (2 H, d, <i>J</i> = 8.0 Hz), 7.57 (1 H, t, <i>J</i> = 2.0 Hz), 8.16 (2 H, d, <i>J</i> = 7.2 Hz), 8.38 (1 H, s).</div></div><div id="sec4_6_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>R</i>)-2-((1<i>S</i>,3<i>S</i>,4<i>R</i>)-4-Methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)propan-1-ol (<b>16a</b>)</h4><div class="NLM_p last">To a stirred solution of <b>14</b> (400 mg/0.90 mmol) in 10 mL of THF at room temperature was added â¼10 mL of a solution made by dissolving sodium hydroxide pellets in methanol. The resulting mixture was stirred until the reaction was complete by TLC (â¼3 h). To the reaction was then added 50 mL of water, and the mixture was extracted 3 Ã with ethyl acetate. The combined extracts were washed 2 Ã with water and saturated brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness <i>in vacuo</i>, affording 196 mg (72%) of <b>16a</b> as a white solid. This material could also be prepared by direct hydroboration of compound <b>12</b> using 9-BBN. LRMS: <i>m</i>/<i>z</i> 303.5 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.81 (1.5 H, d, <i>J</i> = 6.4 Hz), 0.86â1.00 (4.5 H, m), 1.14â1.26 (1 H, m), 1.37â2.49 (5 H, m), 1.55â2.64 (5 H, m), 3.21 (1 H, br s), 3.44â3.59 (1 H, m), 3.60â3.63 (1 H, m), 4.70 (1 H, br s), 6.48 (1 H, d, <i>J</i> = 3.6 Hz), 6.56 (1 H, br s), 7.00 (1 H, d, <i>J</i> = 3.6 Hz), 8.22 (0.5 H, s), 8.44 (0.5 H, s).</div></div><div id="sec4_6_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>,<i>N</i>-Diethyl-2-((<i>R</i>)-2-((1<i>S</i>,3<i>S</i>,4<i>R</i>)-4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)propoxy)acetamide (<b>16b</b>)</h4><div class="NLM_p last">To a slurry of sodium hydride (7.0 mg, 60% dispersion) in 0.5 mL of DMF at 0 Â°C was added 49 mg (0.112 mmol) of <b>14</b> dissolved in 0.5 mL of DMF, the resulting mixture stirred at 0 Â°C for 30 min, at which time 15 Î¼L (0.113 mmol) of 2-chloro-<i>N</i>,<i>N</i>-diethylacetamide (Aldrich) was added, and the resulting solution was stirred at 0 Â°C for 4 h, at which time 10 mL of water was added. This mixture was then extracted 3 Ã 15 mL with ethyl acetate, and the combined extracts were washed with 10 mL of water and then 10 mL of saturated brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure affording 45 mg of intermediate <b>15b</b>. This material (<b>15b</b>) was then dissolved in 1.0 mL of THF, and to this solution was added 1.0 mL of a solution made by dissolving NaOH pellets in methanol. The resulting mixture was stirred until the reaction was complete by TLC (â¼30 min). To the reaction was then added 10 mL of water, and the mixture was extracted 3 Ã with ethyl acetate. The combined extracts were washed 2 Ã with water and saturated brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness <i>in vacuo</i>, affording 20 mg (61%) of <b>16b</b> as a colorless oil. LRMS: <i>m</i>/<i>z</i> 416.4 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.78â0.92 (1 H, m), 0.93â0.96 (1 H, m), 0.97 (3 H, d, <i>J</i> = 7.6 Hz), 1.10 (3 H, t, <i>J</i> = 7.2 Hz), 1.16â1.20 (3 H, m), 1.24 (1 H, s), 1.43 (2 H, br s), 1.52â1.63 (4 H, m), 1.75 (2 H, q, <i>J</i> = 4.0 Hz), 3.15â2.28 (1 H, m), 3.30 (3 H, s), 3.31 (2 H, s), 3.32â3.43 (2 H, m), 4.69 (2 H, br s), 5.01 (4 H, q, <i>J</i> = 11.6 Hz), 6.52 (1 H, d, <i>J</i> = 3.6 Hz), 7.01 (1 H, d, <i>J</i> = 3.6 Hz), 8.27 (1 H, s).</div></div><div id="sec4_6_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-Methyl-2-((<i>R</i>)-2-((1<i>S</i>,3<i>S</i>,4<i>R</i>)-4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)propoxy)acetamide (<b>16c</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 374.1 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.78â1.03 (6 H, m), 1.18â1.84 (9 H, m), 3.27 (1.5 H, s), 3.32 (1.5 H, s), 3.49â3.59 (1 H, m), 3.60â3.69 (1 H, m), 3.91â4.06 (1 H, m), 4.21 (1 H, q, <i>J</i> = 4.0 Hz), 4.72 (1 H, br s), 6.45 (1 H, br s), 6.47 (0.5 H, d, <i>J</i> = 12.0 Hz), 6.52 (0.5 H, d, <i>J</i> = 2.8 Hz), 6.92 (0.5 H, d, <i>J</i> = 3.6 Hz), 6.99 (0.5 H, d, <i>J</i> = 3.6 Hz), 8.23 (0.5 H, s), 8.31 (0.5 H, s).</div></div><div id="sec4_6_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-Benzyl-2-((<i>R</i>)-2-((1<i>S</i>,3<i>S</i>,4<i>R</i>)-4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)propoxy)acetamide (<b>16d</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 450.1 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.78â1.03 (6 H, m), 1.37â1.82 (6 H, m), 2.41 (2 H, br s), 3.23 (3 H, s), 3.26 (1 H, s), 3.29 (1 H, s), 3.44â3.53 (1 H, m), 3.59â3.68 (1 H, m), 4.20 (1 H, q, <i>J</i> = 7.2 Hz), 4.37 (1 H, d, <i>J</i> = 6.4 Hz), 4.45 (1 H, dd, <i>J</i> = 6.4 Hz, <i>J</i> = 4.4 Hz), 4.71 (2 H, d, <i>J</i> = 5.2 Hz), 6.44 (1 H, br s), 6.55 (1 H, d, <i>J</i> = 3.6 Hz), 6.95 (1 H, d, <i>J</i> = 3.6 Hz), 7.19â7.35 (5 H, m), 8.24 (1 H, s).</div></div><div id="sec4_6_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>R</i>)-2-((1<i>S</i>,3<i>S</i>,4<i>R</i>)-4-Methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)propyl Diethylcarbamate (<b>16e</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 402.5 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.72â1.00 (6 H, m), 1.18 (1 H, t, <i>J</i> = 1.2 Hz), 1.22 (3 H, s), 1.23 (3 H, s), 1.39â1.82 (6 H, m), 3.18â3.35 (7 H, m), 3.43â3.66 (1 H, m), 3.87â4.03 (1 H, m), 4.14 (1 H, dd, <i>J</i> = 5.6 Hz, <i>J</i> = 25 Hz), 0.67 (1 H, br s), 6.44 (1 H, br s), 6.82 (1 h, t, <i>J</i> = 4.4 Hz), 6.97 (1 H, d, <i>J</i> = 3.6 Hz), 8.25 (1 H, t, <i>J</i> = 6.2 Hz).</div></div><div id="sec4_6_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>cis</i>-<i>N</i>-Methyl-<i>N</i>-(4-methyl-1-(2,2,2-trifluoroethylsulfonyl)piperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>17a</b>)</h4><div class="NLM_p last">Compound <b>19</b> was deprotected as described above; however, the intermediate hydrogenolysis product <i>cis</i>-<i>N</i>-methyl-<i>N</i>-(4-methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine was isolated by filtration through Celite and concentration under reduced pressure. LRMS: <i>m</i>/<i>z</i> 246.0 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 1.00â1.13 (5 H, m), 1.80 (1 H, br s), 1.95 (1 H, br s), 2.43 (1 H, br s), 3.07â3.18 (1 H, m), 3.38 (1 H, dd, <i>J =</i> 7.6 Hz, <i>J =</i> 4.8 Hz), 3.41 (3 H, s), 3.52 (1 H, q, H = 7.2 Hz), 3.61 (1 H, q, <i>J =</i> 8.8 Hz), 6.74 (1 H, br s), 7.11 (1 H, d, <i>J =</i> 3.2 Hz), 8.35 (1 H, br s). <sup>13</sup>C NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 14.2, 29.4, 32.3, 38.5, 41.7, 43.9, 57.4, 104.3, 104.6, 123.2, 148.9, 149.5, 158.1. HRMS: calcd for C<sub>13</sub>H <sub>20</sub>N<sub>5</sub> (MH<sup>+</sup>) 246.1713, found 246.1715. To this material (30 mg/0.122 mmol) dissolved in 1.0 mL of dichloromethane containing 0.1 mL of pyridine was added 20 Î¼L (0.181 mmol) of 2,2,2-trifluoroethanesulfonyl chloride, and the resulting mixture was stirred at room temperature for 16 h. The reaction mixture was then partitioned between dichloromethane and saturated sodium bicarbonate, the aqueous layer was back-washed 2 Ã with dichloromethane, and the combined organic layers dried over sodium sulfate and concentrated to dryness <i>in vacuo</i>. The crude product was then purified by preparative TLC (silica gel; 20:1 dichloromethane/methanol) affording 9 mg (19%) of <b>17a</b> as a white powder. LRMS: <i>m</i>/<i>z</i> 392.1 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.03 (3 H, d, <i>J =</i> 6.8 Hz), 1.78â1.96 (2 H, m), 2.35 (1 H, br s), 3.55 (1 H, dd, <i>J =</i> 14.8 Hz, <i>J =</i> 4.0 Hz), 3.58 (3 H, s), 3.61â3.75 (1 H, s), 3.75 (2 H, q, <i>J =</i> 9.6 Hz), 3.83 (1 H, dd, <i>J =</i> 8.2 Hz, <i>J =</i> 5.6 Hz), 5.39 (1 H, d, <i>J =</i> 4.0 Hz), 6.61 (1 H, d, <i>J =</i> 3.2 Hz), 7.11 (1 H, d, <i>J =</i> 3.6 Hz), 8.23 (1 H, s). <sup>13</sup>C NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 15.2, 30.8, 32.0, 35.9, 43.9, 47.1, 52.4, 52.5, 103.3, 120.3, 121.6, 123.1, 145.8, 158.2. HRMS: calcd for C<sub>15</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S (MH<sup>+</sup>) 392.1363, found 392.1369.</div></div><div id="sec4_6_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>cis</i>-4-Methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(3-methylisothiazol-5-yl)piperidine-1-carboxamide (<b>17b</b>)</h4><div class="NLM_p last">To a stirred solution of 3-methylisoxazol-5-amine (100 mg/1.00 mmol) in 2 mL of acetonitrile was added 103 mg (0.66 mmol) of phenylchloroformate, and the resulting mixture was stirred at room temperature for 18 h. The reaction mixture was then diluted with dichloromethane, washed with saturated NaHCO<sub>3</sub>, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness <i>in vacuo</i>. The intermediate phenyl (3-methylisoxazol-5-yl)carbamate was carried on without further purification by forming a slurry in <i>tert</i>-butanol (2 mL) and adding 50 mg (0.20 mmol) of <i>cis</i>-<i>N</i>-methyl-<i>N</i>-(4-methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine; the resulting reaction mixture was heated to 80 Â°C for 48 h. After being cooled to room temperature the reaction was concentrated under reduced pressure, redissolved in dichloromethane, washed with saturated NaHCO<sub>3</sub>, dried over MgSO<sub>4</sub>, filtered through Celite, and concentrated to dryness <i>in vacuo</i>. The crude product was then purified by preparative TLC (silica gel; 10:1 dichloromethane/methanol) affording 7 mg of pure <b>17b</b> after two chromatographies. LRMS: <i>m</i>/<i>z</i> 386.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 1.12 (3 H, d, <i>J =</i> 7.2 Hz), 1.70â2.00 (4 H, m), 2.30 (3 H, s), 2.45â2.56 (1 H, m), 3.44 (3 H, s), 3.67 (2 H, t, <i>J =</i> 6.0 Hz), 3.88â4.02 (1 H, m), 4.94 (1 H, br s), 6.62 (1 H, s), 6.71 (1 H, d, <i>J =</i> 3.6 Hz), 7.16 (1 H, d, <i>J =</i> 3.6 Hz), 8.15 (1 H, s). <sup>13</sup>C NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 14.7, 18.8, 32.0, 33.3, 35.6, 42.6, 45.6, 104.0, 104.2, 107.7, 122.6, 155.8, 164.7, 164.9. HRMS: calcd for C<sub>18</sub>H<sub>24</sub>N<sub>7</sub>OS 386.1758 (MH<sup>+</sup>), found 386.1751.</div></div><div id="sec4_6_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>cis</i>-<i>N</i>-(1-(2,3-Difluorobenzyl)-4-methylpiperidin-3-yl)-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>17c</b>)</h4><div class="NLM_p last">To a stirred solution of <i>cis</i>-<i>N</i>-methyl-<i>N</i>-(4-methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (50 mg/0.20 mmol) and 156 Î¼L (1.43 mmol) of 2,3-difluorobenzaldehyde in 3 mL of anhydrous methanol was added 20 mg (0.31 mmol) of sodium cyanoborohydride, and the resulting mixture was stirred at room temperature for 3 h, at which time a second portion of sodium cyanoborohydride was added, and the resulting mixture was stirred for 72 h. The reaction was quenched upon addition of 2 drops of 1 N NaOH, and the reaction was concentrated under reduced pressure. Water was added, the mixture was extracted 3 Ã with chloroform, and the combined chloroform extracts were dried over MgSO<sub>4</sub>, filtered through Celite, and concentrated to dryness <i>in vacuo</i>. The crude product was then purified by flash chromatography (silica gel; 4% methanol in chloroform) affording 24 mg (32%) of <b>17c</b> as a white solid. LRMS: <i>m</i>/<i>z</i> 372.3 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.93 (3 H, d, <i>J =</i> 7.2 Hz), 1.60â1.85 (4 H, m), 2.30 (1 H, br s), 2.62â2.83 (2 H, m), 2.87â2.96 (1 H, m), 3.59 (2 H, s), 3.61 (3 H, s), 5.22 (1 H, br s), 6.58 (1 H, d, <i>J =</i> 4.0 Hz), 6.95â7.08 (3 H, m), 7.13 (1 H, t, <i>J =</i> 5.2 Hz), 8.22 (1 H, s). HRMS: calcd for C<sub>20</sub>H <sub>24</sub>N<sub>5</sub>F<sub>2</sub> (MH<sup>+</sup>) 372.1994, found 372.1985.</div></div><div id="sec4_6_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>cis</i>-2-Hydroxy-1-(4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone (<b>17d</b>)</h4><div class="NLM_p last">To a stirred solution of <i>cis</i>-<i>N</i>-methyl-<i>N</i>-(4-methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (200 mg/0.82 mmol) and 163 mg (0.98 mmol) of 2-(benzyloxy)acetic acid in 10 mL of dichloromethane at 0 Â°C was added 188 mg (0.98 mmol) of 1-ethyl-3-(3-dimethyaminopropyl)carbodiimide followed by 26 mg (0.21 mmol) of 4-dimethylaminopyridine, and the resulting mixture was brought to room temperature and stirred for 24 h, at which time the reaction mixture was partitioned between dichloromethane and saturated NaHCO<sub>3</sub>. The dichloromethane layer was dried over MgSO<sub>4</sub>, filtered through Celite, and concentrated to dryness <i>in vacuo</i> affording crude 2-(benzyloxy)-1-(4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone, which was purified by flash chromatography (silica gel; 4% methanol in dichloromethane) affording 170 mg (53%) of this pure intermediate. LRMS: <i>m</i>/<i>z</i> 394.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) (amide rotamers) Î´: 1.06 (1.5 H, d, <i>J =</i> 7.2 Hz), 1.09 (1.5 H, d, <i>J =</i> 7.2 Hz), 1.61â1.74 (1 H, m), 1.80â1.91 (1 H, m), 2.40â2.52 (1 H, m), 3.31 (1.5 H, s), 3.35 (1.5 H, s), 3.37â6.64 (1 H, m), 3.72â3.99 (2 H, m), 4.09 (0.5 H, 1/2 AB q, <i>J =</i> 12.8 Hz), 4.25 (0.5 H, 1/2 AB q, <i>J =</i> 13.2 Hz), 4.27 (2 H, s), 4.27 (1 H, d, <i>J =</i> 4.8 Hz), 4.59 (2 H, s), 4.83â5.03 (1 H, m), 6.56 (0.5 H, d, <i>J =</i> 3.2 Hz), 6.61 (0.5 H, d, <i>J =</i> 3.2 Hz), 7.00â7.15 (3 H, m), 7.25â7.41 (3 H, m), 8.07 (0.5 H, s), 8.08 (0.5 H, s). HRMS: calcd for C<sub>22</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub> (MH<sup>+</sup>) 394.2238, found 394.2239. To this compound (1.5 g, 3.81 mmol) dissolved in 75 mL of ethanol was added 2.6 g (1.9 mmol) of 20% Pd(OH)<sub>2</sub> on carbon (50% water), and the resulting mixture was agitated under a 50 psi atmosphere of hydrogen gas for 48 h (catalyst was recharged once during this time frame). The reaction mixture was filtered through Celite and concentrated to dryness to produce 720 mg of crude product, which was purified by flash chromatography (silica gel; 10% methanol in dichloromethane) affording 480 mg (42%) of compound <b>17d</b> as a colorless glass. LRMS: <i>m</i>/<i>z</i> 304.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) (amide rotomers) Î´: 1.00â1.13 (3 H, m), 1.61â1.77 (1 H, m), 1.82â1.98 (1 H, m), 3.22â3.47 (2 H, m), 3.41 (3 H, s), 3.65 (1 H, q, <i>J =</i> 7.2 Hz), 3.71â3.85 (2 H, m), 4.09â4.28 (1 H, m), 4.22 (2 H, s), 5.05â5.22 (1 H, m), 6.52 (1 H, s), 7.05 (0.5 H, d, <i>J =</i> 3.2 Hz), 7.08 (0.5 H, d, <i>J =</i> 3.2 Hz), 8.25 (0.5 H, s), 8.27 (0.5 H, s), 10.80 (1 H, br s). <sup>13</sup>C NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 14.0, 14.9, 30.4, 31.4, 31.8, 32.2, 34.4, 35.1, 40.0, 40.6, 42.6, 44.9, 52.8, 53.0, 60.0, 102.3, 102.4, 103.0, 120.2, 120.4, 150.4, 150.6, 157.7, 157.8, 170.3, 170.4. HRMS: calcd for C<sub>15</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub> (MH<sup>+</sup>) 304.1767, found 304.1764.</div></div><div id="sec4_6_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>cis</i>-(5-Chloro-2,3-dihydrobenzofuran-2-yl)(4-methyl-3-(methyl(7H-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)methanone (<b>18a</b>)</h4><div class="NLM_p">To a stirred solution of <i>cis</i>-<i>N</i>-methyl-<i>N</i>-(4-methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (50 mg/0.20 mmol) and 5-chloro-2,3-dihydrobenzofuran-2-carboxylic acid (50 mg/0.25 mmol) in 6 mL of dimethylformamide cooled to 0 Â°C was added 40 mg (0.21 mmol) of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and the resulting mixture was warmed to room temperature and stirred for 16 h, at which point the reaction mixture was partitioned between dichloromethane and saturated NaHCO<sub>3</sub>. The aqueous layer was extracted a second time with dichloromethane, and the combined dichloromethane layers were dried over MgSO<sub>4</sub>, filtered through Celite, and concentrated to dryness <i>in vacuo</i>. The crude product was then purified by preparative TLC (silica gel; 19:1 dichloromethane/methanol) affording 22 mg (26%) of <b>18a</b> as a colorless oil (â¼3:1 mixture of diastereomers). LRMS: <i>m</i>/<i>z</i> 426.3 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.85â1.00 (0.75 H, m), 1.05â1.18 (2.25 H, m), 1.83â2.13 (1 H, m), 2.43â2.71 (1 H, m), 3.15â3.42 (3 H, m), 3.44 (0.75 H, s), 3.48 (2.25 H, s), 3.53â4.27 (4 H, m), 5.21 (1 H, br s), 5.38 (1 H, dd, <i>J =</i> 7.6 Hz, <i>J =</i> 2.4 Hz), 5.46 (1 H, dd, <i>J =</i> 7.6 Hz, <i>J =</i> 2.4 Hz), 6.39â6.78 (2 H, m), 6.90â7.36 (3 H, m), 8.23â8.35 (1 H, m).</div><div class="NLM_p last">Compounds <b>18b</b> through <b>18m</b> were prepared in an analogous manner to that described for <b>17a</b>. The NMR data for these indicate the presence of amide rotamers.</div></div><div id="sec4_6_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 1-Benzyl-3-(4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidine-1-carbonyl)pyrrolidin-2-one (<b>18b</b>)</h4><div class="NLM_p last">Liquid chromatography mass spectrometry (LCMS): <i>m</i>/<i>z</i> 447.4 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 0.81â1.26 (4 H, m), 1.54â1.65 (1 H, m), 1.73â1.92 (1 H, m), 2.40 (1 h, br s), 2.52â2.80 (2 H, m), 3.20 (1.5 H, s), 3.25 (1.5 H, s), 3.29â3.98 (6 H, m), 4.31â4.52 (2 H, m), 6.54â6.64 (1 h, m), 7.04â7.07 (1 H, m), 7.15â7.33 (5 H, m), 8.04â8.06 (1 H, m).</div></div><div id="sec4_6_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>cis</i>-2-Cyclopentyl-1-(4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone (<b>18c</b>)</h4><div class="NLM_p last">Amide rotamers. LRMS: <i>m</i>/<i>z</i> 356.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.01 (3 H, s), 0.90â1.18 (2 H, m), 1.37â1.89 (7 H, m), 1.67 (2 H, s), 2.15â2.50 (4 H, m), 3.30 (1.5 H, s), 3.35 (1.5 H, s), 3.47 (1 H, s), 3.77 (2 H, br s), 3.78 (0.5 H, t, <i>J =</i> 6.8 Hz), 4.07 (0.5 H, d, <i>J =</i> 11.6 Hz), 4.95 (0.5 H, s), 5.05 (0.5 H, s), 6.46 (1 H, s), 6.97 (1 H, d, <i>J =</i> 14.0 Hz), 8.22 (1 H, d, <i>J =</i> 11.2 Hz), 10.15 (0.5 H, br s), 10.22 (0.5 H, br s). <sup>13</sup>C NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 14.1, 14.9, 24.9, 25.0, 30.7, 31.9, 31.9, 32.4, 32.7, 32.8, 34.3, 35.0, 36.6, 36.8, 39.0, 39.4, 39.5, 41.7, 42.7, 47.1, 53.3, 102.3, 102.4, 102.8, 119.7, 120.1, 150.8, 150.9, 151.7, 152.0, 157.8, 157.9, 171.4, 171.6. HRMS: calcd for C<sub>20</sub>H<sub>30</sub>N<sub>5</sub>O (MH<sup>+</sup>) 356.2445, found 356.2438.</div></div><div id="sec4_6_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 3-(4-Methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidine-1-carbonyl)cyclopentanone (<b>18d</b>)</h4><div class="NLM_p last">LCMS: <i>m</i>/<i>z</i> 356.4 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 0.81â0.93 (1 H, m), 1.02â1.15 (2 H, m), 1.60â1.75 (1 H, m), 1.82â1.94 (1 H, m), 2.00â2.52 (5 H, m), 3.03â3.12 (1 H, m), 3.27 (2 H, s), 3.39 (1 H, s), 3.46â3.63 (2 H, m), 3.68â3.73 (1 H, m), 3.80â4.02 (2 H, m), 4.95 (1 H, br s), 6.59â6.60 (1 H, m), 7.05â7.07 (1 H, m), 8.06 (0.7 H, s), 8.09 (0.3 H, s).</div></div><div id="sec4_6_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (4-Methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)(thiophen-3-yl)methanone (<b>18e</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 356.3 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.95â1.15 (4 H, m), 1.22â1.34 (1 H, m), 1.68 (2 H, br s), 3.40 (3 H, s), 3.63 (2 H, br s), 3.85 (2 H, t, <i>J</i> = 8.8 Hz), 5.13 (1 H, br s), 6.54 (1 H, d, <i>J</i> = 3.6 Hz), 7.05 (1 H, d, <i>J</i> = 4.0 Hz), 7.19 (1 H, d, <i>J</i> = 5.6 Hz), 7.30 (1 H, br s), 7.53 (1 H, s), 8.28 (1 H, s).</div></div><div id="sec4_6_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (4-Methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)(tetrahydrofuran-3-yl)methanone (<b>18f</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 344.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.00â1.04 (3 H, m), 1.78 (1 H, br s), 1.75â1.80 (1 H, m), 1.81â2.51 (3 H, m), 3.10â3.34 (2 H, m), 3.23 (3 H, s), 3.40â3.91 (6 H, m), 4.05 (1 H, sp 1/2 ABq), 5.00 (1 H, 1/2 ABq, <i>J =</i> 60 Hz), 6.44 (1 H, d, <i>J =</i> 10.4 Hz), 7.00 (1 H, dd, <i>J =</i> 16.0 Hz, <i>J =</i> 3.2 Hz), 8.21 (0.5 H, s), 8.25 (0.5 H, s), 11.58 (0.5 H, s), 11.80 (0.5 H, s). <sup>13</sup>C NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 13.9, 14.0, 14.7, 14.9, 30.0, 30.1, 30.3, 30.7, 31.8, 31.9, 32.0, 32.2, 32.3, 34.3, 35.1, 35.2, 39.4, 39.6, 41.2, 41.3, 41.5, 41.5, 42.1, 42.4, 46.7, 46.9, 53.3, 53.7, 68.4, 68.5, 70.5, 70.6, 70.7, 102.0, 102.1, 103.0, 103.1, 120.2, 120.6, 150.6, 151.9, 152.0, 157.7, 157.8, 171.3, 171.7. HRMS: calcd for C<sub>18</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub> (MH<sup>+</sup>) 344.2081, found 344.2075.</div></div><div id="sec4_6_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>cis</i>-Cyclopentyl(4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)methanone (<b>18g</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 342.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 0.95â1.05 (3 H, m), 1.38â1.88 (7 H, m), 2.37â2.38 (2 H, m), 2.79â2.89 (2 H, m), 3.29 (1.5 H, s), 3.35 (1.5 H, s), 3.52â3.68 (4 H, m), 3.82 (0.5 H, q, <i>J =</i> 7.6 Hz), 4.09 (0.5 H, d, <i>J =</i> 10.4 Hz), 4.93 (0.5 H, br s), 5.05 (0.5 H, br s), 6.44 (0.5 H, s), 6.46 (0.5 H, s), 6.98 (0.5 H, d, <i>J =</i> 2.8 Hz), 7.03 (0.5 H, d, <i>J =</i> 2.8 Hz), 8.21 (0.5 H, s), 8.25 (0.5 H, s), 11.26 (0.5 H, br s), 11.47 (0.5 H, br s). <sup>13</sup>C NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 14.2, 14.9, 16.0, 30.1, 30.1, 30.4, 30.7, 32.0, 32.1, 32.5, 34.3, 35.1, 39.3, 41.1, 41.4, 42.1, 42.5, 46.9, 53.3, 102.1, 102.3, 102.9, 120.0, 120.4, 150.7, 151.9, 157.8, 174.6, 175.0. HRMS: calcd for C<sub>19</sub>H<sub>28</sub>N<sub>5</sub>O (MH<sup>+</sup>) 342.2288, found 342.2280.</div></div><div id="sec4_6_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 1-(4-Methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)-2-(methylsulfonyl)ethanone (<b>18h</b>)</h4><div class="NLM_p last">LCMS: <i>m</i>/<i>z</i> 366.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CD<sub>3</sub>OD) Î´: 1.05 (2 H, d, <i>J</i> = 6.8 Hz), 1.11 (1 H, d, <i>J</i> = 7.2 Hz), 1.61â1.95 (2 H, m), 2.06â2.15 (1 H, m), 1.40â1.53 (1 H, m), 3.11 (2 H, s), 3.13 (1 H, s), 3.59â3.68 (1 H, m), 3.80â4.09 (2 H, m), 4.35â4.63 (2 H, m), 4.99â5.12 (1 H, m), 6.62 (1 H, d, <i>J</i> = 3.6 Hz), 7.08â7.89 (1 H, m), 8.10 (0.6 H, s), 8.15 (0.4 H, s).</div></div><div id="sec4_6_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>cis</i>-2-Cyclopropyl-1-(4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone (<b>18i</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 328.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: â0.01â0.04 (2 H, m), 0.24â0.41 (2 H, m), 0.78â0.94 (3 H, m), 1.48 (1 H, br s), 1.59â1.76 (1 H, m), 1.94â2.38 (4 H, m), 3.16 (1.5 H, s), 3.20 (1.5 H, s), 3.31 (1 H, d, <i>J =</i> 4.8 Hz), 3.39â3.58 (2 H, m), 3.59â3.68 (0.5 H, m), 3.93 (0.5 H, d, <i>J =</i> 9.6 Hz), 4.82 (0.5 H, br s), 4.92 (0.5 H, br s), 6.31 (0.5 H, s), 6.32 (0.5 H, s), 6.85 (0.5 H, d, <i>J =</i> 3.2 Hz), 6.89 (0.5 H, d, <i>J =</i> 2.8 Hz), 8.07 (0.5 H, s), 8.10 (0.5 H, s), 11.17 (0.5 H, br s), 11.37 (0.5 H, br s). <sup>13</sup>C NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 4.5, 4.7, 7.3, 7.4, 14.1, 14.9, 30.6, 31.9, 32.0, 32.4, 34.3, 35.0, 38.7, 38.9, 39.1, 41.8, 42.8, 47.1, 53.2, 53.5, 102.1, 102.3, 102.9, 120.1, 120.4, 150.7, 151.9, 152.0, 157.8, 157.9, 171.3, 171.5. HRMS: calcd for C<sub>18</sub>H<sub>26</sub>N<sub>5</sub>O (MH<sup>+</sup>) 328.2132, found 328.2124.</div></div><div id="sec4_6_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>cis</i>-3,3,3-Trifluoro-1-(4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)propan-1-one (<b>18j</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 356.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´ TMS: 0.97 (1.5 H, d, <i>J =</i> 7.2 Hz), 1.08 (1.5 H, d, <i>J =</i> 7.2 Hz), 1.60â1.70 (1 H, m), 1.79â1.94 (1 H, m), 2.37â2.50 (1 H, m), 3.14â3.37 (2 H, m), 3.20 (1.5 H, s), 3.35 (1.5 H, s), 3.40â3.62 (2 H, m), 3.72 (1 H, q, <i>J =</i> 12.8 Hz), 3.70â3.86 (0.5 H, m), 4.06 (0.5 H, d, <i>J =</i> 8.8 Hz), 5.05 (1 H, br s), 6.46 (0.5 H, d, <i>J =</i> 3.6 Hz), 6.47 (0.5 H, d, <i>J =</i> 5.2 Hz), 6.99 (0.5 H, d, <i>J =</i> 3.2 Hz), 7.04 (0.5 H, d, <i>J =</i> 3.2 Hz), 8.21 (0.5 H, s), 8.24 (0.5 H, s), 10.96 (1 H, br s), 11.15 (0.5 H, br s). <sup>13</sup>C NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 13.1, 13.6, 29.5, 29.9, 30.5, 30.8, 30.9, 33.3, 34.0, 36.9, 37.2, 37.5, 38.3, 41.4, 42.8, 46.3, 49.7, 51.7, 52.5, 101.0, 101.3, 101.9, 102.0, 119.1, 119.5, 121.8, 124.5, 149.6, 149.7, 150.9, 151.0, 156.7, 160.6, 161.0, 206.1. HRMS: calcd for C<sub>16</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O (MH<sup>+</sup>) 356.1693, found 356.1689.</div></div><div id="sec4_6_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 2,2-Dimethyl-3-(4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (<b>18k</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 341.3 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.09 (3 H, d, <i>J</i> = 7.2 Hz), 1.63 (6 H, s), 1.79 (1 H, br s), 1.99â2.16 (1 H, m), 2.51â2.57 (1 H, m), 3.28â3.42 (1 H, m), 3.42 (3 H, s), 3.88 (2 H, br s), 4.07 (1 H, d, <i>J</i> = 8.4 Hz), 5.15 (1 H, br s), 6.57 (1 H, d, <i>J</i> = 3.6 Hz), 7.09 (1 H, d, <i>J</i> = 3.2 Hz), 8.28 (1 H, s).</div></div><div id="sec4_6_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 2-Methyl-3-(4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (<b>18l</b>)</h4><div class="NLM_p last">LCMS: <i>m</i>/<i>z</i> 327.3 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.03â1.11 (3 H, m), 1.51â1.56 (3 H, m), 1.61 (1 H, br s), 1.78â1.96 (1 H, m), 2.08 (1 H, br s), 3.34 (1 H, s), 3.39 (2 H, s), 3.40â3.59 (1 H, m), 3.60â3.81 (2 H, m), 3.81â4.10 1.5 H, m), 4.21 (1/2 H, d, <i>J</i> = 13.2 Hz), 5.03 (1/2 H, br s), 5.10 (1/2 H, br s), 5.20 (1 H, br s), 6.51 (1/3 H, d, <i>J</i> = 3.2 Hz), 6.55 (2/3 H, d, <i>J</i> = 3.6 Hz), 7.05 (1 H, d, <i>J</i> = 3.6 Hz), 8.23 (1/3 H, s), 8.25 (2/3 H, s).</div></div><div id="sec4_6_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>cis</i>-3-(4-Methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (<b>18m</b>)</h4><div class="NLM_p last">LRMS: <i>m</i>/<i>z</i> 313.3 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.08 (1.5 H, d, <i>J =</i> 7.2 Hz), 1.10 (1.5 H, d, <i>J =</i> 7.2 Hz), 1.63â2.09 (2 H, m), 2.42â2.58 (1 H, m), 3.26â3.68 (2 H, m), 3.41 (1.5 H, s), 3.46 (1.5 H, s), 3.56 (2 H, s), 3.70â3.92 (1.5 H, m), 4.09 (0.5 H, dd, <i>J =</i> 8.8 Hz, <i>J =</i> 4.4 Hz), 5.16 (1 H, br s), 6.57 (1 H, t, <i>J =</i> 3.6 Hz), 7.10 (1 H, t, <i>J =</i> 3.6 Hz), 8.26 (1 H, s). HRMS: calcd for C<sub>16</sub>H<sub>21</sub>N<sub>6</sub>O (MH<sup>+</sup>) 313.1771, found 313.1776.</div></div><div id="sec4_6_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> ((<i>S</i>)-3-Hydroxypyrrolidin-1-yl)((3<i>R</i>,4<i>R</i>)-4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)methanone (<b>20</b>)</h4><div class="NLM_p last">To a stirred solution of (<i>S</i>)-pyrrolidin-3-ol (1.0 g/11.5 mmol) dissolved in 15 mL of dichloromethane and cooled to 0 Â°C was added 2.3 g (11.5 mmol) of 4-nitrophenylchloroformate followed by 1.6 mL (11.5 mmol) of triethylamine, and the resulting mixture was stirred at 0 Â°C for 1.5 h. The reaction mixture was then partitioned between water and chloroform, the aqueous layer was extracted 3 Ã 50 mL with chloroform, and the combined chloroform layers were dried over MgSO4, filtered through Celite, and concentrated to dryness <i>in vacuo</i> affording 2.9 g (quant) of the intermediate (<i>S</i>)-4-nitrophenyl 3-hydroxypyrrolidine-1-carboxylate as a yellow solid. LRMS: <i>m</i>/<i>z</i> 253.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.97â2.16 (2 H, m), 3.48â3.80 (4 H, m), 4.56â4.60 (1 H, m), 7.33 (2 H, dd, <i>J =</i> 6.8 Hz, <i>J =</i> 2.4 Hz), 8.25 (2 H, d, <i>J =</i> 8.8 Hz). HRMS: calcd for C<sub>11</sub>H<sub>13</sub>N <sub>2</sub>O<sub>5</sub> (MH<sup>+</sup>) 253.0819, found 253.0817. Separately, <i>N</i>-methyl-<i>N</i>-((3<i>R</i>,4<i>R</i>)-4-methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (50 mg/0.20 mmol), prepared from <b>19a</b> as described above, dissolved in 5 mL of <i>tert</i>-butanol, was charged to a pressure tube along with 76 mg (0.30 mmol) of (<i>S</i>)-4-nitrophenyl 3-hydroxypyrrolidine-1-carboxylate and 0.5 mL of triethylamine, and the sealed tube then heated at 100 Â°C for 48 h. After being cooled to room temperature the reaction mixture was partitioned between chloroform and saturated NaHCO <sub>3</sub>. The aqueous layer was extracted 3 Ã 30 mL with chloroform, and the combined chloroform layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through Celite, and concentrated to dryness <i>in vacuo</i>. The crude product was then purified by flash chromatography (silica gel; 10â15% methanol in chloroform). The product was then triturated with chloroform/hexanes to yield 24 mg (33%) of <b>20</b> as an off-white solid after drying. LRMS: <i>m</i>/<i>z</i> 359.2 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz) (CDCl<sub>3</sub>) Î´: 1.03 (3 H, d, <i>J =</i> 6.8 Hz), 1.60 (1 H, d, <i>J =</i> 10.8 Hz), 1.93 (2 H, br s), 2.45 (1 H, t, <i>J =</i> 5.2 Hz), 3.22 (1 H, t, <i>J =</i> 10.8 Hz), 3.36 (3 H, s), 3.37â3.71 (8 H, m), 4.44 (1 H, s), 4.94 (1 H, br s), 6.46 (1 H, s), 7.04 (1 H, d, <i>J =</i> 3.6 Hz), 8.20 (1 H, s), 11.81 (1 H, br s). <sup>13</sup>C NMR (400 MHz) (CDCl3) Î´: 13.8, 31.2, 31.5, 33.9, 34.9, 43.1, 45.5, 46.2, 54.8, 56.5, 70.4, 102.8, 102.9, 121.1, 147.3, 147.4, 157.6, 163.2. HRMS: calcd for C<sub>18</sub>H<sub>27</sub>N<sub>6</sub>O<sub>2</sub> (MH<sup>+</sup>) 359.2190, found 359.2188.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78"><a href="/doi/suppl/10.1021/jm1004286">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Additional HSA compounds (<b>6c</b>, S1âS63), with initial JAK3% inhibition data. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm1004286/suppl_file/jm1004286_si_001.pdf">jm1004286_si_001.pdf (143.22 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm1004286" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark E. Flanagan</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#335e5241581d561d555f525d5254525d7343555a4956411d505c5e"><span class="__cf_email__" data-cfemail="325f5340591c571c545e535c5355535c7242545b4857401c515d5f">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Todd A. Blumenkopf</span> - <span class="hlFld-Affiliation affiliation">Pfizer Global Research & Development, 50 Pequot Avenue, New London, Connecticut 06320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William H. Brissette</span> - <span class="hlFld-Affiliation affiliation">Yale University, New Haven, Connecticut 06520, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew F. Brown</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey M. Casavant</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chang Shang-Poa</span> - <span class="hlFld-Affiliation affiliation">Department of Statistics, University of Connecticut, 215 Glenbrook Road U-4120, Storrs, Connecticut 06269, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan L. Doty</span> - <span class="hlFld-Affiliation affiliation">Hill Road, East Lyme, Connecticut 06333, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eileen A. Elliott</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael B. Fisher</span> - <span class="hlFld-Affiliation affiliation">Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Hines</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Craig Kent</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth M. Kudlacz</span> - <span class="hlFld-Affiliation affiliation">Pfizer Global Research & Development, 50 Pequot Avenue, New London, Connecticut 06320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brett M. Lillie</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kelly S. Magnuson</span> - <span class="hlFld-Affiliation affiliation">Pfizer Global Research & Development, 50 Pequot Avenue, New London, Connecticut 06320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra P. McCurdy</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Munchhof</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bret D. Perry</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Perry S. Sawyer</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy J. Strelevitz</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chakrapani Subramanyam</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianmin Sun</span> - <span class="hlFld-Affiliation affiliation">Groton Laboratories, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David A. Whipple</span> - <span class="hlFld-Affiliation affiliation">Del Shankel Structural Biology Center, University of Kansas, 2034 Becker Drive, Lawrence, Kansas 66047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul S. Changelian</span> - <span class="hlFld-Affiliation affiliation">Lycera Corporation, 46701 North Commerce Center Drive, Plymouth, Michigan 48170, United States</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64335" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64335" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This research was sponsored by Pfizer Inc. The authors gratefully acknowledge Dr. Gary Chan MD and Dr. Samuel Zwillich MD for helpful conversations and for providing summaries of clinical results for <b>1</b> citrate relating to the prevention of renal allograft rejection and treatment of rheumatoid arthritis, respectively. The authors also acknowledge Daniel Virtue and Melissa Rockwell for chiral separations performed, Matthew Teague for high-resolution mass spectra, and Jon Bordner and Ivan Samardjiev for the single crystal X-ray structure of compound <b>20</b>. The support provided by Martin Goulding at Complete Medical Communications, funded by Pfizer Inc., consisted solely of manuscript editing and formatting, and no contribution was made to editorial content.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25315" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25315" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 43 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Stock, P. G.</span><span> </span><span class="NLM_article-title">The year in reviewâATC 2002</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1034%2Fj.1600-6143.2003.00115.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=12694058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A280%3ADC%252BD3s7nsF2itg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=373-380&author=P.+G.+Stock&title=The+year+in+review%E2%80%94ATC+2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The year in review--ATC 2002</span></div><div class="casAuthors">Stock Peter G</div><div class="citationInfo"><span class="NLM_cas:title">American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">373-80</span>
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    </div><div class="casAbstract">Strategies for dealing with the exponential growth of the waiting lists for solid organ transplants were the hottest clinical topics in 2002, and dominated the abstracts presented at ATC 2002.  Other clinical topics that were prominent in the 2002 literature and received the highest scores at ATC 2002 included: the development of immunosuppressive regimens minimizing calcineurin inhibitors and eliminating steroids; the increasing frequency and severity of hepatitis C recurrence following transplantation; the safety and efficacy of solid organ transplantation in HIV-positive recipients; the induction of tolerance with donor stem cell infusion and recipient preconditioning; the increasing incidence of BK virus; and beta-cell replacement for the treatment of diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_Sgaeh-ct3HELvajU9pjPfW6udTcc2eZ9MJgjmEtv-rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s7nsF2itg%253D%253D&md5=ee89bf62336cc19d3bca793efc48419a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-6143.2003.00115.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-6143.2003.00115.x%26sid%3Dliteratum%253Aachs%26aulast%3DStock%26aufirst%3DP.%2BG.%26atitle%3DThe%2520year%2520in%2520review%25E2%2580%2594ATC%25202002%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2003%26volume%3D3%26spage%3D373%26epage%3D380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hong, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahan, B. D.</span><span> </span><span class="NLM_article-title">Immunosuppressive agents in organ transplantation: past, present, and future</span> <span class="citation_source-journal">Semin. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">â</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=10746855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD3cXit12qtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=108-125&author=J.+C.+Hongauthor=B.+D.+Kahan&title=Immunosuppressive+agents+in+organ+transplantation%3A+past%2C+present%2C+and+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Immunosuppressive agents in organ transplantation: past, present, and future</span></div><div class="casAuthors">Hong, Johnny C.; Kahan, Barry D.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Nephrology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">108-125</span>CODEN:
                <span class="NLM_cas:coden">SNEPDJ</span>;
        ISSN:<span class="NLM_cas:issn">0270-9295</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review with 174 refs.  The development of immunosuppressive agents reflects the progress in understanding the cellular and mol. mechanisms which mediate allograft rejection.  Six paradigms represent the evolution of immunosuppressive strategies for organ transplantation.  The proliferation paradigm advances agents which interrupt lymphocyte cell division (azathioprine, cyclophosphamide, mycophenolic acid).  The depletion paradigm conscripts drugs that bind to lymphocyte cell surface markers, thereby producing cell lysis and/or inactivation (polyclonal ATGAM and thymoglobulin, and monoclonal OKT3 antilymphocyte antibodies).  The cytokine paradigm uses agents that interrupt lymphocyte maturational events; eg, synthesis (calcineurin inhibitors: cyclosporine/tacrolimus), binding to surface receptors (anti-CD25 mAbs), or signal transduction phases of cytokine stimulation (sirolimus).  The introduction of calcineurin inhibitors markedly reduces the rate of acute rejection episodes and increases short-term graft survival rates; nephrotoxicity and chronic allograft attrition remain as unanswered challenges.  The cyclosporine A (CsA) sparing property of sirolimus permits the use of lower exposure to calcineurin agents, allows for early withdrawal of steroid therapy, and may delay allograft senescence.  Furthermore, the combination of SRL with anti-IL-2R mAbs proffers an induction approach which allows prolonged periods of holiday from calcineurin inhibitors.  To address the tissue nonselectivity of the calcineurin and mTOR inhibitors, which presumably causes the drug toxicities, new agents are being developed to selectively inhibit the T cell target Janus Kinase 3.  In the costimulation paradigm, the accessory signals generated by antigen-presenting cells are interrupted by distinct agents: the receptor conjugate CTLA4-Ig and anti-B7 or anti-CD40 ligand mAbs.  Another set of drugs (selectin blocking agents, anti-ICAM-1 antisense deoxy oligonucleotides, and the lymphocyte homing inhibitor FTY720) seeks to modulate the ischemia-reperfusion injury, which exacerbates cytokine-mediated events in the donor and the subsequent procurement injury and may also accelerate the progression of transplant senescence.  Finally, the transplantation tolerance paradigm is based on the development of strategies which distort alloimmune recognition by antigen reactive cells (MHC peptides or proteins), produce anergy (costimulation blockers), functional inactivation, or deletion of antigen-reactive cells (donor bone marrow infusions and gene therapy).  Presently, the optimal immunosuppressive strategy uses combinations of agents that act in synergistic fashion to provide the potency, freedom from toxic reactions, convenience of administration, and cost appropriate for the individual patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfmCERP9sM_rVg90H21EOLACvtfcHk0lhGN1FVVm3hEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXit12qtLs%253D&md5=1ded3f89d274691cd914f80acf7da368</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DJ.%2BC.%26aulast%3DKahan%26aufirst%3DB.%2BD.%26atitle%3DImmunosuppressive%2520agents%2520in%2520organ%2520transplantation%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DSemin.%2520Nephrol.%26date%3D2000%26volume%3D20%26spage%3D108%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Darnell, J. E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, G. R.</span><span> </span><span class="NLM_article-title">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">â</span> <span class="NLM_lpage">1421</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1126%2Fscience.8197455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=8197455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1994&pages=1415-1421&author=J.+E.+J.+Darnellauthor=I.+M.+Kerrauthor=G.+R.+Stark&title=Jak-STAT+pathways+and+transcriptional+activation+in+response+to+IFNs+and+other+extracellular+signaling+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span></div><div class="casAuthors">Darnell, James E., Jr.; Kerr, Ian M.; Stark, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">5164</span>),
    <span class="NLM_cas:pages">1415-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with 97 refs.  Through the study of transcriptional activation in response to interferon Î± (IFN-Î±) and interferon Î³ (IFN-Î³), a previously unrecognized direct signal transduction pathway to the nucleus has been uncovered: IFN-receptor interaction at the cell surface leads to the activation of kinases of the Jak family that then phosphorylate substrate proteins called STATs (signal transducers and activators of transcription).  The phosphorylated STAT proteins move to the nucleus, bind specific DNA elements, and direct transcription.  Recognition of the mols. involved in the IFN-Î± and IFN-Î³ pathway has led to discoveries that a no. of STAT family members exist and that other polypeptide ligands also use the Jak-STAT mols. in signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo64rvN_qWlmLVg90H21EOLACvtfcHk0lhGN1FVVm3hEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D&md5=f63d2c7bb3c1aeca6f36fef38aff713c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.8197455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8197455%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DKerr%26aufirst%3DI.%2BM.%26aulast%3DStark%26aufirst%3DG.%2BR.%26atitle%3DJak-STAT%2520pathways%2520and%2520transcriptional%2520activation%2520in%2520response%2520to%2520IFNs%2520and%2520other%2520extracellular%2520signaling%2520proteins%26jtitle%3DScience%26date%3D1994%26volume%3D264%26spage%3D1415%26epage%3D1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">â</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1038%2Fni.1701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19295632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=356-360&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Selectivity+and+therapeutic+inhibition+of+kinases%3A+to+be+or+not+to+be%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">356-360</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases, which serve crit. functions in signaling pathways in all cells, are popular therapeutic targets.  At present, eight kinase inhibitors have been approved in the United States, each of which shows nanomolar potency.  Although the initial goal was to generate inhibitors with a high degree of selectivity, recent experience has revealed that many of these approved compds. target more than one kinase.  Surprisingly, this promiscuity is less problematic than one would have imagined; indeed, it opens new therapeutic opportunities.  In this Perspective, we discuss the present status of Janus kinase inhibitors-a new class of immunosuppressive drugs-and the advantages and disadvantages of selectively inhibiting this class of kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU0w6t4jgqirVg90H21EOLACvtfcHk0lg8fEpqjpoGbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D&md5=64dd47e897181d00e5dce6be3bc5db6e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fni.1701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1701%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSelectivity%2520and%2520therapeutic%2520inhibition%2520of%2520kinases%253A%2520to%2520be%2520or%2520not%2520to%2520be%253F%26jtitle%3DNat.%2520Immunol.%26date%3D2009%26volume%3D10%26spage%3D356%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">â</span> <span class="NLM_lpage">287</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lg8fEpqjpoGbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by IL-2 and related cytokines: JAKs, STATs and relationship to immunodeficiency</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=8864127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1996&pages=441-452&author=J.+A.+Johnstonauthor=C.+M.+Baconauthor=M.+C.+Riedyauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+IL-2+and+related+cytokines%3A+JAKs%2C+STATs+and+relationship+to+immunodeficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span></div><div class="casAuthors">Johnston, James A.; Bacon, Chris M.; Riedy, M. C.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 153 refs.  Cytokines that bind to the interleukin-2 (IL-2) receptor common gamma chain (Î³c), including IL-2, IL-4, IL-7, IL-9, and IL-15, are important for the growth and differentiation of T and B lymphocytes, natural killer cells, macrophages, and monocytes.  These cytokines have overlapping biol. effects that in part result from the use of the shared receptor subunit Î³c.  Recently it has become clear that these cytokines activate a no. of important intracellular signaling mols., including the Janus kinases JAK1 and JAK3 and members of the transcription factor family of signal transducers and activators of transcription (STATs).  The discovery of these signaling pathways has led to important new insights into their role of lymphocyte maturation, as it has emerged that mutations in the genes encoding both Î³c and JAK3 result in similar forms of severe combined immunodeficiency (SCID).  In this review we examine the structure and function of cytokine receptors and the signaling pathways involved in their regulation of gene expression.  Furthermore, we discuss recent advances that have led to a better understanding of how cytokines elicit intracellular responses, as well as their role in normal lymphoid development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBS-4Fw4Io7Vg90H21EOLACvtfcHk0lg8fEpqjpoGbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D&md5=6ccea65ed0126878728f639506a565ac</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DBacon%26aufirst%3DC.%2BM.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520IL-2%2520and%2520related%2520cytokines%253A%2520JAKs%252C%2520STATs%2520and%2520relationship%2520to%2520immunodeficiency%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D1996%26volume%3D60%26spage%3D441%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Oakes, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henninghausen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaese, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">â</span> <span class="NLM_lpage">615</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1996&pages=605-615&author=S.+A.+Oakesauthor=F.+Candottiauthor=J.+A.+Johnstonauthor=Y.+Q.+Chenauthor=J.+J.+Ryanauthor=N.+Taylorauthor=X.+Liuauthor=L.+Henninghausenauthor=L.+D.+Notarangeloauthor=W.+E.+Paulauthor=R.+M.+Blaeseauthor=J.+J.+O%E2%80%99Shea&title=Signaling+via+IL-2+and+IL-4+in+JAK3-deficient+severe+combined+immunodeficiency+lymphocytes%3A+JAK3-dependent+and+independent+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOakes%26aufirst%3DS.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DRyan%26aufirst%3DJ.%2BJ.%26aulast%3DTaylor%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHenninghausen%26aufirst%3DL.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26aulast%3DPaul%26aufirst%3DW.%2BE.%26aulast%3DBlaese%26aufirst%3DR.%2BM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520via%2520IL-2%2520and%2520IL-4%2520in%2520JAK3-deficient%2520severe%2520combined%2520immunodeficiency%2520lymphocytes%253A%2520JAK3-dependent%2520and%2520independent%2520pathways%26jtitle%3DImmunity%26date%3D1996%26volume%3D5%26spage%3D605%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">6910</span><span class="NLM_x">â</span> <span class="NLM_lpage">6915</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=6910-6915&author=M.+Chenauthor=A.+Chengauthor=Y.+Q.+Chenauthor=A.+Hymelauthor=E.+P.+Hansonauthor=L.+Kimmelauthor=Y.+Minamiauthor=T.+Taniguchiauthor=P.+S.+Changelianauthor=J.+J.+O%E2%80%99Shea&title=The+amino+terminus+of+JAK3+is+necessary+and+sufficient+for+binding+to+the+common+gamma+chain+and+confers+the+ability+to+transmit+interleukin+2-mediated+signals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DHymel%26aufirst%3DA.%26aulast%3DHanson%26aufirst%3DE.%2BP.%26aulast%3DKimmel%26aufirst%3DL.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520amino%2520terminus%2520of%2520JAK3%2520is%2520necessary%2520and%2520sufficient%2520for%2520binding%2520to%2520the%2520common%2520gamma%2520chain%2520and%2520confers%2520the%2520ability%2520to%2520transmit%2520interleukin%25202-mediated%2520signals%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1997%26volume%3D94%26spage%3D6910%26epage%3D6915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Cytokines and their role in lymphoid development, differentiation and homeostasis</span> <span class="citation_source-journal">Curr. Opin. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">â</span> <span class="NLM_lpage">506</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1097%2F00130832-200212000-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=14752332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=495-506&author=S.+R.+Hofmannauthor=R.+Ettingerauthor=Y.+J.+Zhouauthor=M.+Gadinaauthor=P.+Lipskyauthor=R.+Siegelauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Shea&title=Cytokines+and+their+role+in+lymphoid+development%2C+differentiation+and+homeostasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines and their role in lymphoid development, differentiation and homeostasis</span></div><div class="casAuthors">Hofmann Sigrun R; Ettinger Rachel; Zhou Yong-Jie; Gadina Massimo; Lipsky Peter; Siegel Richard; Candotti Fabio; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-506</span>
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The development of lymphoid tissues as well as the ultimate differentiation of naive and memory T cells are dependent on cytokines.  In this review, we will focus on recent advances in the understanding of molecular mechanisms that regulate lymphoid development, homeostasis and tolerance.  RECENT FINDINGS:  Cytokines play a critical role in the development and differentiation of lymphoid cells.  In addition, newer data indicate important roles of interleukin-7 and interleukin-15 in lymphoid homeostasis and memory.  Furthermore, a new family of heterodimeric cytokines comprising interleukin-12, interleukin-23 and -27 is important for differentiation of helper T cells and cell-mediated immunity.  Finally the importance of tumor necrosis factor superfamily members in the development of lymphoid organs has recently been elucidated and will be discussed in detail.  SUMMARY:  New cytokines and receptors continue to be identified.  The discovery and characterization of cytokines, their receptors and signaling molecules will provide a more complete understanding of normal lymphoid development, differentiation and function.  In addition, this knowledge should improve our understanding of the pathogenesis of immunological diseases and hopefully will provide new treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTci7HKMzLxgUNHe_gFldTbfW6udTcc2ebPmJKn34Uqpbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D&md5=9480ae8620e9053745c038149a08a607</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2F00130832-200212000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200212000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DEttinger%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DCytokines%2520and%2520their%2520role%2520in%2520lymphoid%2520development%252C%2520differentiation%2520and%2520homeostasis%26jtitle%3DCurr.%2520Opin.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2002%26volume%3D2%26spage%3D495%26epage%3D506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Macchi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giliani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacco, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frattini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugazio, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">â</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1038%2F377065a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=7659163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1995&pages=65-68&author=P.+Macchiauthor=A.+Villaauthor=S.+Gilianiauthor=M.+G.+Saccoauthor=A.+Frattiniauthor=F.+Portaauthor=A.+G.+Ugazioauthor=J.+A.+Johnstonauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Shea&title=Mutations+of+Jak-3+gene+in+patients+with+autosomal+severe+combined+immune+deficiency+%28SCID%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span></div><div class="casAuthors">Macchi, Paolo; Villa, Anna; Giliani, Silvia; Sacco, Maria G.; Frattini, Annalisa; Porta, Fulvio; Ugazio, Alberto G.; Johnston, James A.; Candotti, Fabio; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6544</span>),
    <span class="NLM_cas:pages">65-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Severe combined immune deficiency (SCID) represents a heterogeneous group of hereditary diseases.  Mutations in the common Î³-chain (Î³c), which is part of several cytokine receptors including those for interleukin (IL)-2, IL-4, IL-7, IL-9 and IL-15, are responsible for X-linked SCID, which is usually assocd. with a lack of circulating T cells and the presence of B lymphocytes (T- B+ SCID).  The gene(s) responsible for autosomal recessive T- B+ SCID is still unknown.  The Jak-3 protein kinase has been found to assoc. with the Î³c-chain-contg. cytokine receptors.  Therefore Jak-3 or other STAT proteins with which it interacts are candidate genes for autosomal recessive T- B+ SCID.  Here the authors investigate two unrelated T- B+ SCID patients (both from consanguineous parents) who have homozygous mutations in the gene for Jak-3.  One patient carries a mutation (Tyr100âCys) in a conserved tyrosine residue in the JH7 domain of Jak-3 which is absent in more than 150 investigated chromosomes.  The other patient carries a homozygous 151-base-pair deletion in the kinase-like domain, leading to a frameshift and premature termination.  Both mutations resulted in markedly reduced levels of Jak-3.  These findings show that abnormalities in the Jak/STAT signaling pathway can account for SCID in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJWFs-Wbegq7Vg90H21EOLACvtfcHk0lhTDkrnzryxTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D&md5=ac5a7064e6c3361c8906813770e1b6d9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2F377065a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F377065a0%26sid%3Dliteratum%253Aachs%26aulast%3DMacchi%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DGiliani%26aufirst%3DS.%26aulast%3DSacco%26aufirst%3DM.%2BG.%26aulast%3DFrattini%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DUgazio%26aufirst%3DA.%2BG.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DMutations%2520of%2520Jak-3%2520gene%2520in%2520patients%2520with%2520autosomal%2520severe%2520combined%2520immune%2520deficiency%2520%2528SCID%2529%26jtitle%3DNature%26date%3D1995%26volume%3D377%26spage%3D65%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovich, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">â</span> <span class="NLM_lpage">157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=147-157&author=M.+Noguchiauthor=H.+M.+Rosenblattauthor=A.+H.+Filipovichauthor=S.+Adelsteinauthor=W.+S.+Modiauthor=O.+W.+McBrideauthor=W.+J.+Leonard&title=Interleukin-2+receptor+gamma+chain+mutation+results+in+X-linked+severe+combined+immunodeficiency+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DRosenblatt%26aufirst%3DH.%2BM.%26aulast%3DFilipovich%26aufirst%3DA.%2BH.%26aulast%3DAdelstein%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DW.%2BS.%26aulast%3DMcBride%26aufirst%3DO.%2BW.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DInterleukin-2%2520receptor%2520gamma%2520chain%2520mutation%2520results%2520in%2520X-linked%2520severe%2520combined%2520immunodeficiency%2520in%2520humans%26jtitle%3DCell%26date%3D1993%26volume%3D73%26spage%3D147%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Russell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tayebi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migone, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">â</span> <span class="NLM_lpage">800</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=797-800&author=S.+M.+Russellauthor=N.+Tayebiauthor=H.+Nakajimaauthor=M.+C.+Riedyauthor=J.+L.+Robertsauthor=M.+J.+Amanauthor=T.+S.+Migoneauthor=M.+Noguchiauthor=M.+L.+Markertauthor=R.+H.+Buckleyauthor=J.+J.+O%E2%80%99Sheaauthor=W.+J.+Leonard&title=Mutation+of+Jak3+in+a+patient+with+SCID%3A+essential+role+of+Jak3+in+lymphoid+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DS.%2BM.%26aulast%3DTayebi%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DAman%26aufirst%3DM.%2BJ.%26aulast%3DMigone%26aufirst%3DT.%2BS.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMarkert%26aufirst%3DM.%2BL.%26aulast%3DBuckley%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DMutation%2520of%2520Jak3%2520in%2520a%2520patient%2520with%2520SCID%253A%2520essential%2520role%2520of%2520Jak3%2520in%2520lymphoid%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D797%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">203</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1111%2Fj.0105-2896.2005.00220.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=15661026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2005&pages=127-142&author=M.+Pesuauthor=F.+Candottiauthor=M.+Husaauthor=S.+R.+Hofmannauthor=L.+D.+Notarangeloauthor=J.+J.+O%E2%80%99Shea&title=Jak3%2C+severe+combined+immunodeficiency%2C+and+a+new+class+of+immunosuppressive+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs</span></div><div class="casAuthors">Pesu, Marko; Candotti, Fabio; Husa, Matthew; Hofmann, Sigrun R.; Notarangelo, Luigi D.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The recent elucidation of the multiple mol. mechanisms underlying severe combined immunodeficiency (SCID) is an impressive example of the power of mol. medicine.  Anal. of patients and the concomitant generation of animal models mimicking these disorders have quickly provided great insights into the pathophysiol. of these potentially devastating illnesses.  Here, the authors summarize the discoveries that led to the understanding of the role of cytokine receptors and a specific tyrosine kinase, Janus kinase 3 (Jak3), in the pathogenesis of SCID.  The authors discuss how the identification of mutations of Jak3 in autosomal recessive SCID has facilitated the diagnosis of these disorders, offered new insights into the biol. of this kinase, permitted new avenues for therapy, and provided the rationale for a generation of a new class of immunosuppressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYir7OTbMwFbVg90H21EOLACvtfcHk0lg-SDMjcgGZ5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7o%253D&md5=038b25b97798eda4b6aa1818238e45ba</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.0105-2896.2005.00220.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0105-2896.2005.00220.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DHusa%26aufirst%3DM.%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJak3%252C%2520severe%2520combined%2520immunodeficiency%252C%2520and%2520a%2520new%2520class%2520of%2520immunosuppressive%2520drugs%26jtitle%3DImmunol.%2520Rev.%26date%3D2005%26volume%3D203%26spage%3D127%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzuti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koslov, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckius, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beals, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagouras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magna, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltarelli, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelms, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Des Etages, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finco-Kent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paniagua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">â</span> <span class="NLM_lpage">878</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=C.+Shang-Poaauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=S.+G.+Des+Etagesauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.+S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.+J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0lg-SDMjcgGZ5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%2BEtages%26aufirst%3DS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">West, K.</span><span> </span><span class="NLM_article-title">CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">491</span><span class="NLM_x">â</span> <span class="NLM_lpage">504</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=491-504&author=K.+West&title=CP-690550%2C+a+JAK3+inhibitor+as+an+immunosuppressant+for+the+treatment+of+rheumatoid+arthritis%2C+transplant+rejection%2C+psoriasis+and+other+immune-mediated+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DK.%26atitle%3DCP-690550%252C%2520a%2520JAK3%2520inhibitor%2520as%2520an%2520immunosuppressant%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%252C%2520transplant%2520rejection%252C%2520psoriasis%2520and%2520other%2520immune-mediated%2520disorders%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D10%26spage%3D491%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Sorbera, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serradell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bozzo, J.</span><span> </span><span class="NLM_article-title">CP-690,550</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">674</span><span class="NLM_x">â</span> <span class="NLM_lpage">680</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1358%2Fdof.2007.032.08.1125174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yktL7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=674-680&author=L.+A.+Sorberaauthor=N.+Serradellauthor=J.+Bolosauthor=E.+Rosaauthor=J.+Bozzo&title=CP-690%2C550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">CP-690550 JAK3 inhibitor immunosuppressant treatment of rheumatoid arthritis treatment of transplant rejection</span></div><div class="casAuthors">Sorbera, L. A.; Serradell, N.; Bolos, J.; Rosa, E.; Bozzo, J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">674-680</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Std. immunosuppressive agents used in the clinic for the prevention of organ transplant rejection and autoimmune diseases, although generally effective, target ubiquitously expressed mols. and are assocd. with significant adverse events.  Identification of potential targets selectively expressed by immune cells has become a research priority in order to develop immunosuppressants devoid of the toxicities obsd. with current therapies.  In this regard, targeting of Janus kinase 3 (JAK3) represents a potentially effective immunosuppressive strategy since expression of this signaling mol. is relatively restricted to immune cells and it is only used by cytokine receptors contg. the Î³-chain (Î³c).  CP-690550 is a novel JAK3 inhibitor that has exhibited potent immunosuppressive effects in preclin. transplantation and arthritis models and has been shown to be clin. safe and effective in preventing transplant rejection and improving symptoms of rheumatoid arthritis and psoriasis.  CP-690550 continues to undergo phase II development as an immunosuppressive agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRtqSvl2_tJrVg90H21EOLACvtfcHk0lgYR34nHrgXxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yktL7E&md5=91e10457b300bc2cb43e3c5c8f385c3d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1358%2Fdof.2007.032.08.1125174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2007.032.08.1125174%26sid%3Dliteratum%253Aachs%26aulast%3DSorbera%26aufirst%3DL.%2BA.%26aulast%3DSerradell%26aufirst%3DN.%26aulast%3DBolos%26aufirst%3DJ.%26aulast%3DRosa%26aufirst%3DE.%26aulast%3DBozzo%26aufirst%3DJ.%26atitle%3DCP-690%252C550%26jtitle%3DDrugs%2520Future%26date%3D2007%26volume%3D32%26spage%3D674%26epage%3D680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wrobleski, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts, W. J.</span><span> </span><span class="NLM_article-title">Chapter 12 Advances in the discovery of small molecule JAK3 inhibitors</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">â</span> <span class="NLM_lpage">264</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=247-264&author=S.+T.+Wrobleskiauthor=W.+J.+Pitts&title=Chapter+12+Advances+in+the+discovery+of+small+molecule+JAK3+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26atitle%3DChapter%252012%2520Advances%2520in%2520the%2520discovery%2520of%2520small%2520molecule%2520JAK3%2520inhibitors%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D247%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kudlacz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P.</span><span> </span><span class="NLM_article-title">The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">â</span> <span class="NLM_lpage">57</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1046%2Fj.1600-6143.2003.00281.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=14678034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVCmtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=51-57&author=E.+Kudlaczauthor=B.+Perryauthor=P.+Sawyerauthor=M.+Conklynauthor=S.+McCurdyauthor=W.+Brissetteauthor=A.+Flanaganauthor=P.+Changelian&title=The+novel+JAK-3+inhibitor+CP-690550+is+a+potent+immunosuppressive+agent+in+various+murine+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models</span></div><div class="casAuthors">Kudlacz, Elizabeth; Perry, Bret; Sawyer, Perry; Conklyn, Maryrose; McCurdy, Sandra; Brissette, William; Flanagan, Mark; Changelian, Paul</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-57</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">JAK-3 kinase has been shown to play a key role in cytokine signaling via Î³c, e.g. IL-2, 4, 7, 9, 15, and 21.  The current study describes the immunosuppressive effects of CP-690550, a novel, small mol. inhibitor of JAK-3, in various murine models.  In vitro, CP-690550 effectively inhibited a murine mixed lymphocyte reaction (MLR).  Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrated dose- and time-dependent alterations in lymphocyte subsets when examd. by flow cytometry.  The most dramatic change obsd. was a 96% redn. in splenic NK1.1+TCRÎ²- cell nos. following 21 days of treatment.  Delayed-type hypersensitivity (DTH) responses in sensitized mice were reduced in a dose-dependent manner following treatment with the JAK-3 inhibitor (1.87-30 mg/kg, s.c.).  Extended survival of neonatal Balb/c hearts implanted into the ear pinna of MHC mismatched C3H/HEN mice was obsd. with CP-690550 monotherapy (10-30 mg/kg/day), but improved upon combination with cyclosporin (10 mg/kg/day).  These data support the participation of JAK-3 in various lymphocyte homeostatic functions in mature mice.  Furthermore, the ability of CP-690550 to extend cardiac allograft survival in murine models suggests it may afford a new treatment for prevention of transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJAFi7wg6_7Vg90H21EOLACvtfcHk0lgYR34nHrgXxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVCmtbs%253D&md5=33f2f4c56b1463036d92943bddd4e0e6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1046%2Fj.1600-6143.2003.00281.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1600-6143.2003.00281.x%26sid%3Dliteratum%253Aachs%26aulast%3DKudlacz%26aufirst%3DE.%26aulast%3DPerry%26aufirst%3DB.%26aulast%3DSawyer%26aufirst%3DP.%26aulast%3DConklyn%26aufirst%3DM.%26aulast%3DMcCurdy%26aufirst%3DS.%26aulast%3DBrissette%26aufirst%3DW.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DChangelian%26aufirst%3DP.%26atitle%3DThe%2520novel%2520JAK-3%2520inhibitor%2520CP-690550%2520is%2520a%2520potent%2520immunosuppressive%2520agent%2520in%2520various%2520murine%2520models%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2004%26volume%3D4%26spage%3D51%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Meyer, D. M.; Jesson, M. I.; Li, W.; Elrick, M. M.; Funckes-Shippy, C. L.; Warner, J. D.; Gross, C. J.; Dowty, M. E.; Ramaiah, S. K.; Hirsch, J. L.; Saabye, M. J.; Barks, J. L.; Kishore, N.; Morris, D. L.</span><span> </span><span class="NLM_article-title">Anti-inflammatory activity and neutrophil reductions mediated by JAK1 and JAK3 inhibition in the rat AIA model</span>.  <span class="citation_source-journal">J. Inflammation (London)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=20701804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41&author=D.+M.+Meyer&author=M.+I.+Jesson&author=W.+Li&author=M.+M.+Elrick&author=C.+L.+Funckes-Shippy&author=J.+D.+Warner&author=C.+J.+Gross&author=M.+E.+Dowty&author=S.+K.+Ramaiah&author=J.+L.+Hirsch&author=M.+J.+Saabye&author=J.+L.+Barks&author=N.+Kishore&author=D.+L.+Morris&title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+JAK1+and+JAK3+inhibition+in+the+rat+AIA+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Meyer Debra M; Jesson Michael I; Li Xiong; Elrick Mollisa M; Funckes-Shippy Christie L; Warner James D; Gross Cindy J; Dowty Martin E; Ramaiah Shashi K; Hirsch Jeffrey L; Saabye Matthew J; Barks Jennifer L; Kishore Nandini; Morris Dale L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of inflammation (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors.  CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.  In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment.  These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment.  METHODS:  Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays.  The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays.  In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model.  RESULTS:  CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays.  Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment.  Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease.  At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels.  The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2.  CONCLUSION:  Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2.  In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550.  Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17.  Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2.  Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-l9vqy6452oNpW7w2tapOfW6udTcc2eaKRbItzsc99Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D&md5=1190d7c5509fde79a7b56024a3aec9d9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26atitle%3DAnti-inflammatory%2520activity%2520and%2520neutrophil%2520reductions%2520mediated%2520by%2520JAK1%2520and%2520JAK3%2520inhibition%2520in%2520the%2520rat%2520AIA%2520model%26jtitle%3DJ.%2520Inflammation%2520%2528London%2529%26date%3D2010%26volume%3D7%26spage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Simonsen, J.</span> <span class="citation_source-book">The Terpenes</span>; <span class="NLM_publisher-name">Cambridge University Press</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">1953</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">394</span>â <span class="NLM_lpage">408</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1953&pages=394-408&author=J.+Simonsen&title=The+Terpenes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSimonsen%26aufirst%3DJ.%26btitle%3DThe%2520Terpenes%26pub%3DCambridge%2520University%2520Press%26date%3D1953%26spage%3D394%26epage%3D408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Brown Ripin, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koecher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laue, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouwer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sha, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teixeira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vries, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcox, G.</span><span> </span><span class="NLM_article-title">Development of a scaleable route for the production of <i>cis</i>-<i>N</i>-benzyl-3-methylamino-4-methylpiperidine</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">â</span> <span class="NLM_lpage">120</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=115-120&author=D.+H.+Brown+Ripinauthor=S.+Abeleauthor=W.+Caiauthor=T.+Blumenkopfauthor=J.+M.+Casavantauthor=J.+L.+Dotyauthor=M.+Flanaganauthor=C.+Koecherauthor=K.+W.+Laueauthor=K.+McCarthyauthor=C.+Meltzauthor=M.+J.+Munchhofauthor=K.+Pouwerauthor=B.+Shaauthor=J.+Sunauthor=J.+Teixeiraauthor=T.+Vriesauthor=D.+A.+Whippleauthor=G.+Wilcox&title=Development+of+a+scaleable+route+for+the+production+of+cis-N-benzyl-3-methylamino-4-methylpiperidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%2BRipin%26aufirst%3DD.%2BH.%26aulast%3DAbele%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DW.%26aulast%3DBlumenkopf%26aufirst%3DT.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DFlanagan%26aufirst%3DM.%26aulast%3DKoecher%26aufirst%3DC.%26aulast%3DLaue%26aufirst%3DK.%2BW.%26aulast%3DMcCarthy%26aufirst%3DK.%26aulast%3DMeltz%26aufirst%3DC.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPouwer%26aufirst%3DK.%26aulast%3DSha%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DTeixeira%26aufirst%3DJ.%26aulast%3DVries%26aufirst%3DT.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DWilcox%26aufirst%3DG.%26atitle%3DDevelopment%2520of%2520a%2520scaleable%2520route%2520for%2520the%2520production%2520of%2520cis-N-benzyl-3-methylamino-4-methylpiperidine%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2003%26volume%3D7%26spage%3D115%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Jiang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deflorian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span> </span><span class="NLM_article-title">Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">8012</span><span class="NLM_x">â</span> <span class="NLM_lpage">8018</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801142b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8012-8018&author=J.+K.+Jiangauthor=K.+Ghoreschiauthor=F.+Deflorianauthor=Z.+Chenauthor=M.+Perreiraauthor=M.+Pesuauthor=J.+Smithauthor=D.+T.+Nguyenauthor=E.+H.+Liuauthor=W.+Leisterauthor=S.+Costanziauthor=J.+J.+O%E2%80%99Sheaauthor=C.+J.+Thomas&title=Examining+the+chirality%2C+conformation+and+selective+kinase+inhibition+of+3-%28%283R%2C4R%29-4-methyl-3-%28methyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%29piperidin-1-yl%29-3-oxopropanenitrile+%28CP-690%2C550%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm801142b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801142b%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPerreira%26aufirst%3DM.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DD.%2BT.%26aulast%3DLiu%26aufirst%3DE.%2BH.%26aulast%3DLeister%26aufirst%3DW.%26aulast%3DCostanzi%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26atitle%3DExamining%2520the%2520chirality%252C%2520conformation%2520and%2520selective%2520kinase%2520inhibition%2520of%25203-%2528%25283R%252C4R%2529-4-methyl-3-%2528methyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529piperidin-1-yl%2529-3-oxopropanenitrile%2520%2528CP-690%252C550%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8012%26epage%3D8018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0lj4jUBeszalYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Chrencik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gormley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommers, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenbrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, T. E.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">â</span> <span class="NLM_lpage">433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.+C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lj4jUBeszalYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span>World Intellectual Property Organization. (WO/2003/048162) Novel Crystalline Compound. <a href="http://www.wipo.int/pctdb/en/wo.jsp?wo=2003048162&amp;IA=IB2002004948&amp;DISPLAY=DOCS" class="extLink">http://www.wipo.int/pctdb/en/wo.jsp?wo=2003048162&IA=IB2002004948&DISPLAY=DOCS</a>. Accessed 3 August 2010.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Intellectual+Property+Organization.+%28WO%2F2003%2F048162%29+Novel+Crystalline+Compound.+http%3A%2F%2Fwww.wipo.int%2Fpctdb%2Fen%2Fwo.jsp%3Fwo%3D2003048162%26IA%3DIB2002004948%26DISPLAY%3DDOCS.+Accessed+3+August+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">van Gurp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimar, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pescovitz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Phase 1 dose-escalation study of CP-690-550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1711</span><span class="NLM_x">â</span> <span class="NLM_lpage">1718</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1111%2Fj.1600-6143.2008.02307.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=18557720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGhu7nJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1711-1718&author=E.+van+Gurpauthor=W.+Weimarauthor=R.+Gastonauthor=D.+Brennanauthor=R.+Mendezauthor=J.+Pruschauthor=S.+Swanauthor=M.+D.+Pescovitzauthor=G.+Niauthor=C.+Wangauthor=S.+Krishnaswamiauthor=V.+Chowauthor=G.+Chan&title=Phase+1+dose-escalation+study+of+CP-690-550+in+stable+renal+allograft+recipients%3A+preliminary+findings+of+safety%2C+tolerability%2C+effects+on+lymphocyte+subsets+and+pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics</span></div><div class="casAuthors">van Gurp, E.; Weimar, W.; Gaston, R.; Brennan, D.; Mendez, R.; Pirsch, J.; Swan, S.; Pescovitz, M. D.; Ni, G.; Wang, C.; Krishnaswami, S.; Chow, V.; Chan, G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1711-1718</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">CP-690 550 inhibits Janus kinase 3 with nanomolar potency.  In this dose-escalation study, we assessed the safety, tolerability, effects on lymphocyte subsets, and pharmacokinetics of CP-690 550 when coadministered with mycophenolate mofetil in stable renal allograft recipients for 28 days.  Twenty-eight patients were enrolled.  Six patients received CP-690 550 5 mg twice daily (BID), 6 patients received 15 mg BID, 10 patients received 30 mg BID, and 6 patients received placebo.  The most frequent adverse events were infections and gastrointestinal (abdominal pain, diarrhea, dyspepsia, and vomiting).  CP-690 550 15 mg BID and 30 mg BID were assocd. with a mean decrease in Hb from baseline of 11% and a mean decrease in abs. natural killer cell counts of 50%.  CP-690 550 30 mg BID was also assocd. with a mean increase in abs. CD19+ B-lymphocytes of 130%.  There were no changes in the no. of neutrophils, total lymphocytes, platelets, or CD4+ or CD8+ T cells; clin. chem.; vital signs; or electrocardiograms from the pretreatment baseline.  Administration of CP-690 550 without a concomitant calcineurin inhibitor resulted in CP-690 550 exposures consistent with previous studies in nontransplant subjects.  Addnl. dose-ranging studies are warranted to evaluate the safety and efficacy of CP-690 550 in renal transplant recipients over longer treatment duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo69SNdm7tfMrVg90H21EOLACvtfcHk0lj4jUBeszalYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGhu7nJ&md5=14582e231681d5cb704f11d1cdfd54d5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2008.02307.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2008.02307.x%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BGurp%26aufirst%3DE.%26aulast%3DWeimar%26aufirst%3DW.%26aulast%3DGaston%26aufirst%3DR.%26aulast%3DBrennan%26aufirst%3DD.%26aulast%3DMendez%26aufirst%3DR.%26aulast%3DPrusch%26aufirst%3DJ.%26aulast%3DSwan%26aufirst%3DS.%26aulast%3DPescovitz%26aufirst%3DM.%2BD.%26aulast%3DNi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DChow%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DPhase%25201%2520dose-escalation%2520study%2520of%2520CP-690-550%2520in%2520stable%2520renal%2520allograft%2520recipients%253A%2520preliminary%2520findings%2520of%2520safety%252C%2520tolerability%252C%2520effects%2520on%2520lymphocyte%2520subsets%2520and%2520pharmacokinetics%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2008%26volume%3D8%26spage%3D1711%26epage%3D1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Lawendy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">â</span> <span class="NLM_lpage">429</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1177%2F0091270008330982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19318693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFWls7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=423-429&author=N.+Lawendyauthor=S.+Krishnaswamiauthor=R.+Wangauthor=D.+Grubenauthor=C.+Cannonauthor=S.+Swanauthor=G.+Chan&title=Effect+of+CP-690%2C550%2C+an+orally+active+janus+kinase+inhibitor%2C+on+renal+function+in+healthy+adult+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of CP-690,550, an orally active Janus kinase inhibitor, on renal function in healthy adult volunteers</span></div><div class="casAuthors">Lawendy, Nervin; Krishnaswami, Sriram; Wang, Rong; Gruben, David; Cannon, Courtney; Swan, Suzanne; Chan, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">423-429</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">CP-690,550 is a Janus kinase inhibitor being developed to prevent allograft rejection and treat several autoimmune diseases.  This study examines the effect of multiple doses of CP-690,550 on renal function in healthy volunteers.  Thirty-four volunteers are randomized in a 2:1 ratio in a double-blinded manner to receive CP-690,550 15 mg twice daily or placebo twice daily for 14 days.  Volunteers are confined inhouse to receive a controlled regimen of water intake and sodium intake of 4 to 5 g/d.  The effect of CP-690,550 on glomerular filtration rate (GFR) is measured by iohexol serum clearance, effective renal plasma flow (ERPF) by para-aminohippuric acid (PAH) urinary clearance, and creatinine clearance by 24-h urine collection on day 1 (predose) and day 15.  Steady-state pharmacokinetics and tolerability are assessed.  Comparing the day 15 and day 1 (predose) values shows that geometric mean ratios for iohexol serum clearance, PAH urinary clearance, and creatinine clearance are 0.995, 0.925, and 0.948, resp.  When adjusted for the corresponding placebo day ratios, the geometric mean ratios are 1.09, 0.978, and 1.05, resp. CP-690,550 is well tolerated.  These findings indicate that CP-690,550 does not affect GFR, ERPF, or creatinine clearance in healthy volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrakPq3AS-HJLVg90H21EOLACvtfcHk0liIQTu_hYKvmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFWls7s%253D&md5=906b01548522e36f4a8685b490015128</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1177%2F0091270008330982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270008330982%26sid%3Dliteratum%253Aachs%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DCannon%26aufirst%3DC.%26aulast%3DSwan%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DEffect%2520of%2520CP-690%252C550%252C%2520an%2520orally%2520active%2520janus%2520kinase%2520inhibitor%252C%2520on%2520renal%2520function%2520in%2520healthy%2520adult%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D423%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nedderman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span> </span><span class="NLM_article-title">Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">â</span> <span class="NLM_lpage">368</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx8004357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=357-368&author=D.+Dalvieauthor=R.+S.+Obachauthor=P.+Kangauthor=C.+Prakashauthor=C.+M.+Loiauthor=S.+Hurstauthor=A.+Neddermanauthor=L.+Gouletauthor=E.+Smithauthor=H.+Z.+Buauthor=D.+A.+Smith&title=Assessment+of+three+human+in+vitro+systems+in+the+generation+of+major+human+excretory+and+circulating+metabolites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Ftx8004357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx8004357%26sid%3Dliteratum%253Aachs%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKang%26aufirst%3DP.%26aulast%3DPrakash%26aufirst%3DC.%26aulast%3DLoi%26aufirst%3DC.%2BM.%26aulast%3DHurst%26aufirst%3DS.%26aulast%3DNedderman%26aufirst%3DA.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DBu%26aufirst%3DH.%2BZ.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26atitle%3DAssessment%2520of%2520three%2520human%2520in%2520vitro%2520systems%2520in%2520the%2520generation%2520of%2520major%2520human%2520excretory%2520and%2520circulating%2520metabolites%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D357%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flloyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A qualitive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Flloydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+qualitive+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFlloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520qualitive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_publisher-name">Pfizer Inc</span>. Data on file.<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Inc.+Data+on+file.+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26pub%3DPfizer%2520Inc%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Borie, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousvoal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates</span> <span class="citation_source-journal">Transplantation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">1756</span><span class="NLM_x">â</span> <span class="NLM_lpage">1764</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2005&pages=1756-1764&author=D.+C.+Borieauthor=M.+J.+Larsonauthor=M.+G.+Floresauthor=A.+Campbellauthor=G.+Rousvoalauthor=S.+Zhangauthor=J.+P.+Higginsauthor=D.+J.+Ballauthor=E.+M.+Kudlaczauthor=W.+H.+Brissetteauthor=E.+A.+Elliottauthor=B.+A.+Reitzauthor=P.+S.+Changelian&title=Combined+use+of+the+JAK3+inhibitor+CP-690%2C550+with+mycophenolate+mofetil+to+prevent+kidney+allograft+rejection+in+nonhuman+primates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBorie%26aufirst%3DD.%2BC.%26aulast%3DLarson%26aufirst%3DM.%2BJ.%26aulast%3DFlores%26aufirst%3DM.%2BG.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DRousvoal%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DJ.%2BP.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DReitz%26aufirst%3DB.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DCombined%2520use%2520of%2520the%2520JAK3%2520inhibitor%2520CP-690%252C550%2520with%2520mycophenolate%2520mofetil%2520to%2520prevent%2520kidney%2520allograft%2520rejection%2520in%2520nonhuman%2520primates%26jtitle%3DTransplantation%26date%3D2005%26volume%3D80%26spage%3D1756%26epage%3D1764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Rousvoal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy</span> <span class="citation_source-journal">Transplant Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1014</span><span class="NLM_x">â</span> <span class="NLM_lpage">1021</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1111%2Fj.1432-2277.2006.00387.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=17081232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGhsLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=1014-1021&author=G.+Rousvoalauthor=M.+S.+Siauthor=M.+Lauauthor=S.+Zhangauthor=G.+J.+Berryauthor=M.+G.+Floresauthor=P.+S.+Changelianauthor=B.+A.+Reitzauthor=D.+C.+Borie&title=Janus+kinase+3+inhibition+with+CP-690%2C550+prevents+allograft+vasculopathy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy</span></div><div class="casAuthors">Rousvoal, Geraldine; Si, Ming-Sing; Lau, Macy; Zhang, Sally; Berry, Gerald J.; Flores, Mona G.; Changelian, Paul S.; Reitz, Bruce A.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Transplant International</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1014-1021</span>CODEN:
                <span class="NLM_cas:coden">TRINE5</span>;
        ISSN:<span class="NLM_cas:issn">0934-0874</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Janus kinase 3 (JAK3) mediates signal transduction from cytokine receptors using the common Î³ chain.  The rationally designed inhibitor of JAK3, CP-690,550, prevents acute allograft rejection in rodents and in nonhuman primates.  Here we investigated the ability of CP-690,550, to prevent allograft vasculopathy in a rodent model of aorta transplantation.  Aortas from AxC Irish (RT1a) or Lewis (RT1l) rats were heterotopically transplanted into the infra-renal aorta of Lewis recipients and harvested at 28 or 56 days.  Treated recipients received CP-690,550 by osmotic pumps (mean drug exposure of 110 Â± 38 ng/mL).  Significant intimal hyperplasia was demonstrated in untreated allografts when compared with isografts at 28 days (2.08 Â± 0.85% vs. 0.43 Â± 0.2% luminal obliteration, resp., P = 0.001) and 56 days (5.3 Â± 2.4% vs. 0.38 Â± 0.3%, P = 0.002).  Treatment caused a 51% redn. in intimal hyperplasia at day 56.  CP-690,550-treated animals also had a significant redn. of donor-specific IgG prodn. and of the gene expression for suppressor of cytokine signaling-3 and with unchanged levels of expression of RANTES, IP-10 and transforming growth factor-Î²1.  These results are the first to show that JAK3 blockade by CP-690,550 effectively prevents allograft vasculopathy in this rat model of aorta transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL2Os-h6o7uLVg90H21EOLACvtfcHk0liQCm9P1hNRmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGhsLbM&md5=59bc3ae042addab7c02f21555bc9e269</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-2277.2006.00387.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-2277.2006.00387.x%26sid%3Dliteratum%253Aachs%26aulast%3DRousvoal%26aufirst%3DG.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DLau%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DBerry%26aufirst%3DG.%2BJ.%26aulast%3DFlores%26aufirst%3DM.%2BG.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DReitz%26aufirst%3DB.%2BA.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DJanus%2520kinase%25203%2520inhibition%2520with%2520CP-690%252C550%2520prevents%2520allograft%2520vasculopathy%26jtitle%3DTransplant%2520Int.%26date%3D2006%26volume%3D19%26spage%3D1014%26epage%3D1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Busque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leventhal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klintmalm, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulgaonkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bromberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincenti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hariharan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slakey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peddi, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawendy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP690,550: a pilot study in de novo kidney allograft recipients</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1936</span><span class="NLM_x">â</span> <span class="NLM_lpage">1945</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1111%2Fj.1600-6143.2009.02720.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19660021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGrurrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1936-1945&author=S.+Busqueauthor=J.+Leventhalauthor=D.+Brennanauthor=S.+Steinbergauthor=G.+Klintmalmauthor=T.+Shahauthor=S.+Mulgaonkarauthor=J.+Brombergauthor=F.+Vincentiauthor=S.+Hariharanauthor=D.+Slakeyauthor=V.+R.+Peddiauthor=R.+A.+Fisherauthor=N.+Lawendyauthor=C.+Wangauthor=G.+Chan&title=Calcineurin-inhibitor-free+immunosuppression+based+on+the+JAK+inhibitor+CP690%2C550%3A+a+pilot+study+in+de+novo+kidney+allograft+recipients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in De novo kidney allograft recipients</span></div><div class="casAuthors">Busque, S.; Leventhal, J.; Brennan, D. C.; Steinberg, S.; Klintmalm, G.; Shah, T.; Mulgaonkar, S.; Bromberg, J. S.; Vincenti, F.; Hariharan, S.; Slakey, D.; Peddi, V. R.; Fisher, R. A.; Lawendy, N.; Wang, C.; Chan, G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1936-1945</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This randomized, pilot study compared the Janus kinase inhibitor CP-690,550 (15 mg BID [CP15] and 30 mg BID [CP30], n = 20 each) with tacrolimus (n = 21) in de novo kidney allograft recipients.  Patients received an IL-2 receptor antagonist, concomitant mycophenolate mofetil (MMF) and corticosteroids.  CP-690,550 doses were reduced after 6 mo.  Due to a high incidence of BK virus nephropathy (BKN) in CP30, MMF was discontinued in this group.  The 6-mo biopsy-proven acute rejection rates were 1 of 20, 4 of 20 and 1 of 21 for CP15, CP30 and tacrolimus groups, resp.  BKN developed in 4 of 20 patients in CP30 group.  The 6-mo rates of cytomegalovirus disease were 2 of 20, 4 of 20 and none of 21 for CP15, CP30 and tacrolimus groups, resp.  Estd. glomerular filtration rate was >70 mL/min at 6 and 12 mo (all groups).  NK cells were reduced by <77% in CP-690,550-treated patients.  In the CP-690,550 arms, there were modest lipid elevations and a trend toward more frequent anemia and neutropenia during the first 6 mo.  These data suggest that coadministration of CP-690,550 30 mg BID with MMF is assocd. with overimmunosuppression.  At 15 mg BID, the efficacy/safety profile was comparable to the tacrolimus control group, excepting a higher rate of viral infection.  Further dose-ranging evaluation of CP-690,550 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptskDnsVhSnrVg90H21EOLACvtfcHk0liQCm9P1hNRmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGrurrP&md5=c63d35ad46e6041c3b63886aa75e424d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2009.02720.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2009.02720.x%26sid%3Dliteratum%253Aachs%26aulast%3DBusque%26aufirst%3DS.%26aulast%3DLeventhal%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DD.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DKlintmalm%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DT.%26aulast%3DMulgaonkar%26aufirst%3DS.%26aulast%3DBromberg%26aufirst%3DJ.%26aulast%3DVincenti%26aufirst%3DF.%26aulast%3DHariharan%26aufirst%3DS.%26aulast%3DSlakey%26aufirst%3DD.%26aulast%3DPeddi%26aufirst%3DV.%2BR.%26aulast%3DFisher%26aufirst%3DR.%2BA.%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DCalcineurin-inhibitor-free%2520immunosuppression%2520based%2520on%2520the%2520JAK%2520inhibitor%2520CP690%252C550%253A%2520a%2520pilot%2520study%2520in%2520de%2520novo%2520kidney%2520allograft%2520recipients%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2009%26volume%3D9%26spage%3D1936%26epage%3D1945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audoly, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P.</span><span> </span><span class="NLM_article-title">Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">R14</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=R14&author=A.+J.+Miliciauthor=E.+M.+Kudlaczauthor=L.+Audolyauthor=S.+Zwillichauthor=P.+Changelian&title=Cartilage+preservation+by+inhibition+of+Janus+kinase+3+in+two+rodent+models+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DAudoly%26aufirst%3DL.%26aulast%3DZwillich%26aufirst%3DS.%26aulast%3DChangelian%26aufirst%3DP.%26atitle%3DCartilage%2520preservation%2520by%2520inhibition%2520of%2520Janus%2520kinase%25203%2520in%2520two%2520rodent%2520models%2520of%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2008%26volume%3D10%26spage%3DR14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombs, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgos-Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C. A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dose levels of CP-690,550 versus placebo</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1895</span><span class="NLM_x">â</span> <span class="NLM_lpage">1905</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+F.+Zerbiniauthor=S.+H.+Zwillich&title=The+safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis%3A+results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dose+levels+of+CP-690%2C550+versus+placebo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0liQCm9P1hNRmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%2BF.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dose%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez Reino, J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Ramos, V</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S.</span><span> </span><span class="NLM_article-title">The oral JAK inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) is efficacious, safe and well tolerated in patients with active rheumatoid arthritis (RA) with an inadequate response to methotrexate alone</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4030</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2008&pages=4030&author=J.+M.+Kremerauthor=S.+Cohenauthor=B.+Wilkinsonauthor=C+Connellauthor=J+Frenchauthor=J+Gomez+Reinoauthor=D.+Grubenauthor=K+Kanikauthor=S.+Krishnaswamiauthor=V+Pascual-Ramosauthor=G+Wallensteinauthor=S.+Zwillich&title=The+oral+JAK+inhibitor+CP-690%2C550+%28CP%29+in+combination+with+methotrexate+%28MTX%29+is+efficacious%2C+safe+and+well+tolerated+in+patients+with+active+rheumatoid+arthritis+%28RA%29+with+an+inadequate+response+to+methotrexate+alone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DConnell%26aufirst%3DC%26aulast%3DFrench%26aufirst%3DJ%26aulast%3DGomez%2BReino%26aufirst%3DJ%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKanik%26aufirst%3DK%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DPascual-Ramos%26aufirst%3DV%26aulast%3DWallenstein%26aufirst%3DG%26aulast%3DZwillich%26aufirst%3DS.%26atitle%3DThe%2520oral%2520JAK%2520inhibitor%2520CP-690%252C550%2520%2528CP%2529%2520in%2520combination%2520with%2520methotrexate%2520%2528MTX%2529%2520is%2520efficacious%252C%2520safe%2520and%2520well%2520tolerated%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520%2528RA%2529%2520with%2520an%2520inadequate%2520response%2520to%2520methotrexate%2520alone%26jtitle%3DArthritis%2520Rheum.%26date%3D2008%26volume%3D58%26spage%3D4030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">Safety and efficacy after 24 week (WK) dosing of the oral JAK inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) in patients (PTS) with active rheumatoid arthritis (RA)</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">S719</span><div class="note"><p class="first last">, 1925 (abstract)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=S719&issue=Suppl.+10&author=J.+M.+Kremerauthor=S.+Cohenauthor=B.+Wilkinsonauthor=D.+Grubenauthor=G+Wallensteinauthor=K+Kanikauthor=S.+H.+Zwillich&title=Safety+and+efficacy+after+24+week+%28WK%29+dosing+of+the+oral+JAK+inhibitor+CP-690%2C550+%28CP%29+in+combination+with+methotrexate+%28MTX%29+in+patients+%28PTS%29+with+active+rheumatoid+arthritis+%28RA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DWallenstein%26aufirst%3DG%26aulast%3DKanik%26aufirst%3DK%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DSafety%2520and%2520efficacy%2520after%252024%2520week%2520%2528WK%2529%2520dosing%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520CP-690%252C550%2520%2528CP%2529%2520in%2520combination%2520with%2520methotrexate%2520%2528MTX%2529%2520in%2520patients%2520%2528PTS%2529%2520with%2520active%2520rheumatoid%2520arthritis%2520%2528RA%2529%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26issue%3DSuppl.%252010%26spage%3DS719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Kanik, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S.</span><span> </span><span class="NLM_article-title">Phase 2b dose ranging monotherapy study of the oral JAK inhibitor CP-690,550 (CP) or adalimumab (ADA) vs placebo (PBO) in patients (pts) with active rheumatoid arthritis (RA) with an inadequate response to DMARDs</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">123</span><div class="note"><p class="first last">, OP-0159 (abstract)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2009&pages=123&issue=Suppl.+3&author=K.+Kanikauthor=R.+Fleischmannauthor=M.+Cutoloauthor=M.+Genoveseauthor=E.+Leeauthor=S.+Sadisauthor=C.+Connellauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=G.+Wallensteinauthor=B.+Wilkinsonauthor=S.+Zwillich&title=Phase+2b+dose+ranging+monotherapy+study+of+the+oral+JAK+inhibitor+CP-690%2C550+%28CP%29+or+adalimumab+%28ADA%29+vs+placebo+%28PBO%29+in+patients+%28pts%29+with+active+rheumatoid+arthritis+%28RA%29+with+an+inadequate+response+to+DMARDs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKanik%26aufirst%3DK.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCutolo%26aufirst%3DM.%26aulast%3DGenovese%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DSadis%26aufirst%3DS.%26aulast%3DConnell%26aufirst%3DC.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZwillich%26aufirst%3DS.%26atitle%3DPhase%25202b%2520dose%2520ranging%2520monotherapy%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520CP-690%252C550%2520%2528CP%2529%2520or%2520adalimumab%2520%2528ADA%2529%2520vs%2520placebo%2520%2528PBO%2529%2520in%2520patients%2520%2528pts%2529%2520with%2520active%2520rheumatoid%2520arthritis%2520%2528RA%2529%2520with%2520an%2520inadequate%2520response%2520to%2520DMARDs%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2009%26volume%3D68%26issue%3DSuppl.%25203%26spage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Fleischmann, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">Safety and efficacy after 24 week (wk) dosing of the oral JAK inhibitor CP-690,550 (CP) as monotherapy in patients (pts) with active rheumatoid arthritis (RA)</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">S718</span><div class="note"><p class="first last">, 1924 (abstract)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=S718&issue=Suppl.+10&author=R.+M.+Fleischmannauthor=M.+C.+Genoveseauthor=D.+Grubenauthor=K+Kanikauthor=G+Wallensteinauthor=B.+Wilkinsonauthor=S.+H.+Zwillich&title=Safety+and+efficacy+after+24+week+%28wk%29+dosing+of+the+oral+JAK+inhibitor+CP-690%2C550+%28CP%29+as+monotherapy+in+patients+%28pts%29+with+active+rheumatoid+arthritis+%28RA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%2BM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKanik%26aufirst%3DK%26aulast%3DWallenstein%26aufirst%3DG%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DSafety%2520and%2520efficacy%2520after%252024%2520week%2520%2528wk%2529%2520dosing%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520CP-690%252C550%2520%2528CP%2529%2520as%2520monotherapy%2520in%2520patients%2520%2528pts%2529%2520with%2520active%2520rheumatoid%2520arthritis%2520%2528RA%2529%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26issue%3DSuppl.%252010%26spage%3DS718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marfat, A.</span><span> </span><span class="NLM_article-title">Disposition of CP-671,305, a selective phosphodiesterase 4 inhibitor in preclinical species</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">â</span> <span class="NLM_lpage">770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2004&pages=755-770&author=A.+S.+Kalgutkarauthor=E.+Chooauthor=T.+J.+Taylorauthor=A.+Marfat&title=Disposition+of+CP-671%2C305%2C+a+selective+phosphodiesterase+4+inhibitor+in+preclinical+species"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DChoo%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DT.%2BJ.%26aulast%3DMarfat%26aufirst%3DA.%26atitle%3DDisposition%2520of%2520CP-671%252C305%252C%2520a%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520in%2520preclinical%2520species%26jtitle%3DXenobiotica%26date%3D2004%26volume%3D34%26spage%3D755%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Inhibition of human cytochrome P450 enzymes by constituents of St. Johnâs wort, an herbal preparation used in the treatment of depression</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">â</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=10871299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksFyht7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2000&pages=88-95&author=R.+S.+Obach&title=Inhibition+of+human+cytochrome+P450+enzymes+by+constituents+of+St.+John%E2%80%99s+wort%2C+an+herbal+preparation+used+in+the+treatment+of+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-95</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Com. available St. John's wort (Hypericum perforatum) exts., prepns. that are used in the treatment of depression, were examd. for the potential to inhibit human cytochrome P 450 (CYP) enzyme activities, specifically CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.  Crude exts. demonstrated inhibition of each of these five enzymes, with CYP2D6, CYP2C9, and CYP3A4 being more sensitive than CYP1A2 and CYP2C19.  Exts. were fractionated by HPLC, and each of the fractions was tested for inhibition of these five CYPs to identify individual constituents with inhibitory activity.  Several fractions were shown to possess inhibitory activity, including the fractions contg. hyperforin (the putative active antidepressant constituent), I3,II8-biapigenin, and hypericin.  Hyperforin and I3,II8-biapigenin were isolated from the ext., and inhibition consts. for the five CYP activities were measured.  In addn., three other constituents, hypericin, quercetin, and chlorogenic acid, were tested for inhibitory activity toward the CYP enzymes.  The flavonoid compd. I3,II8-biapigenin was shown to be a potent, competitive inhibitor of CYP3A4, CYP2C9, and CYP1A2 activities with Ki values of 0.038, 0.32, and 0.95 Î¼M, resp.  Hyperforin was a potent noncompetitive inhibitor of CYP2D6 activity (Ki = 1.5 Î¼M) and competitive inhibitor of CYP2C9 and CYP3A4 activities (Ki = 1.8 and 0.48 Î¼M, resp.).  Hypericin also demonstrated potent inhibition of several CYP activities.  These in vitro data indicate that St. John's wort prepns. contain constituents that can potently inhibit the activities of major human drug-metabolizing enzymes and suggest that these prepns. should be examd. for potential pharmacokinetic drug interactions in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3yqNwV8QP4bVg90H21EOLACvtfcHk0lgQIVwajJ6nyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksFyht7s%253D&md5=790574093452449f411ff2c79ac4348c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DInhibition%2520of%2520human%2520cytochrome%2520P450%2520enzymes%2520by%2520constituents%2520of%2520St.%2520John%25E2%2580%2599s%2520wort%252C%2520an%2520herbal%2520preparation%2520used%2520in%2520the%2520treatment%2520of%2520depression%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D294%26spage%3D88%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosea, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClure, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuperman, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombroski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes</span> <span class="citation_source-journal">Biopharm. Drug Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">â</span> <span class="NLM_lpage">386</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1002%2Fbdd.520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=16944451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12htb7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=371-386&author=A.+S.+Kalgutkarauthor=H.+L.+Hatchauthor=F.+Koseaauthor=H.+T.+Nguyenauthor=E.+F.+Chooauthor=K.+F.+McClureauthor=T.+J.+Taylorauthor=K.+R.+Henneauthor=A.+V.+Kupermanauthor=M.+A.+Dombroskiauthor=M.+A.+Letavic&title=Preclinical+pharmacokinetics+and+metabolism+of+6-%284-%282%2C5-difluorophenyl%29oxazol-5-yl%29-3-isopropyl-%5B1%2C2%2C4%5D-triazolo%5B4%2C3-a%5Dpyridine%2C+a+novel+and+selective+p38alpha+inhibitor%3A+identification+of+an+active+metabolite+in+preclinical+species+and+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38Î± inhibitor: identification of an active metabolite in preclinical species and human liver microsomes</span></div><div class="casAuthors">Kalgutkar, Amit S.; Hatch, Heather L.; Kosea, Frederick; Nguyen, Hang T.; Choo, Edna F.; McClure, Kim F.; Taylor, Timothy J.; Henne, Kirk R.; Kuperman, Alexander V.; Dombroski, Mark A.; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">371-386</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The disposition of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine (1), a potent and selective inhibitor of mitogen activated protein (MAP) kinase p38Î±, was characterized in several animal species in support of its selection for preclin. safety studies and potential clin. development.  This p38Î± inhibitor demonstrated generally favorable pharmacokinetic properties in all species examd.  Following i.v. administration, 1 exhibited low vols. of distribution at steady state (Vdss) ranging from 0.4-1.3 l/kg (2.4-26 l/m2) in the rat, dog and monkey.  Systemic plasma clearance was low in cynomolgus monkeys (6.00 mL/min/kg, 72.0 mL/min/m2) and Sprague-Dawley rats (7.65 Â± 1.08 mL/min/kg, 45.9 Â± 6.48 mL/min/m2 in male rats and 3.15 Â± 0.27 mL/min/kg, 18.9 Â± 1.62 mL/min/m2 in female rats) and moderate in beagle dogs (12.3 Â± 5.1 mL/min/kg, 246 Â± 102 mL/min/m2) resulting in plasma half-lives ranging from 1-5 h in preclin. species.  Moderate to high bioavailability of 1 was obsd. in rats (30-65%), dogs (87%) and monkeys (40%) after oral (p.o.) dosing consistent with the in vitro absorption profile of 1 in the Caco-2 permeability assay.  In rats, the oral pharmacokinetics were dose dependent over the dose range studied (5, 50, and 100 mg/kg).  The principal route of clearance of 1 in rat, dog, monkey and human liver microsomes and in vivo in preclin. species involved oxidative metab. mediated by cytochrome P 450 enzymes.  The major metabolic fate of 1 in preclin. species and humans involved hydroxylation on the iso-Pr group to yield the tertiary alc. metabolite 2.  In human liver microsomes, this transformation was catalyzed by CYP3A4 as judged from reaction phenotyping anal. using isoenzyme-specific inhibitors and recombinant CYP enzymes.  Metabolite 2 was also shown to possess inhibitory potency against p38Î± in a variety of in vitro assays.  As well as the active metabolite 2 were moderately to highly bound to plasma proteins (fu â¼ 0.1-0.33) in rat, mouse, dog, monkey and human.  As well as the active metabolite 2 did not exhibit competitive inhibition of the five major cytochrome P 450 enzymes namely CYP1A2, 2C9, 2C19, 2D6 and 3A4 (IC50>50 Î¼M).  Overall, these results indicate that the absorption, distribution, metab. and excretion (ADME) profile of 1 is relatively consistent across preclin. species and predict potentially favorable pharmacokinetic properties in humans,.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYaH40KCab97Vg90H21EOLACvtfcHk0lgWbFtyRz2G7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12htb7L&md5=2ce867cf95aeb6f9aa4227a12ddc0749</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fbdd.520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.520%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DHatch%26aufirst%3DH.%2BL.%26aulast%3DKosea%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DH.%2BT.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DTaylor%26aufirst%3DT.%2BJ.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DKuperman%26aufirst%3DA.%2BV.%26aulast%3DDombroski%26aufirst%3DM.%2BA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520metabolism%2520of%25206-%25284-%25282%252C5-difluorophenyl%2529oxazol-5-yl%2529-3-isopropyl-%255B1%252C2%252C4%255D-triazolo%255B4%252C3-a%255Dpyridine%252C%2520a%2520novel%2520and%2520selective%2520p38alpha%2520inhibitor%253A%2520identification%2520of%2520an%2520active%2520metabolite%2520in%2520preclinical%2520species%2520and%2520human%2520liver%2520microsomes%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2006%26volume%3D27%26spage%3D371%26epage%3D386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Davoll, J.</span><span> </span><span class="NLM_article-title">Pyrrolo[2,3-d]pyrimidines</span> <span class="citation_source-journal">J. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1960</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">â</span> <span class="NLM_lpage">138</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1960&pages=131-138&author=J.+Davoll&title=Pyrrolo%5B2%2C3-d%5Dpyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavoll%26aufirst%3DJ.%26atitle%3DPyrrolo%255B2%252C3-d%255Dpyrimidines%26jtitle%3DJ.%2520Chem.%2520Soc.%26date%3D1960%26volume%3D82%26spage%3D131%26epage%3D138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 211 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Sarah Duggan, Ursula Sheridan, Rebecca Deasy, Deirdre Murphy, <span class="NLM_string-name hlFld-ContribAuthor">Lorna Moynihan</span>. </span><span class="cited-content_cbyCitation_article-title">How Women and Six Sigma Have Contributed to Pfizerâs Robustness Program. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (3)
                                     , 616-620. <a href="https://doi.org/10.1021/acs.oprd.0c00415" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00415</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00415%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DHow%252BWomen%252Band%252BSix%252BSigma%252BHave%252BContributed%252Bto%252BPfizer%2525E2%252580%252599s%252BRobustness%252BProgram%26aulast%3DDuggan%26aufirst%3DSarah%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D21092020%26date%3D04122020%26volume%3D25%26issue%3D3%26spage%3D616%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Priyadeep Bhutani, Gaurav Joshi, Nivethitha Raja, Namrata Bachhav, Prabhakar K. Rajanna, Hemant Bhutani, Atish T. Paul, <span class="NLM_string-name hlFld-ContribAuthor">Raj Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">U.S. FDA Approved Drugs from 2015âJune 2020: A Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2339-2381. <a href="https://doi.org/10.1021/acs.jmedchem.0c01786" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01786%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DU.S.%252BFDA%252BApproved%252BDrugs%252Bfrom%252B2015%2525E2%252580%252593June%252B2020%25253A%252BA%252BPerspective%26aulast%3DBhutani%26aufirst%3DPriyadeep%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12102020%26date%3D22022021%26volume%3D64%26issue%3D5%26spage%3D2339%26epage%3D2381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lennart R. S. Huizing, James McDuffie, Filip Cuyckens, Marjolein van Heerden, Tatiana Koudriakova, Ron M. A. Heeren, <span class="NLM_string-name hlFld-ContribAuthor">Rob J. Vreeken</span>. </span><span class="cited-content_cbyCitation_article-title">Quantitative Mass Spectrometry Imaging to Study Drug Distribution in the Intestine Following Oral Dosing. </span><span class="cited-content_cbyCitation_journal-name">Analytical Chemistry</span><span> <strong>2021,</strong> <em>93 </em>
                                    (4)
                                     , 2144-2151. <a href="https://doi.org/10.1021/acs.analchem.0c03956" title="DOI URL">https://doi.org/10.1021/acs.analchem.0c03956</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.analchem.0c03956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.analchem.0c03956%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Chemistry%26atitle%3DQuantitative%252BMass%252BSpectrometry%252BImaging%252Bto%252BStudy%252BDrug%252BDistribution%252Bin%252Bthe%252BIntestine%252BFollowing%252BOral%252BDosing%26aulast%3DHuizing%26aufirst%3DLennart%2BR.%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D18092020%26date%3D05012021%26date%3D20012021%26volume%3D93%26issue%3D4%26spage%3D2144%26epage%3D2151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Eunsun Park, Sun Joo Lee, Heegyum Moon, Jongmi Park, Hyeonho Jeon, Ji Sun Hwang, Hayoung Hwang, Ki Bum Hong, Seung-Hee Han, Sun Choi, <span class="NLM_string-name hlFld-ContribAuthor">Soosung Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 958-979. <a href="https://doi.org/10.1021/acs.jmedchem.0c01026" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BBiological%252BEvaluation%252Bof%252BN-Methyl-pyrrolo%25255B2%25252C3-b%25255Dpyridine-5-carboxamide%252BDerivatives%252Bas%252BJAK1-Selective%252BInhibitors%26aulast%3DPark%26aufirst%3DEunsun%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D16062020%26date%3D11012021%26volume%3D64%26issue%3D2%26spage%3D958%26epage%3D979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chunjian Liu, James Lin, Charles Langevine, Daniel Smith, Jianqing Li, John S. Tokarski, Javed Khan, Max Ruzanov, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, Kathleen M. Gillooly, David Shuster, Yifan Zhang, Anil Thankappan, Kim W. McIntyre, Charu Chaudhry, Paul A. Elzinga, Manoj Chiney, Anjaneya Chimalakonda, Louis J. Lombardo, John E. Macor, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 677-694. <a href="https://doi.org/10.1021/acs.jmedchem.0c01698" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01698%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBMS-986202%25253A%252BA%252BClinical%252BTyk2%252BInhibitor%252Bthat%252BBinds%252Bto%252BTyk2%252BJH2%26aulast%3DLiu%26aufirst%3DChunjian%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D28092020%26date%3D28122020%26volume%3D64%26issue%3D1%26spage%3D677%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Emily J. Hanan, Jun Liang, Xiaojing Wang, Robert A. Blake, Nicole Blaquiere, <span class="NLM_string-name hlFld-ContribAuthor">Steven T. Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Monomeric Targeted Protein Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11330-11361. <a href="https://doi.org/10.1021/acs.jmedchem.0c00093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMonomeric%252BTargeted%252BProtein%252BDegraders%26aulast%3DHanan%26aufirst%3DEmily%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17012020%26date%3D15062020%26date%3D30042020%26volume%3D63%26issue%3D20%26spage%3D11330%26epage%3D11361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Satoru Noji, Yoshinori Hara, Tomoya Miura, Hiroshi Yamanaka, Katsuya Maeda, Akimi Hori, Hiroshi Yamamoto, Shingo Obika, Masafumi Inoue, Yasunori Hase, Takuya Orita, Satoki Doi, Tsuyoshi Adachi, Atsuo Tanimoto, Chika Oki, Yukari Kimoto, Yoshihiro Ogawa, Tamotsu Negoro, Hiromasa Hashimoto, <span class="NLM_string-name hlFld-ContribAuthor">Makoto Shiozaki</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 7163-7185. <a href="https://doi.org/10.1021/acs.jmedchem.0c00450" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00450</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00450%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BJanus%252BKinase%252BInhibitor%252BBearing%252Ba%252BHighly%252BThree-Dimensional%252BSpiro%252BScaffold%25253A%252BJTE-052%252B%252528Delgocitinib%252529%252Bas%252Ba%252BNew%252BDermatological%252BAgent%252Bto%252BTreat%252BInflammatory%252BSkin%252BDisorders%26aulast%3DNoji%26aufirst%3DSatoru%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17032020%26date%3D29062020%26date%3D08062020%26volume%3D63%26issue%3D13%26spage%3D7163%26epage%3D7185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qibin Su, Erica Banks, Geraldine Bebernitz, Kirsten Bell, Cassandra F. Borenstein, Huawei Chen, Claudio E. Chuaqui, Nanhua Deng, Andrew D. Ferguson, Sameer Kawatkar, Neil P. Grimster, Linette Ruston, Paul D. Lyne, Jon A. Read, Xianyou Peng, Xiaohui Pei, Stephen Fawell, Zhanlei Tang, Scott Throner, Melissa M. Vasbinder, Haoyu Wang, Jon Winter-Holt, Richard Woessner, Allan Wu, Wenzhan Yang, Michael Zinda, <span class="NLM_string-name hlFld-ContribAuthor">Jason G. Kettle</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4517-4527. <a href="https://doi.org/10.1021/acs.jmedchem.9b01392" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01392%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%2525282R%252529-N-%25255B3-%25255B2-%25255B%2525283-Methoxy-1-methyl-pyrazol-4-yl%252529amino%25255Dpyrimidin-4-yl%25255D-1H-indol-7-yl%25255D-2-%2525284-methylpiperazin-1-yl%252529propenamide%252B%252528AZD4205%252529%252Bas%252Ba%252BPotent%252Band%252BSelective%252BJanus%252BKinase%252B1%252BInhibitor%26aulast%3DSu%26aufirst%3DQibin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D22082019%26date%3D28042020%26date%3D16042020%26volume%3D63%26issue%3D9%26spage%3D4517%26epage%3D4527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 441-469. <a href="https://doi.org/10.1021/acs.jmedchem.9b00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BExploration%252Bof%252BChirality%252Bfor%252BImproved%252BDruggability%252Bwithin%252Bthe%252BHuman%252BKinome%26aulast%3DSaha%26aufirst%3DDebasmita%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15042019%26date%3D09102019%26date%3D24092019%26volume%3D63%26issue%3D2%26spage%3D441%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Minjian Yang, Bingzhong Tao, Chengjuan Chen, Wenqiang Jia, Shaolei Sun, Tiantai Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojian Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (12)
                                     , 5002-5012. <a href="https://doi.org/10.1021/acs.jcim.9b00798" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00798%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMachine%252BLearning%252BModels%252BBased%252Bon%252BMolecular%252BFingerprints%252Band%252Ban%252BExtreme%252BGradient%252BBoosting%252BMethod%252BLead%252Bto%252Bthe%252BDiscovery%252Bof%252BJAK2%252BInhibitors%26aulast%3DYang%26aufirst%3DMinjian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15092019%26date%3D04122019%26date%3D20112019%26volume%3D59%26issue%3D12%26spage%3D5002%26epage%3D5012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yong Tao, J. Christopher McWilliams, Kristin E. Wiglesworth, Kevin P. Girard, Teresa M. Makowski, Neal W. Sach, Jason G. Mustakis, Ruchi Mehta, John I. Trujillo, Xiaofeng Chen, Tangqing Li, Feng Shi, Chengfu Xie, <span class="NLM_string-name hlFld-ContribAuthor">Qing Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Process Development and Scale Up of a Selective JAK3 Covalent Inhibitor PF-06651600. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (9)
                                     , 1872-1880. <a href="https://doi.org/10.1021/acs.oprd.9b00198" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00198</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00198%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DProcess%252BDevelopment%252Band%252BScale%252BUp%252Bof%252Ba%252BSelective%252BJAK3%252BCovalent%252BInhibitor%252BPF-06651600%26aulast%3DTao%26aufirst%3DYong%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D01052019%26date%3D31072019%26date%3D19072019%26volume%3D23%26issue%3D9%26spage%3D1872%26epage%3D1880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liyang Shi, Zhenpeng Zhong, Xitao Li, Yiqing Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Zhengying Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (2)
                                     , 1054-1066. <a href="https://doi.org/10.1021/acs.jmedchem.8b01823" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01823%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ban%252BOrally%252BAvailable%252BJanus%252BKinase%252B3%252BSelective%252BCovalent%252BInhibitor%26aulast%3DShi%26aufirst%3DLiyang%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21112018%26date%3D07012019%26volume%3D62%26issue%3D2%26spage%3D1054%26epage%3D1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sharan K. Bagal, Kiyoyuki Omoto, David C. Blakemore, Peter J. Bungay, James G. Bilsland, Philip J. Clarke, Matthew S. Corbett, Ciaran N. Cronin, J. Jean Cui, Rebecca Dias, Neil J. Flanagan, Samantha E. Greasley, Rachel Grimley, Eric Johnson, David Fengas, Linda Kitching, Michelle L. Kraus, Indrawan McAlpine, Asako Nagata, Gareth J. Waldron, <span class="NLM_string-name hlFld-ContribAuthor">Joseph S. Warmus</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (1)
                                     , 247-265. <a href="https://doi.org/10.1021/acs.jmedchem.8b00280" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00280%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BAllosteric%25252C%252BPotent%25252C%252BSubtype%252BSelective%25252C%252Band%252BPeripherally%252BRestricted%252BTrkA%252BKinase%252BInhibitors%26aulast%3DBagal%26aufirst%3DSharan%2BK.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D19022018%26date%3D03052018%26date%3D19042018%26volume%3D62%26issue%3D1%26spage%3D247%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Agustin Casimiro-Garcia, John I. Trujillo, Felix Vajdos, Brian Juba, Mary Ellen Banker, Ann Aulabaugh, Paul Balbo, Jonathan Bauman, Jill Chrencik, Jotham W. Coe, Robert Czerwinski, Martin Dowty, John D. Knafels, Soojin Kwon, Louis Leung, Sidney Liang, Ralph P. Robinson, Jean-Baptiste Telliez, Ray Unwalla, Xin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Atli Thorarensen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (23)
                                     , 10665-10699. <a href="https://doi.org/10.1021/acs.jmedchem.8b01308" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01308</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01308%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BCyanamide-Based%252BJanus%252BKinase%252B3%252B%252528JAK3%252529%252BCovalent%252BInhibitors%26aulast%3DCasimiro-Garcia%26aufirst%3DAgustin%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D18082018%26date%3D30112018%26date%3D13112018%26volume%3D61%26issue%3D23%26spage%3D10665%26epage%3D10699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marian C. Bryan, <span class="NLM_string-name hlFld-ContribAuthor">Naomi S. Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9030-9058. <a href="https://doi.org/10.1021/acs.jmedchem.8b00667" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDisorders%25253A%252BRecent%252BAdvances%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26042018%26date%3D15062018%26date%3D05062018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ted W. Johnson, Rebecca A. Gallego, <span class="NLM_string-name hlFld-ContribAuthor">Martin P. Edwards</span>. </span><span class="cited-content_cbyCitation_article-title">Lipophilic Efficiency as an Important Metric in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6401-6420. <a href="https://doi.org/10.1021/acs.jmedchem.8b00077" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLipophilic%252BEfficiency%252Bas%252Ban%252BImportant%252BMetric%252Bin%252BDrug%252BDesign%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16012018%26date%3D17042018%26date%3D28032018%26volume%3D61%26issue%3D15%26spage%3D6401%26epage%3D6420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Neil P. Grimster, Erica Anderson, Marat Alimzhanov, Geraldine Bebernitz, Kirsten Bell, Claudio Chuaqui, Tracy Deegan, Andrew D. Ferguson, Thomas Gero, Andreas Harsch, Dennis Huszar, Aarti Kawatkar, Jason G. Kettle, Paul Lyne, Jon A. Read, Caroline Rivard Costa, Linette Ruston, Patricia Schroeder, Jie Shi, Qibin Su, Scott Throner, Dorin Toader, Melissa Vasbinder, Richard Woessner, Haixia Wang, Allan Wu, Minwei Ye, Weijia Zheng, <span class="NLM_string-name hlFld-ContribAuthor">Michael Zinda</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5235-5244. <a href="https://doi.org/10.1021/acs.jmedchem.8b00076" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00076%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252Ba%252BNovel%252BSeries%252Bof%252BHighly%252BSelective%252BJAK1%252BKinase%252BInhibitors%26aulast%3DGrimster%26aufirst%3DNeil%2BP.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16012018%26date%3D13062018%26date%3D01062018%26volume%3D61%26issue%3D12%26spage%3D5235%26epage%3D5244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael Forster, Apirat Chaikuad, Teodor Dimitrov, Eva DÃ¶ring, Julia Holstein, Benedict-Tilman Berger, Matthias Gehringer, Kamran Ghoreschi, Susanne MÃ¼ller, Stefan Knapp, <span class="NLM_string-name hlFld-ContribAuthor">Stefan A. Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">Development, Optimization, and StructureâActivity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5350-5366. <a href="https://doi.org/10.1021/acs.jmedchem.8b00571" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00571%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%25252C%252BOptimization%25252C%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BCovalent-Reversible%252BJAK3%252BInhibitors%252BBased%252Bon%252Ba%252BTricyclic%252BImidazo%25255B5%25252C4-d%25255Dpyrrolo%25255B2%25252C3-b%25255Dpyridine%252BScaffold%26aulast%3DForster%26aufirst%3DMichael%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D11042018%26date%3D13062018%26date%3D31052018%26volume%3D61%26issue%3D12%26spage%3D5350%26epage%3D5366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael L.  Vazquez</span>, <span class="hlFld-ContribAuthor ">Neelu  Kaila</span>, <span class="hlFld-ContribAuthor ">Joseph W.  Strohbach</span>, <span class="hlFld-ContribAuthor ">John D.  Trzupek</span>, <span class="hlFld-ContribAuthor ">Matthew F.  Brown</span>, <span class="hlFld-ContribAuthor ">Mark E.  Flanagan</span>, <span class="hlFld-ContribAuthor ">Mark J.  Mitton-Fry</span>, <span class="hlFld-ContribAuthor ">Timothy A.  Johnson</span>, <span class="hlFld-ContribAuthor ">Ruth E.  TenBrink</span>, <span class="hlFld-ContribAuthor ">Eric P.  Arnold</span>, <span class="hlFld-ContribAuthor ">Arindrajit  Basak</span>, <span class="hlFld-ContribAuthor ">Steven E.  Heasley</span>, <span class="hlFld-ContribAuthor ">Soojin  Kwon</span>, <span class="hlFld-ContribAuthor ">Jonathan  Langille</span>, <span class="hlFld-ContribAuthor ">Mihir D.  Parikh</span>, <span class="hlFld-ContribAuthor ">Sarah H.  Griffin</span>, <span class="hlFld-ContribAuthor ">Jeffrey M.  Casavant</span>, <span class="hlFld-ContribAuthor ">Brian A.  Duclos</span>, <span class="hlFld-ContribAuthor ">Ashley E.  Fenwick</span>, <span class="hlFld-ContribAuthor ">Thomas M.  Harris</span>, <span class="hlFld-ContribAuthor ">Seungil  Han</span>, <span class="hlFld-ContribAuthor ">Nicole  Caspers</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Xin  Yang</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">Martin  Hegen</span>, <span class="hlFld-ContribAuthor ">Peter T.  Symanowicz</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Tsung H.  Lin</span>, <span class="hlFld-ContribAuthor ">Jason  Jussif</span>, <span class="hlFld-ContribAuthor ">James D.  Clark</span>, <span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>, <span class="hlFld-ContribAuthor ">Ralph P.  Robinson</span>, and <span class="hlFld-ContribAuthor ">Ray  Unwalla</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (3)
                                     , 1130-1152. <a href="https://doi.org/10.1021/acs.jmedchem.7b01598" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01598</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BN-%25257Bcis-3-%25255BMethyl%2525287H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%252529amino%25255Dcyclobutyl%25257Dpropane-1-sulfonamide%252B%252528PF-04965842%252529%25253A%252BA%252BSelective%252BJAK1%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DVazquez%26aufirst%3DMichael%2BL.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D30102017%26date%3D23012018%26date%3D08022018%26date%3D03012018%26volume%3D61%26issue%3D3%26spage%3D1130%26epage%3D1152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tony  Siu</span>, <span class="hlFld-ContribAuthor ">Jason  Brubaker</span>, <span class="hlFld-ContribAuthor ">Peter  Fuller</span>, <span class="hlFld-ContribAuthor ">Luis  Torres</span>, <span class="hlFld-ContribAuthor ">Hongbo  Zeng</span>, <span class="hlFld-ContribAuthor ">Joshua  Close</span>, <span class="hlFld-ContribAuthor ">Dawn M.  Mampreian</span>, <span class="hlFld-ContribAuthor ">Feng  Shi</span>, <span class="hlFld-ContribAuthor ">Duan  Liu</span>, <span class="hlFld-ContribAuthor ">Xavier  Fradera</span>, <span class="hlFld-ContribAuthor ">Kevin  Johnson</span>, <span class="hlFld-ContribAuthor ">Nathan  Bays</span>, <span class="hlFld-ContribAuthor ">Elma  Kadic</span>, <span class="hlFld-ContribAuthor ">Fang  He</span>, <span class="hlFld-ContribAuthor ">Peter  Goldenblatt</span>, <span class="hlFld-ContribAuthor ">Lynsey  Shaffer</span>, <span class="hlFld-ContribAuthor ">Sangita B.  Patel</span>, <span class="hlFld-ContribAuthor ">Charles A.  Lesburg</span>, <span class="hlFld-ContribAuthor ">Carla  Alpert</span>, <span class="hlFld-ContribAuthor ">Lauren  Dorosh</span>, <span class="hlFld-ContribAuthor ">Sujal V.  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Hongshi  Yu</span>, <span class="hlFld-ContribAuthor ">Joel  Klappenbach</span>, <span class="hlFld-ContribAuthor ">Fiona  Elwood</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Dinsmore</span>, <span class="hlFld-ContribAuthor ">Rafael  Fernandez</span>, <span class="hlFld-ContribAuthor ">Lily  Moy</span>, and <span class="hlFld-ContribAuthor ">Jonathan R.  Young</span>  . </span><span class="cited-content_cbyCitation_article-title">The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (23)
                                     , 9676-9690. <a href="https://doi.org/10.1021/acs.jmedchem.7b01135" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01135</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01135%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BDiscovery%252Bof%252B3-%252528%2525284-Chloro-3-methoxyphenyl%252529amino%252529-1-%252528%2525283R%25252C4S%252529-4-cyanotetrahydro-2H-pyran-3-yl%252529-1H-pyrazole-4-carboxamide%25252C%252Ba%252BHighly%252BLigand%252BEfficient%252Band%252BEfficacious%252BJanus%252BKinase%252B1%252BSelective%252BInhibitor%252Bwith%252BFavorable%252BPharmacokinetic%252BProperties%26aulast%3DSiu%26aufirst%3DTony%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D04082017%26date%3D04122017%26date%3D14122017%26date%3D20112017%26volume%3D60%26issue%3D23%26spage%3D9676%26epage%3D9690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Jones</span>, <span class="hlFld-ContribAuthor ">R. Ian  Storer</span>, <span class="hlFld-ContribAuthor ">Yogesh A.  Sabnis</span>, <span class="hlFld-ContribAuthor ">Florian M.  Wakenhut</span>, <span class="hlFld-ContribAuthor ">Gavin A.  Whitlock</span>, <span class="hlFld-ContribAuthor ">Katherine S.  England</span>, <span class="hlFld-ContribAuthor ">Takasuke  Mukaiyama</span>, <span class="hlFld-ContribAuthor ">Christoph M.  Dehnhardt</span>, <span class="hlFld-ContribAuthor ">Jotham W.  Coe</span>, <span class="hlFld-ContribAuthor ">Steve W.  Kortum</span>, <span class="hlFld-ContribAuthor ">Jill E.  Chrencik</span>, <span class="hlFld-ContribAuthor ">David G.  Brown</span>, <span class="hlFld-ContribAuthor ">Rhys M.  Jones</span>, <span class="hlFld-ContribAuthor ">John R.  Murphy</span>, <span class="hlFld-ContribAuthor ">Thean  Yeoh</span>, <span class="hlFld-ContribAuthor ">Paul  Morgan</span>, and <span class="hlFld-ContribAuthor ">Iain  Kilty</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (2)
                                     , 767-786. <a href="https://doi.org/10.1021/acs.jmedchem.6b01634" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01634%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252Ba%252BPan-Janus%252BKinase%252BInhibitor%252BClinical%252BCandidate%252B%252528PF-06263276%252529%252BSuitable%252Bfor%252BInhaled%252Band%252BTopical%252BDelivery%252Bfor%252Bthe%252BTreatment%252Bof%252BInflammatory%252BDiseases%252Bof%252Bthe%252BLungs%252Band%252BSkin%26aulast%3DJones%26aufirst%3DPeter%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D08112016%26date%3D04012017%26date%3D26012017%26date%3D16122016%26volume%3D60%26issue%3D2%26spage%3D767%26epage%3D786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Andrea J.  Gonzales</span>, <span class="hlFld-ContribAuthor ">Julie A.  Spicer</span>, <span class="hlFld-ContribAuthor ">Helen  Lee</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Reed</span>, <span class="hlFld-ContribAuthor ">Karen  Sexton</span>, <span class="hlFld-ContribAuthor ">Irene W.  Althaus</span>, <span class="hlFld-ContribAuthor ">Tong  Zhu</span>, <span class="hlFld-ContribAuthor ">Shannon L.  Black</span>, <span class="hlFld-ContribAuthor ">Adrian  Blaser</span>, <span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Paul A.  Ellis</span>, <span class="hlFld-ContribAuthor ">Stephen  Fakhoury</span>, <span class="hlFld-ContribAuthor ">Patricia J.  Harvey</span>, <span class="hlFld-ContribAuthor ">Ken  Hook</span>, <span class="hlFld-ContribAuthor ">Florence O. J.  McCarthy</span>, <span class="hlFld-ContribAuthor ">Brian D.  Palmer</span>, <span class="hlFld-ContribAuthor ">Freddy  Rivault</span>, <span class="hlFld-ContribAuthor ">Kevin  Schlosser</span>, <span class="hlFld-ContribAuthor ">Teresa  Ellis</span>, <span class="hlFld-ContribAuthor ">Andrew M.  Thompson</span>, <span class="hlFld-ContribAuthor ">Erin  Trachet</span>, <span class="hlFld-ContribAuthor ">R. Thomas  Winters</span>, <span class="hlFld-ContribAuthor ">Haile  Tecle</span>, and <span class="hlFld-ContribAuthor ">Alexander  Bridges</span>  . </span><span class="cited-content_cbyCitation_article-title">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (17)
                                     , 8103-8124. <a href="https://doi.org/10.1021/acs.jmedchem.6b00883" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00883</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTyrosine%252BKinase%252BInhibitors.%252B20.%252BOptimization%252Bof%252BSubstituted%252BQuinazoline%252Band%252BPyrido%25255B3%25252C4-d%25255Dpyrimidine%252BDerivatives%252Bas%252BOrally%252BActive%25252C%252BIrreversible%252BInhibitors%252Bof%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BFamily%26aulast%3DSmaill%26aufirst%3DJeff%2BB.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D15062016%26date%3D22082016%26date%3D08092016%26date%3D04082016%26volume%3D59%26issue%3D17%26spage%3D8103%26epage%3D8124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Deodial  Guiadeen</span>, <span class="hlFld-ContribAuthor ">Arto  Krikorian</span>, <span class="hlFld-ContribAuthor ">Xiaolei  Gao</span>, <span class="hlFld-ContribAuthor ">James  Wang</span>, <span class="hlFld-ContribAuthor ">Sobhana Babu  Boga</span>, <span class="hlFld-ContribAuthor ">Abdul-Basit  Alhassan</span>, <span class="hlFld-ContribAuthor ">Younong  Yu</span>, <span class="hlFld-ContribAuthor ">Henry  Vaccaro</span>, <span class="hlFld-ContribAuthor ">Shilan  Liu</span>, <span class="hlFld-ContribAuthor ">Chundao  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Wu</span>, <span class="hlFld-ContribAuthor ">Alan  Cooper</span>, <span class="hlFld-ContribAuthor ">Jos  de Man</span>, <span class="hlFld-ContribAuthor ">Allard  Kaptein</span>, <span class="hlFld-ContribAuthor ">Kevin  Maloney</span>, <span class="hlFld-ContribAuthor ">Viktor  Hornak</span>, <span class="hlFld-ContribAuthor ">Ying-Duo  Gao</span>, <span class="hlFld-ContribAuthor ">Thierry O.  Fischmann</span>, <span class="hlFld-ContribAuthor ">Hans  Raaijmakers</span>, <span class="hlFld-ContribAuthor ">Diep  Vu-Pham</span>, <span class="hlFld-ContribAuthor ">Jeremy  Presland</span>, <span class="hlFld-ContribAuthor ">My  Mansueto</span>, <span class="hlFld-ContribAuthor ">Zangwei  Xu</span>, <span class="hlFld-ContribAuthor ">Erica  Leccese</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang-Hoover</span>, <span class="hlFld-ContribAuthor ">Ian  Knemeyer</span>, <span class="hlFld-ContribAuthor ">Charles G.  Garlisi</span>, <span class="hlFld-ContribAuthor ">Nathan  Bays</span>, <span class="hlFld-ContribAuthor ">Peter  Stivers</span>, <span class="hlFld-ContribAuthor ">Philip E.  Brandish</span>, <span class="hlFld-ContribAuthor ">Alexandra  Hicks</span>, <span class="hlFld-ContribAuthor ">Ronald  Kim</span>, and <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (2)
                                     , 198-203. <a href="https://doi.org/10.1021/acsmedchemlett.5b00463" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00463%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B8-Amino-imidazo%25255B1%25252C5-a%25255Dpyrazines%252Bas%252BReversible%252BBTK%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DLiu%26aufirst%3DJian%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D01122015%26date%3D18122015%26date%3D30122015%26date%3D11022016%26date%3D19122015%26volume%3D7%26issue%3D2%26spage%3D198%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pan  Li</span>, <span class="hlFld-ContribAuthor ">Ming  Zhou</span>, <span class="hlFld-ContribAuthor ">Qingyang  Zhao</span>, <span class="hlFld-ContribAuthor ">Weilong  Wu</span>, <span class="hlFld-ContribAuthor ">Xinquan  Hu</span>, <span class="hlFld-ContribAuthor ">Xiu-Qin  Dong</span>, and <span class="hlFld-ContribAuthor ">Xumu  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Chiral Î²-Amino Nitroalkanes via Rhodium-Catalyzed Asymmetric Hydrogenation. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2016,</strong> <em>18 </em>
                                    (1)
                                     , 40-43. <a href="https://doi.org/10.1021/acs.orglett.5b03158" title="DOI URL">https://doi.org/10.1021/acs.orglett.5b03158</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.5b03158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.5b03158%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BChiral%252B%2525CE%2525B2-Amino%252BNitroalkanes%252Bvia%252BRhodium-Catalyzed%252BAsymmetric%252BHydrogenation%26aulast%3DLi%26aufirst%3DPan%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D01112015%26date%3D11122015%26date%3D04012016%26volume%3D18%26issue%3D1%26spage%3D40%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luc J.  Farmer</span>, <span class="hlFld-ContribAuthor ">Mark W.  Ledeboer</span>, <span class="hlFld-ContribAuthor ">Thomas  Hoock</span>, <span class="hlFld-ContribAuthor ">Michael J.  Arnost</span>, <span class="hlFld-ContribAuthor ">Randy S.  Bethiel</span>, <span class="hlFld-ContribAuthor ">Youssef L.  Bennani</span>, <span class="hlFld-ContribAuthor ">James J.  Black</span>, <span class="hlFld-ContribAuthor ">Christopher L.  Brummel</span>, <span class="hlFld-ContribAuthor ">Ananthsrinivas  Chakilam</span>, <span class="hlFld-ContribAuthor ">Warren A.  Dorsch</span>, <span class="hlFld-ContribAuthor ">Bin  Fan</span>, <span class="hlFld-ContribAuthor ">John E.  Cochran</span>, <span class="hlFld-ContribAuthor ">Summer  Halas</span>, <span class="hlFld-ContribAuthor ">Edmund M.  Harrington</span>, <span class="hlFld-ContribAuthor ">James K.  Hogan</span>, <span class="hlFld-ContribAuthor ">David  Howe</span>, <span class="hlFld-ContribAuthor ">Hui  Huang</span>, <span class="hlFld-ContribAuthor ">Dylan H.  Jacobs</span>, <span class="hlFld-ContribAuthor ">Leena M.  Laitinen</span>, <span class="hlFld-ContribAuthor ">Shengkai  Liao</span>, <span class="hlFld-ContribAuthor ">Sudipta  Mahajan</span>, <span class="hlFld-ContribAuthor ">Valerie  Marone</span>, <span class="hlFld-ContribAuthor ">Gabriel  Martinez-Botella</span>, <span class="hlFld-ContribAuthor ">Pamela  McCarthy</span>, <span class="hlFld-ContribAuthor ">David  Messersmith</span>, <span class="hlFld-ContribAuthor ">Mark  Namchuk</span>, <span class="hlFld-ContribAuthor ">Luke  Oh</span>, <span class="hlFld-ContribAuthor ">Marina S.  Penney</span>, <span class="hlFld-ContribAuthor ">Albert C.  Pierce</span>, <span class="hlFld-ContribAuthor ">Scott A.  Raybuck</span>, <span class="hlFld-ContribAuthor ">Arthur  Rugg</span>, <span class="hlFld-ContribAuthor ">Francesco G.  Salituro</span>, <span class="hlFld-ContribAuthor ">Kumkum  Saxena</span>, <span class="hlFld-ContribAuthor ">Dean  Shannon</span>, <span class="hlFld-ContribAuthor ">Dina  Shlyakter</span>, <span class="hlFld-ContribAuthor ">Lora  Swenson</span>, <span class="hlFld-ContribAuthor ">Shi-Kai  Tian</span>, <span class="hlFld-ContribAuthor ">Christopher  Town</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Tiansheng  Wang</span>, <span class="hlFld-ContribAuthor ">M. Woods  Wannamaker</span>, <span class="hlFld-ContribAuthor ">Raymond J.  Winquist</span>, and <span class="hlFld-ContribAuthor ">Harmon J.  Zuccola</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (18)
                                     , 7195-7216. <a href="https://doi.org/10.1021/acs.jmedchem.5b00301" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00301</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00301%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BVX-509%252B%252528Decernotinib%252529%25253A%252BA%252BPotent%252Band%252BSelective%252BJanus%252BKinase%252B3%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DFarmer%26aufirst%3DLuc%2BJ.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D20022015%26date%3D10092015%26date%3D24092015%26date%3D31072015%26volume%3D58%26issue%3D18%26spage%3D7195%26epage%3D7216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mi Kyoung  Kim</span>, <span class="hlFld-ContribAuthor ">Heerim  Shin</span>, <span class="hlFld-ContribAuthor ">Kwang-su  Park</span>, <span class="hlFld-ContribAuthor ">Hyungmi  Kim</span>, <span class="hlFld-ContribAuthor ">Jiseon  Park</span>, <span class="hlFld-ContribAuthor ">Kangjeon  Kim</span>, <span class="hlFld-ContribAuthor ">Joonwoo  Nam</span>, <span class="hlFld-ContribAuthor ">Hyunah  Choo</span>, and <span class="hlFld-ContribAuthor ">Youhoon  Chong</span>  . </span><span class="cited-content_cbyCitation_article-title">Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (18)
                                     , 7596-7602. <a href="https://doi.org/10.1021/acs.jmedchem.5b01263" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01263%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBenzimidazole%252BDerivatives%252Bas%252BPotent%252BJAK1-Selective%252BInhibitors%26aulast%3DKim%26aufirst%3DMi%2BKyoung%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D10052015%26date%3D15092015%26date%3D24092015%26date%3D09092015%26volume%3D58%26issue%3D18%26spage%3D7596%26epage%3D7602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Koshi  Akahane</span>, <span class="hlFld-ContribAuthor ">Randall  McNally</span>, <span class="hlFld-ContribAuthor ">Kathleen M. S. E.  Reyskens</span>, <span class="hlFld-ContribAuthor ">Scott B.  Ficarro</span>, <span class="hlFld-ContribAuthor ">Suhu  Liu</span>, <span class="hlFld-ContribAuthor ">Grit S.  Herter-Sprie</span>, <span class="hlFld-ContribAuthor ">Shohei  Koyama</span>, <span class="hlFld-ContribAuthor ">Michael J.  Pattison</span>, <span class="hlFld-ContribAuthor ">Katherine  Labella</span>, <span class="hlFld-ContribAuthor ">Liv  Johannessen</span>, <span class="hlFld-ContribAuthor ">Esra A.  Akbay</span>, <span class="hlFld-ContribAuthor ">Kwok-Kin  Wong</span>, <span class="hlFld-ContribAuthor ">David A.  Frank</span>, <span class="hlFld-ContribAuthor ">Jarrod A.  Marto</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Look</span>, <span class="hlFld-ContribAuthor ">J. Simon C.  Arthur</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>, and <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Selective Covalent Janus Kinase 3 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (16)
                                     , 6589-6606. <a href="https://doi.org/10.1021/acs.jmedchem.5b00710" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00710%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BSelective%252BCovalent%252BJanus%252BKinase%252B3%252BInhibitors%26aulast%3DTan%26aufirst%3DLi%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D07052015%26date%3D18082015%26date%3D27082015%26date%3D10082015%26volume%3D58%26issue%3D16%26spage%3D6589%26epage%3D6606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher R.  Smith</span>, <span class="hlFld-ContribAuthor ">Douglas R.  Dougan</span>, <span class="hlFld-ContribAuthor ">Mallareddy  Komandla</span>, <span class="hlFld-ContribAuthor ">Toufike  Kanouni</span>, <span class="hlFld-ContribAuthor ">Beverly  Knight</span>, <span class="hlFld-ContribAuthor ">J. David  Lawson</span>, <span class="hlFld-ContribAuthor ">Mark  Sabat</span>, <span class="hlFld-ContribAuthor ">Ewan R.  Taylor</span>, <span class="hlFld-ContribAuthor ">Phong  Vu</span>, and <span class="hlFld-ContribAuthor ">Corey  Wyrick</span>  . </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Discovery of a Small Molecule Inhibitor of Brutonâs Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (14)
                                     , 5437-5444. <a href="https://doi.org/10.1021/acs.jmedchem.5b00734" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00734</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00734%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFragment-Based%252BDiscovery%252Bof%252Ba%252BSmall%252BMolecule%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DSmith%26aufirst%3DChristopher%2BR.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D19022015%26date%3D02072015%26date%3D23072015%26date%3D18062015%26volume%3D58%26issue%3D14%26spage%3D5437%26epage%3D5444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Lou</span>, <span class="hlFld-ContribAuthor ">Xiaochun  Han</span>, <span class="hlFld-ContribAuthor ">Andreas  Kuglstatter</span>, <span class="hlFld-ContribAuthor ">Rama K.  Kondru</span>, <span class="hlFld-ContribAuthor ">Zachary K.  Sweeney</span>, <span class="hlFld-ContribAuthor ">Michael  Soth</span>, <span class="hlFld-ContribAuthor ">Joel  McIntosh</span>, <span class="hlFld-ContribAuthor ">Renee  Litman</span>, <span class="hlFld-ContribAuthor ">Judy  Suh</span>, <span class="hlFld-ContribAuthor ">Buelent  Kocer</span>, <span class="hlFld-ContribAuthor ">Dana  Davis</span>, <span class="hlFld-ContribAuthor ">Jaehyeon  Park</span>, <span class="hlFld-ContribAuthor ">Sandra  Frauchiger</span>, <span class="hlFld-ContribAuthor ">Nolan  Dewdney</span>, <span class="hlFld-ContribAuthor ">Hasim  Zecic</span>, <span class="hlFld-ContribAuthor ">Joshua P.  Taygerly</span>, <span class="hlFld-ContribAuthor ">Keshab  Sarma</span>, <span class="hlFld-ContribAuthor ">Junbae  Hong</span>, <span class="hlFld-ContribAuthor ">Ronald J.  Hill</span>, <span class="hlFld-ContribAuthor ">Tobias  Gabriel</span>, <span class="hlFld-ContribAuthor ">David M.  Goldstein</span>, and <span class="hlFld-ContribAuthor ">Timothy D.  Owens</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Drug Design of RN486, a Potent and Selective Brutonâs Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (1)
                                     , 512-516. <a href="https://doi.org/10.1021/jm500305p" title="DOI URL">https://doi.org/10.1021/jm500305p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500305p%26sid%3Dliteratum%253Aachs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDrug%252BDesign%252Bof%252BRN486%25252C%252Ba%252BPotent%252Band%252BSelective%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitor%25252C%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DLou%26aufirst%3DYan%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D03032014%26date%3D16042014%26date%3D08012015%26date%3D08042014%26volume%3D58%26issue%3D1%26spage%3D512%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James D.  Clark</span>, <span class="hlFld-ContribAuthor ">Mark E.  Flanagan</span>, and <span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (12)
                                     , 5023-5038. <a href="https://doi.org/10.1021/jm401490p" title="DOI URL">https://doi.org/10.1021/jm401490p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401490p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BJanus%252BKinase%252B%252528JAK%252529%252BInhibitors%252Bfor%252BInflammatory%252BDiseases%26aulast%3DClark%26aufirst%3DJames%2BD.%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D25092013%26date%3D23012014%26date%3D26062014%26date%3D13012014%26volume%3D57%26issue%3D12%26spage%3D5023%26epage%3D5038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  Zhou</span>, <span class="hlFld-ContribAuthor ">Dejun  Dong</span>, <span class="hlFld-ContribAuthor ">Baolin  Zhu</span>, <span class="hlFld-ContribAuthor ">Huiling  Geng</span>, <span class="hlFld-ContribAuthor ">Yan  Wang</span>, and <span class="hlFld-ContribAuthor ">Xumu  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Rhodium-Catalyzed Enantioselective Hydrogenation of Î²-Acylamino Nitroolefins: A New Approach to Chiral Î²-Amino Nitroalkanes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2013,</strong> <em>15 </em>
                                    (21)
                                     , 5524-5527. <a href="https://doi.org/10.1021/ol4026843" title="DOI URL">https://doi.org/10.1021/ol4026843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol4026843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol4026843%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRhodium-Catalyzed%252BEnantioselective%252BHydrogenation%252Bof%252B%2525CE%2525B2-Acylamino%252BNitroolefins%25253A%252BA%252BNew%252BApproach%252Bto%252BChiral%252B%2525CE%2525B2-Amino%252BNitroalkanes%26aulast%3DZhou%26aufirst%3DMing%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D18092013%26date%3D23102013%26date%3D01112013%26volume%3D15%26issue%3D21%26spage%3D5524%26epage%3D5527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Liang</span>, <span class="hlFld-ContribAuthor ">Anne  van Abbema</span>, <span class="hlFld-ContribAuthor ">Mercedesz  Balazs</span>, <span class="hlFld-ContribAuthor ">Kathy  Barrett</span>, <span class="hlFld-ContribAuthor ">Leo  Berezhkovsky</span>, <span class="hlFld-ContribAuthor ">Wade  Blair</span>, <span class="hlFld-ContribAuthor ">Christine  Chang</span>, <span class="hlFld-ContribAuthor ">Donnie  Delarosa</span>, <span class="hlFld-ContribAuthor ">Jason  DeVoss</span>, <span class="hlFld-ContribAuthor ">Jim  Driscoll</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Jason  Halladay</span>, <span class="hlFld-ContribAuthor ">Adam  Johnson</span>, <span class="hlFld-ContribAuthor ">Pawan Bir  Kohli</span>, <span class="hlFld-ContribAuthor ">Yingjie  Lai</span>, <span class="hlFld-ContribAuthor ">Yanzhou  Liu</span>, <span class="hlFld-ContribAuthor ">Joseph  Lyssikatos</span>, <span class="hlFld-ContribAuthor ">Priscilla  Mantik</span>, <span class="hlFld-ContribAuthor ">Kapil  Menghrajani</span>, <span class="hlFld-ContribAuthor ">Jeremy  Murray</span>, <span class="hlFld-ContribAuthor ">Ivan  Peng</span>, <span class="hlFld-ContribAuthor ">Amy  Sambrone</span>, <span class="hlFld-ContribAuthor ">Steven  Shia</span>, <span class="hlFld-ContribAuthor ">Young  Shin</span>, <span class="hlFld-ContribAuthor ">Jan  Smith</span>, <span class="hlFld-ContribAuthor ">Sue  Sohn</span>, <span class="hlFld-ContribAuthor ">Vickie  Tsui</span>, <span class="hlFld-ContribAuthor ">Mark  Ultsch</span>, <span class="hlFld-ContribAuthor ">Lawren C.  Wu</span>, <span class="hlFld-ContribAuthor ">Yisong  Xiao</span>, <span class="hlFld-ContribAuthor ">Wenqian  Yang</span>, <span class="hlFld-ContribAuthor ">Judy  Young</span>, <span class="hlFld-ContribAuthor ">Birong  Zhang</span>, <span class="hlFld-ContribAuthor ">Bing-yan  Zhu</span>, and <span class="hlFld-ContribAuthor ">Steven  Magnuson</span>  . </span><span class="cited-content_cbyCitation_article-title">Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (11)
                                     , 4521-4536. <a href="https://doi.org/10.1021/jm400266t" title="DOI URL">https://doi.org/10.1021/jm400266t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400266t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400266t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLead%252BOptimization%252Bof%252Ba%252B4-Aminopyridine%252BBenzamide%252BScaffold%252BTo%252BIdentify%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BBioavailable%252BTYK2%252BInhibitors%26aulast%3DLiang%26aufirst%3DJun%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D20022013%26date%3D29052013%26date%3D13062013%26date%3D14052013%26volume%3D56%26issue%3D11%26spage%3D4521%26epage%3D4536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Hurley</span>, <span class="hlFld-ContribAuthor ">Stuart I.  Ward</span>, <span class="hlFld-ContribAuthor ">Philippe  Bergeron</span>, <span class="hlFld-ContribAuthor ">Kathy  Barrett</span>, <span class="hlFld-ContribAuthor ">Mercedesz  Balazs</span>, <span class="hlFld-ContribAuthor ">Wade S.  Blair</span>, <span class="hlFld-ContribAuthor ">Richard  Bull</span>, <span class="hlFld-ContribAuthor ">Paroma  Chakravarty</span>, <span class="hlFld-ContribAuthor ">Christine  Chang</span>, <span class="hlFld-ContribAuthor ">Peter  Crackett</span>, <span class="hlFld-ContribAuthor ">Gauri  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Jason  DeVoss</span>, <span class="hlFld-ContribAuthor ">Peter S.  Dragovich</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Charles  Ellwood</span>, <span class="hlFld-ContribAuthor ">Simon  Gaines</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Stefan  Gradl</span>, <span class="hlFld-ContribAuthor ">Peter  Gribling</span>, <span class="hlFld-ContribAuthor ">Chris  Hamman</span>, <span class="hlFld-ContribAuthor ">Eric  Harstad</span>, <span class="hlFld-ContribAuthor ">Peter  Hewitt</span>, <span class="hlFld-ContribAuthor ">Adam  Johnson</span>, <span class="hlFld-ContribAuthor ">Tony  Johnson</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Michael F. T.  Koehler</span>, <span class="hlFld-ContribAuthor ">Pawan  Bir Kohli</span>, <span class="hlFld-ContribAuthor ">Sharada  Labadie</span>, <span class="hlFld-ContribAuthor ">Wyne P.  Lee</span>, <span class="hlFld-ContribAuthor ">Jiangpeng  Liao</span>, <span class="hlFld-ContribAuthor ">Marya  Liimatta</span>, <span class="hlFld-ContribAuthor ">Rohan  Mendonca</span>, <span class="hlFld-ContribAuthor ">Raman  Narukulla</span>, <span class="hlFld-ContribAuthor ">Rebecca  Pulk</span>, <span class="hlFld-ContribAuthor ">Austin  Reeve</span>, <span class="hlFld-ContribAuthor ">Scott  Savage</span>, <span class="hlFld-ContribAuthor ">Steven  Shia</span>, <span class="hlFld-ContribAuthor ">Micah  Steffek</span>, <span class="hlFld-ContribAuthor ">Savita  Ubhayakar</span>, <span class="hlFld-ContribAuthor ">Anne  van Abbema</span>, <span class="hlFld-ContribAuthor ">Ignacio  Aliagas</span>, <span class="hlFld-ContribAuthor ">Barbara  Avitabile-Woo</span>, <span class="hlFld-ContribAuthor ">Yisong  Xiao</span>, <span class="hlFld-ContribAuthor ">Jing  Yang</span>, and <span class="hlFld-ContribAuthor ">Janusz J.  Kulagowski</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (11)
                                     , 4764-4785. <a href="https://doi.org/10.1021/jm4004895" title="DOI URL">https://doi.org/10.1021/jm4004895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4004895%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BC-2%252BHydroxyethyl%252BImidazopyrrolopyridines%252Bas%252BPotent%252BJAK1%252BInhibitors%252Bwith%252BFavorable%252BPhysicochemical%252BProperties%252Band%252BHigh%252BSelectivity%252Bover%252BJAK2%26aulast%3DZak%26aufirst%3DMark%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D04042013%26date%3D31052013%26date%3D13062013%26date%3D09052013%26volume%3D56%26issue%3D11%26spage%3D4764%26epage%3D4785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weihe  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Michael A.  Stashko</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Wang</span>  . </span><span class="cited-content_cbyCitation_article-title">Efficient Solution-Phase Synthesis of 4,5,7-Trisubstituted Pyrrolo[3,2-d]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2013,</strong> <em>15 </em>
                                    (1)
                                     , 10-19. <a href="https://doi.org/10.1021/co300106f" title="DOI URL">https://doi.org/10.1021/co300106f</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/co300106f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fco300106f%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DEfficient%252BSolution-Phase%252BSynthesis%252Bof%252B4%25252C5%25252C7-Trisubstituted%252BPyrrolo%25255B3%25252C2-d%25255Dpyrimidines%26aulast%3DZhang%26aufirst%3DWeihe%26date%3D2013%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D10092012%26date%3D19112012%26date%3D05122012%26date%3D14012013%26date%3D26112012%26volume%3D15%26issue%3D1%26spage%3D10%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Soth</span>, <span class="hlFld-ContribAuthor ">Johannes C.  Hermann</span>, <span class="hlFld-ContribAuthor ">Calvin  Yee</span>, <span class="hlFld-ContribAuthor ">Muzaffar  Alam</span>, <span class="hlFld-ContribAuthor ">Jim W.  Barnett</span>, <span class="hlFld-ContribAuthor ">Pamela  Berry</span>, <span class="hlFld-ContribAuthor ">Michelle F.  Browner</span>, <span class="hlFld-ContribAuthor ">Karl  Frank</span>, <span class="hlFld-ContribAuthor ">Sandra  Frauchiger</span>, <span class="hlFld-ContribAuthor ">Seth  Harris</span>, <span class="hlFld-ContribAuthor ">Yang  He</span>, <span class="hlFld-ContribAuthor ">Mohammad  Hekmat-Nejad</span>, <span class="hlFld-ContribAuthor ">Than  Hendricks</span>, <span class="hlFld-ContribAuthor ">Robert  Henningsen</span>, <span class="hlFld-ContribAuthor ">Ramona  Hilgenkamp</span>, <span class="hlFld-ContribAuthor ">Hoangdung  Ho</span>, <span class="hlFld-ContribAuthor ">Ann  Hoffman</span>, <span class="hlFld-ContribAuthor ">Pei-Yuan  Hsu</span>, <span class="hlFld-ContribAuthor ">Dong-Qing  Hu</span>, <span class="hlFld-ContribAuthor ">Andrea  Itano</span>, <span class="hlFld-ContribAuthor ">Saul  Jaime-Figueroa</span>, <span class="hlFld-ContribAuthor ">Alam  Jahangir</span>, <span class="hlFld-ContribAuthor ">Sue  Jin</span>, <span class="hlFld-ContribAuthor ">Andreas  Kuglstatter</span>, <span class="hlFld-ContribAuthor ">Alan K.  Kutach</span>, <span class="hlFld-ContribAuthor ">Cheng  Liao</span>, <span class="hlFld-ContribAuthor ">Stephen  Lynch</span>, <span class="hlFld-ContribAuthor ">John  Menke</span>, <span class="hlFld-ContribAuthor ">Linghao  Niu</span>, <span class="hlFld-ContribAuthor ">Vaishali  Patel</span>, <span class="hlFld-ContribAuthor ">Aruna  Railkar</span>, <span class="hlFld-ContribAuthor ">Douglas  Roy</span>, <span class="hlFld-ContribAuthor ">Ada  Shao</span>, <span class="hlFld-ContribAuthor ">David  Shaw</span>, <span class="hlFld-ContribAuthor ">Sandra  Steiner</span>, <span class="hlFld-ContribAuthor ">Yongliang  Sun</span>, <span class="hlFld-ContribAuthor ">Seng-Lai  Tan</span>, <span class="hlFld-ContribAuthor ">Sandra  Wang</span>, and <span class="hlFld-ContribAuthor ">Minh Diem  Vu</span>  . </span><span class="cited-content_cbyCitation_article-title">3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (1)
                                     , 345-356. <a href="https://doi.org/10.1021/jm301646k" title="DOI URL">https://doi.org/10.1021/jm301646k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301646k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301646k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D3-Amido%252BPyrrolopyrazine%252BJAK%252BKinase%252BInhibitors%25253A%252BDevelopment%252Bof%252Ba%252BJAK3%252Bvs%252BJAK1%252BSelective%252BInhibitor%252Band%252BEvaluation%252Bin%252BCellular%252Band%252Bin%252BVivo%252BModels%26aulast%3DSoth%26aufirst%3DMichael%26date%3D2013%26date%3D2012%26date%3D2012%26date%3D07112012%26date%3D19122012%26date%3D10012013%26date%3D09122012%26volume%3D56%26issue%3D1%26spage%3D345%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Rohan  Mendonca</span>, <span class="hlFld-ContribAuthor ">Mercedesz  Balazs</span>, <span class="hlFld-ContribAuthor ">Kathy  Barrett</span>, <span class="hlFld-ContribAuthor ">Philippe  Bergeron</span>, <span class="hlFld-ContribAuthor ">Wade S.  Blair</span>, <span class="hlFld-ContribAuthor ">Christine  Chang</span>, <span class="hlFld-ContribAuthor ">Gauri  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Jason  DeVoss</span>, <span class="hlFld-ContribAuthor ">Peter S.  Dragovich</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Stefan  Gradl</span>, <span class="hlFld-ContribAuthor ">Chris  Hamman</span>, <span class="hlFld-ContribAuthor ">Emily J.  Hanan</span>, <span class="hlFld-ContribAuthor ">Eric  Harstad</span>, <span class="hlFld-ContribAuthor ">Peter R.  Hewitt</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Hurley</span>, <span class="hlFld-ContribAuthor ">Tian  Jin</span>, <span class="hlFld-ContribAuthor ">Adam  Johnson</span>, <span class="hlFld-ContribAuthor ">Tony  Johnson</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Michael F. T.  Koehler</span>, <span class="hlFld-ContribAuthor ">Pawan  Bir Kohli</span>, <span class="hlFld-ContribAuthor ">Janusz J.  Kulagowski</span>, <span class="hlFld-ContribAuthor ">Sharada  Labadie</span>, <span class="hlFld-ContribAuthor ">Jiangpeng  Liao</span>, <span class="hlFld-ContribAuthor ">Marya  Liimatta</span>, <span class="hlFld-ContribAuthor ">Zhonghua  Lin</span>, <span class="hlFld-ContribAuthor ">Patrick J.  Lupardus</span>, <span class="hlFld-ContribAuthor ">Robert J.  Maxey</span>, <span class="hlFld-ContribAuthor ">Jeremy M.  Murray</span>, <span class="hlFld-ContribAuthor ">Rebecca  Pulk</span>, <span class="hlFld-ContribAuthor ">Madeleine  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Scott  Savage</span>, <span class="hlFld-ContribAuthor ">Steven  Shia</span>, <span class="hlFld-ContribAuthor ">Micah  Steffek</span>, <span class="hlFld-ContribAuthor ">Savita  Ubhayakar</span>, <span class="hlFld-ContribAuthor ">Mark  Ultsch</span>, <span class="hlFld-ContribAuthor ">Anne  van Abbema</span>, <span class="hlFld-ContribAuthor ">Stuart I.  Ward</span>, <span class="hlFld-ContribAuthor ">Ling  Xiao</span>, and <span class="hlFld-ContribAuthor ">Yisong  Xiao</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (13)
                                     , 6176-6193. <a href="https://doi.org/10.1021/jm300628c" title="DOI URL">https://doi.org/10.1021/jm300628c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm300628c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm300628c%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252BC-2%252BMethyl%252BImidazopyrrolopyridines%252Bas%252BPotent%252Band%252BOrally%252BBioavailable%252BJAK1%252BInhibitors%252Bwith%252BSelectivity%252Bover%252BJAK2%26aulast%3DZak%26aufirst%3DMark%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D05052012%26date%3D28062012%26date%3D12072012%26date%3D14062012%26volume%3D55%26issue%3D13%26spage%3D6176%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Janusz J.  Kulagowski</span>, <span class="hlFld-ContribAuthor ">Wade  Blair</span>, <span class="hlFld-ContribAuthor ">Richard J.  Bull</span>, <span class="hlFld-ContribAuthor ">Christine  Chang</span>, <span class="hlFld-ContribAuthor ">Gauri  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Hazel J.  Dyke</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Trevor K.  Harrison</span>, <span class="hlFld-ContribAuthor ">Peter R.  Hewitt</span>, <span class="hlFld-ContribAuthor ">Marya  Liimatta</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Hurley</span>, <span class="hlFld-ContribAuthor ">Adam  Johnson</span>, <span class="hlFld-ContribAuthor ">Tony  Johnson</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Pawan  Bir Kohli</span>, <span class="hlFld-ContribAuthor ">Robert J.  Maxey</span>, <span class="hlFld-ContribAuthor ">Rohan  Mendonca</span>, <span class="hlFld-ContribAuthor ">Kyle  Mortara</span>, <span class="hlFld-ContribAuthor ">Jeremy  Murray</span>, <span class="hlFld-ContribAuthor ">Raman  Narukulla</span>, <span class="hlFld-ContribAuthor ">Steven  Shia</span>, <span class="hlFld-ContribAuthor ">Micah  Steffek</span>, <span class="hlFld-ContribAuthor ">Savita  Ubhayakar</span>, <span class="hlFld-ContribAuthor ">Mark  Ultsch</span>, <span class="hlFld-ContribAuthor ">Anne  van Abbema</span>, <span class="hlFld-ContribAuthor ">Stuart I.  Ward</span>, <span class="hlFld-ContribAuthor ">Bohdan  Waszkowycz</span>, and <span class="hlFld-ContribAuthor ">Mark  Zak</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (12)
                                     , 5901-5921. <a href="https://doi.org/10.1021/jm300438j" title="DOI URL">https://doi.org/10.1021/jm300438j</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm300438j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm300438j%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BImidazo-Pyrrolopyridines%252Bas%252BNovel%252Band%252BPotent%252BJAK1%252BInhibitors%26aulast%3DKulagowski%26aufirst%3DJanusz%2BJ.%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D29032012%26date%3D11062012%26date%3D28062012%26date%3D16052012%26volume%3D55%26issue%3D12%26spage%3D5901%26epage%3D5921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony D.  William</span>, <span class="hlFld-ContribAuthor ">Angeline C.-H.  Lee</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Kee Chuan  Goh</span>, <span class="hlFld-ContribAuthor ">Babita  Madan</span>, <span class="hlFld-ContribAuthor ">Stefan  Hart</span>, <span class="hlFld-ContribAuthor ">Evelyn  Tan</span>, <span class="hlFld-ContribAuthor ">Haishan  Wang</span>, <span class="hlFld-ContribAuthor ">Harish  Nagaraj</span>, <span class="hlFld-ContribAuthor ">Dizhong  Chen</span>, <span class="hlFld-ContribAuthor ">Chai Ping  Lee</span>, <span class="hlFld-ContribAuthor ">Eric T.  Sun</span>, <span class="hlFld-ContribAuthor ">Ramesh  Jayaraman</span>, <span class="hlFld-ContribAuthor ">Mohammad Khalid  Pasha</span>, <span class="hlFld-ContribAuthor ">Kantharaj  Ethirajulu</span>, <span class="hlFld-ContribAuthor ">Jeanette M.  Wood</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (6)
                                     , 2623-2640. <a href="https://doi.org/10.1021/jm201454n" title="DOI URL">https://doi.org/10.1021/jm201454n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201454n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201454n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthe%252BMacrocycle%252B%2525289E%252529-15-%2525282-%252528Pyrrolidin-1-yl%252529ethoxy%252529-7%25252C12%25252C25-trioxa-19%25252C21%25252C24-triaza-tetracyclo%25255B18.3.1.1%2525282%25252C5%252529.1%25252814%25252C18%252529%25255Dhexacosa-1%25252824%252529%25252C2%25252C4%25252C9%25252C14%25252826%252529%25252C15%25252C17%25252C20%25252C22-nonaene%252B%252528SB1578%252529%25252C%252Ba%252BPotent%252BInhibitor%252Bof%252BJanus%252BKinase%252B2%25252FFms-LikeTyrosine%252BKinase-3%252B%252528JAK2%25252FFLT3%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DWilliam%26aufirst%3DAnthony%2BD.%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D27102011%26date%3D06032012%26date%3D22032012%26date%3D17022012%26volume%3D55%26issue%3D6%26spage%3D2623%26epage%3D2640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurie B.  Schenkel</span>, <span class="hlFld-ContribAuthor ">Xin  Huang</span>, <span class="hlFld-ContribAuthor ">Alan  Cheng</span>, <span class="hlFld-ContribAuthor ">Holly L.  Deak</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Doherty</span>, <span class="hlFld-ContribAuthor ">Renee  Emkey</span>, <span class="hlFld-ContribAuthor ">Yan  Gu</span>, <span class="hlFld-ContribAuthor ">Hakan  Gunaydin</span>, <span class="hlFld-ContribAuthor ">Joseph L.  Kim</span>, <span class="hlFld-ContribAuthor ">Josie  Lee</span>, <span class="hlFld-ContribAuthor ">Robert  Loberg</span>, <span class="hlFld-ContribAuthor ">Philip  Olivieri</span>, <span class="hlFld-ContribAuthor ">Jeanne  Pistillo</span>, <span class="hlFld-ContribAuthor ">Jin  Tang</span>, <span class="hlFld-ContribAuthor ">Qian  Wan</span>, <span class="hlFld-ContribAuthor ">Hui-Ling  Wang</span>, <span class="hlFld-ContribAuthor ">Shen-Wu  Wang</span>, <span class="hlFld-ContribAuthor ">Mary C.  Wells</span>, <span class="hlFld-ContribAuthor ">Bin  Wu</span>, <span class="hlFld-ContribAuthor ">Violeta  Yu</span>, <span class="hlFld-ContribAuthor ">Liqin  Liu</span>, and <span class="hlFld-ContribAuthor ">Stephanie  Geuns-Meyer</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Highly Selective Thienopyridine Janus Kinase 2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>54 </em>
                                    (24)
                                     , 8440-8450. <a href="https://doi.org/10.1021/jm200911r" title="DOI URL">https://doi.org/10.1021/jm200911r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm200911r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm200911r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BHighly%252BSelective%252BThienopyridine%252BJanus%252BKinase%252B2%252BInhibitors%26aulast%3DSchenkel%26aufirst%3DLaurie%2BB.%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D11072011%26date%3D16112011%26date%3D22122011%26volume%3D54%26issue%3D24%26spage%3D8440%26epage%3D8450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alastair K.  Williams</span>, <span class="hlFld-ContribAuthor ">Carol  Dou</span>, <span class="hlFld-ContribAuthor ">Luke Y. C.  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Treatment of lymphocyteâvariant hypereosinophilic syndrome (LâHES): what to consider after confirming the elusive diagnosis. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Haematology</span><span> <strong>2021,</strong> <em>155 </em><a href="https://doi.org/10.1111/bjh.17615" title="DOI URL">https://doi.org/10.1111/bjh.17615</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bjh.17615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbjh.17615%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Haematology%26atitle%3DTreatment%252Bof%252Blymphocyte%2525E2%252580%252590variant%252Bhypereosinophilic%252Bsyndrome%252B%252528L%2525E2%252580%252590HES%252529%25253A%252Bwhat%252Bto%252Bconsider%252Bafter%252Bconfirming%252Bthe%252Belusive%252Bdiagnosis%26aulast%3DWilliams%26aufirst%3DAlastair%2BK.%26date%3D2021%26date%3D2021%26volume%3D155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert M.  Borzilleri</span>, <span class="hlFld-ContribAuthor ">Amy C.  Hart</span>, <span class="hlFld-ContribAuthor ">Ryan  Moslin</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Stephen T.  Wrobleski</span>. </span><span class="cited-content_cbyCitation_article-title">JAK
              Family Inhibitors for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-86. <a href="https://doi.org/10.1002/0471266949.bmc279" title="DOI URL">https://doi.org/10.1002/0471266949.bmc279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc279%26sid%3Dliteratum%253Aachs%26atitle%3DJAK%252BFamily%252BInhibitors%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DBorzilleri%26aufirst%3DRobert%2BM.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D86%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hayley  James</span>, <span class="hlFld-ContribAuthor ">Grace L.  Paley</span>, <span class="hlFld-ContribAuthor ">Richard  Brasington</span>, <span class="hlFld-ContribAuthor ">Philip L.  Custer</span>, <span class="hlFld-ContribAuthor ">Todd P.  Margolis</span>, <span class="hlFld-ContribAuthor ">Michael A.  Paley</span>. </span><span class="cited-content_cbyCitation_article-title">Tofacitinib for refractory ocular mucous membrane pemphigoid. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Ophthalmology Case Reports</span><span> <strong>2021,</strong> <em>125 </em>, 101104. <a href="https://doi.org/10.1016/j.ajoc.2021.101104" title="DOI URL">https://doi.org/10.1016/j.ajoc.2021.101104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ajoc.2021.101104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ajoc.2021.101104%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Ophthalmology%2520Case%2520Reports%26atitle%3DTofacitinib%252Bfor%252Brefractory%252Bocular%252Bmucous%252Bmembrane%252Bpemphigoid%26aulast%3DJames%26aufirst%3DHayley%26date%3D2021%26volume%3D125%26spage%3D101104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed  Ummey Khalecha Bintha</span>, <span class="hlFld-ContribAuthor ">Amani  Souwelimatou Amadou</span>, <span class="hlFld-ContribAuthor ">Mursalin  Md Huzzatul</span>, <span class="hlFld-ContribAuthor ">Muhammad  Fauziyya</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Potential of IL-9 in Allergic and Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.5772/intechopen.96266" title="DOI URL">https://doi.org/10.5772/intechopen.96266</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.96266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.96266%26sid%3Dliteratum%253Aachs%26atitle%3DTherapeutic%252BPotential%252Bof%252BIL-9%252Bin%252BAllergic%252Band%252BAutoimmune%252BDiseases%26aulast%3DUmmey%2BKhalecha%2BBintha%26aufirst%3DAhmed%26date%3D2021%26date%3D2021%26pub%3DIntechOpen%26atitle%3DInterleukin%252B%25255BWorking%252BTitle%25255D%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy L.  Foley</span>, <span class="hlFld-ContribAuthor ">Woodrow  Burchett</span>, <span class="hlFld-ContribAuthor ">Qiuxia  Chen</span>, <span class="hlFld-ContribAuthor ">Mark E.  Flanagan</span>, <span class="hlFld-ContribAuthor ">Brendon  Kapinos</span>, <span class="hlFld-ContribAuthor ">Xianyang  Li</span>, <span class="hlFld-ContribAuthor ">Justin I.  Montgomery</span>, <span class="hlFld-ContribAuthor ">Anokha S.  Ratnayake</span>, <span class="hlFld-ContribAuthor ">Hongyao  Zhu</span>, <span class="hlFld-ContribAuthor ">Marie-Claire  Peakman</span>. </span><span class="cited-content_cbyCitation_article-title">Selecting Approaches for Hit Identification and Increasing Options by Building the Efficient Discovery of Actionable Chemical Matter from DNA-Encoded Libraries. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2021,</strong> <em>26 </em>
                                    (2)
                                     , 263-280. <a href="https://doi.org/10.1177/2472555220979589" title="DOI URL">https://doi.org/10.1177/2472555220979589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555220979589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555220979589%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DSelecting%252BApproaches%252Bfor%252BHit%252BIdentification%252Band%252BIncreasing%252BOptions%252Bby%252BBuilding%252Bthe%252BEfficient%252BDiscovery%252Bof%252BActionable%252BChemical%252BMatter%252Bfrom%252BDNA-Encoded%252BLibraries%26aulast%3DFoley%26aufirst%3DTimothy%2BL.%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D2%26spage%3D263%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kris  Meier</span>, <span class="hlFld-ContribAuthor ">Josep  ArÃºsâPous</span>, <span class="hlFld-ContribAuthor ">JeanâLouis  Reymond</span>. </span><span class="cited-content_cbyCitation_article-title">A Potent and Selective Janus Kinase Inhibitor with a Chiral 3DâShaped Triquinazine Ring System from Chemical Space. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (4)
                                     , 2102-2105. <a href="https://doi.org/10.1002/ange.202012049" title="DOI URL">https://doi.org/10.1002/ange.202012049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202012049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202012049%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DA%252BPotent%252Band%252BSelective%252BJanus%252BKinase%252BInhibitor%252Bwith%252Ba%252BChiral%252B3D%2525E2%252580%252590Shaped%252BTriquinazine%252BRing%252BSystem%252Bfrom%252BChemical%252BSpace%26aulast%3DMeier%26aufirst%3DKris%26date%3D2021%26date%3D2020%26volume%3D133%26issue%3D4%26spage%3D2102%26epage%3D2105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kris  Meier</span>, <span class="hlFld-ContribAuthor ">Josep  ArÃºsâPous</span>, <span class="hlFld-ContribAuthor ">JeanâLouis  Reymond</span>. </span><span class="cited-content_cbyCitation_article-title">A Potent and Selective Janus Kinase Inhibitor with a Chiral 3DâShaped Triquinazine Ring System from Chemical Space. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (4)
                                     , 2074-2077. <a href="https://doi.org/10.1002/anie.202012049" title="DOI URL">https://doi.org/10.1002/anie.202012049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202012049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202012049%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DA%252BPotent%252Band%252BSelective%252BJanus%252BKinase%252BInhibitor%252Bwith%252Ba%252BChiral%252B3D%2525E2%252580%252590Shaped%252BTriquinazine%252BRing%252BSystem%252Bfrom%252BChemical%252BSpace%26aulast%3DMeier%26aufirst%3DKris%26date%3D2021%26date%3D2020%26volume%3D60%26issue%3D4%26spage%3D2074%26epage%3D2077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Judy L.  Chen</span>, <span class="hlFld-ContribAuthor ">Parinaz  Abiri</span>, <span class="hlFld-ContribAuthor ">Edmund  Tsui</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the treatment of juvenile idiopathic arthritisâassociated uveitis. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Ophthalmology</span><span> <strong>2021,</strong> <em>13 </em>, 251584142098457. <a href="https://doi.org/10.1177/2515841420984572" title="DOI URL">https://doi.org/10.1177/2515841420984572</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2515841420984572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2515841420984572%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Ophthalmology%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Btreatment%252Bof%252Bjuvenile%252Bidiopathic%252Barthritis%2525E2%252580%252593associated%252Buveitis%26aulast%3DChen%26aufirst%3DJudy%2BL.%26date%3D2021%26date%3D2021%26volume%3D13%26spage%3D251584142098457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chella Krishna  Vadivel</span>, <span class="hlFld-ContribAuthor ">Maria  Gluud</span>, <span class="hlFld-ContribAuthor ">Sara  Torres-Rusillo</span>, <span class="hlFld-ContribAuthor ">Lasse  Boding</span>, <span class="hlFld-ContribAuthor ">Andreas  Willerslev-Olsen</span>, <span class="hlFld-ContribAuthor ">Terkild B.  Buus</span>, <span class="hlFld-ContribAuthor ">Tea Kirkegaard  Nielsen</span>, <span class="hlFld-ContribAuthor ">Jenny L.  Persson</span>, <span class="hlFld-ContribAuthor ">Charlotte M.  Bonefeld</span>, <span class="hlFld-ContribAuthor ">Carsten  Geisler</span>, <span class="hlFld-ContribAuthor ">Thorbjorn  Krejsgaard</span>, <span class="hlFld-ContribAuthor ">Anja T.  Fuglsang</span>, <span class="hlFld-ContribAuthor ">Niels  Odum</span>, <span class="hlFld-ContribAuthor ">Anders  Woetmann</span>. </span><span class="cited-content_cbyCitation_article-title">JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL). </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (2)
                                     , 280. <a href="https://doi.org/10.3390/cancers13020280" title="DOI URL">https://doi.org/10.3390/cancers13020280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13020280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13020280%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DJAK3%252BIs%252BExpressed%252Bin%252Bthe%252BNucleus%252Bof%252BMalignant%252BT%252BCells%252Bin%252BCutaneous%252BT%252BCell%252BLymphoma%252B%252528CTCL%252529%26aulast%3DVadivel%26aufirst%3DChella%2BKrishna%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D2%26spage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Jiang</span>, <span class="hlFld-ContribAuthor ">Baishan  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhixiang  He</span>, <span class="hlFld-ContribAuthor ">Scott B.  Ficarro</span>, <span class="hlFld-ContribAuthor ">Jianwei  Che</span>, <span class="hlFld-ContribAuthor ">Jarrod A.  Marto</span>, <span class="hlFld-ContribAuthor ">Yang  Gao</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Covalent MKK4/7 Dual Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2020,</strong> <em>27 </em>
                                    (12)
                                     , 1553-1560.e8. <a href="https://doi.org/10.1016/j.chembiol.2020.08.014" title="DOI URL">https://doi.org/10.1016/j.chembiol.2020.08.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2020.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2020.08.014%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DDiscovery%252Bof%252BCovalent%252BMKK4%25252F7%252BDual%252BInhibitor%26aulast%3DJiang%26aufirst%3DJie%26date%3D2020%26volume%3D27%26issue%3D12%26spage%3D1553%26epage%3D1560.e8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nader  Morshed</span>, <span class="hlFld-ContribAuthor ">William T  Ralvenius</span>, <span class="hlFld-ContribAuthor ">Alexi  Nott</span>, <span class="hlFld-ContribAuthor ">L Ashley  Watson</span>, <span class="hlFld-ContribAuthor ">Felicia H  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Leyla A  Akay</span>, <span class="hlFld-ContribAuthor ">Brian A  Joughin</span>, <span class="hlFld-ContribAuthor ">PingâChieh  Pao</span>, <span class="hlFld-ContribAuthor ">Jay  Penney</span>, <span class="hlFld-ContribAuthor ">Lauren  LaRocque</span>, <span class="hlFld-ContribAuthor ">Diego  Mastroeni</span>, <span class="hlFld-ContribAuthor ">LiâHuei  Tsai</span>, <span class="hlFld-ContribAuthor ">Forest M  White</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphoproteomics identifies microglial SiglecâF inflammatory response during neurodegeneration. </span><span class="cited-content_cbyCitation_journal-name">Molecular Systems Biology</span><span> <strong>2020,</strong> <em>16 </em>
                                    (12)
                                     <a href="https://doi.org/10.15252/msb.20209819" title="DOI URL">https://doi.org/10.15252/msb.20209819</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.15252/msb.20209819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.15252%2Fmsb.20209819%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Systems%2520Biology%26atitle%3DPhosphoproteomics%252Bidentifies%252Bmicroglial%252BSiglec%2525E2%252580%252590F%252Binflammatory%252Bresponse%252Bduring%252Bneurodegeneration%26aulast%3DMorshed%26aufirst%3DNader%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian S.  Gerstenberger</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">James D.  Clark</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Andrew  Fensome</span>, <span class="hlFld-ContribAuthor ">Roger  Gifford</span>, <span class="hlFld-ContribAuthor ">Matthew C.  Griffor</span>, <span class="hlFld-ContribAuthor ">Martin  Hegen</span>, <span class="hlFld-ContribAuthor ">Brett D.  Hollingshead</span>, <span class="hlFld-ContribAuthor ">John D.  Knafels</span>, <span class="hlFld-ContribAuthor ">Tsung H.  Lin</span>, <span class="hlFld-ContribAuthor ">James F.  Smith</span>, <span class="hlFld-ContribAuthor ">Felix F.  Vajdos</span>. </span><span class="cited-content_cbyCitation_article-title">Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-65762-y" title="DOI URL">https://doi.org/10.1038/s41598-020-65762-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-65762-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-65762-y%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDemonstration%252Bof%252BIn%252BVitro%252Bto%252BIn%252BVivo%252BTranslation%252Bof%252Ba%252BTYK2%252BInhibitor%252BThat%252BShows%252BCross%252BSpecies%252BPotency%252BDifferences%26aulast%3DGerstenberger%26aufirst%3DBrian%2BS.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Francis</span>, <span class="hlFld-ContribAuthor ">Adam  Nelson</span>, <span class="hlFld-ContribAuthor ">Stephen P.  Marsden</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Î²âDiamine Building Blocks by Photocatalytic Hydroamination of Enecarbamates with Amines, Ammonia and NâH Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Chemistry â A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (65)
                                     , 14861-14865. <a href="https://doi.org/10.1002/chem.202003562" title="DOI URL">https://doi.org/10.1002/chem.202003562</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202003562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202003562%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DSynthesis%252Bof%252B%2525CE%2525B2%2525E2%252580%252590Diamine%252BBuilding%252BBlocks%252Bby%252BPhotocatalytic%252BHydroamination%252Bof%252BEnecarbamates%252Bwith%252BAmines%25252C%252BAmmonia%252Band%252BN%2525E2%252588%252592H%252BHeterocycles%26aulast%3DFrancis%26aufirst%3DDaniel%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D65%26spage%3D14861%26epage%3D14865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan  Wong</span>, <span class="hlFld-ContribAuthor ">Meaghan  Wall</span>, <span class="hlFld-ContribAuthor ">Gregory Philip  Corboy</span>, <span class="hlFld-ContribAuthor ">Nadine  Taubenheim</span>, <span class="hlFld-ContribAuthor ">Gareth Peter  Gregory</span>, <span class="hlFld-ContribAuthor ">Stephen  Opat</span>, <span class="hlFld-ContribAuthor ">Jake  Shortt</span>. </span><span class="cited-content_cbyCitation_article-title">Failure of tofacitinib to achieve an objective response in a
              DDX3X-MLLT10
              T-lymphoblastic leukemia with activating
              JAK3
              mutations. </span><span class="cited-content_cbyCitation_journal-name">Molecular Case Studies</span><span> <strong>2020,</strong> <em>6 </em>
                                    (4)
                                     , a004994. <a href="https://doi.org/10.1101/mcs.a004994" title="DOI URL">https://doi.org/10.1101/mcs.a004994</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1101/mcs.a004994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1101%2Fmcs.a004994%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Case%2520Studies%26atitle%3DFailure%252Bof%252Btofacitinib%252Bto%252Bachieve%252Ban%252Bobjective%252Bresponse%252Bin%252Ba%252BDDX3X-MLLT10%252BT-lymphoblastic%252Bleukemia%252Bwith%252Bactivating%252BJAK3%252Bmutations%26aulast%3DWong%26aufirst%3DJonathan%26date%3D2020%26date%3D2020%26volume%3D6%26issue%3D4%26spage%3Da004994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kinga  Majchrzak</span>, <span class="hlFld-ContribAuthor ">Jakub  Fichna</span>. </span><span class="cited-content_cbyCitation_article-title">Biologic Therapy in Crohnâs DiseaseâWhat We Have Learnt So Far. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Targets</span><span> <strong>2020,</strong> <em>21 </em>
                                    (8)
                                     , 792-806. <a href="https://doi.org/10.2174/1389450121666191218123203" title="DOI URL">https://doi.org/10.2174/1389450121666191218123203</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389450121666191218123203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389450121666191218123203%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Targets%26atitle%3DBiologic%252BTherapy%252Bin%252BCrohn%2525E2%252580%252599s%252BDisease%2525E2%252580%252593What%252BWe%252BHave%252BLearnt%252BSo%252BFar%26aulast%3DMajchrzak%26aufirst%3DKinga%26date%3D2020%26volume%3D21%26issue%3D8%26spage%3D792%26epage%3D806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajesh  Bahekar</span>, <span class="hlFld-ContribAuthor ">Nandini  Panchal</span>, <span class="hlFld-ContribAuthor ">Shubhangi  Soman</span>, <span class="hlFld-ContribAuthor ">Jigar  Desai</span>, <span class="hlFld-ContribAuthor ">Dipam  Patel</span>, <span class="hlFld-ContribAuthor ">Anil  Argade</span>, <span class="hlFld-ContribAuthor ">Archana  Gite</span>, <span class="hlFld-ContribAuthor ">Sanjay  Gite</span>, <span class="hlFld-ContribAuthor ">Bhaumin  Patel</span>, <span class="hlFld-ContribAuthor ">Jeevan  Kumar</span>, <span class="hlFld-ContribAuthor ">Sachchidanand  S</span>, <span class="hlFld-ContribAuthor ">Harilal  Patel</span>, <span class="hlFld-ContribAuthor ">Rajesh  Sundar</span>, <span class="hlFld-ContribAuthor ">Abhijit  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Jogeswar  Mahapatra</span>, <span class="hlFld-ContribAuthor ">Hoshang  Patel</span>, <span class="hlFld-ContribAuthor ">Krishnarup  Ghoshdastidar</span>, <span class="hlFld-ContribAuthor ">Debdutta  Bandyopadhyay</span>, <span class="hlFld-ContribAuthor ">Ranjit C.  Desai</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103851. <a href="https://doi.org/10.1016/j.bioorg.2020.103851" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103851%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bdiaminopyrimidine-carboxamide%252Bderivatives%252Bas%252BJAK3%252Binhibitors%26aulast%3DBahekar%26aufirst%3DRajesh%26date%3D2020%26volume%3D99%26spage%3D103851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingyu  Zhu</span>, <span class="hlFld-ContribAuthor ">Qianqian  Yu</span>, <span class="hlFld-ContribAuthor ">Yanfei  Cai</span>, <span class="hlFld-ContribAuthor ">Yun  Chen</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Wenqing  Liang</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Theoretical Exploring Selective-Binding Mechanisms of JAK3 by 3D-QSAR, Molecular Dynamics Simulation and Free Energy Calculation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Molecular Biosciences</span><span> <strong>2020,</strong> <em>7 </em><a href="https://doi.org/10.3389/fmolb.2020.00083" title="DOI URL">https://doi.org/10.3389/fmolb.2020.00083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmolb.2020.00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmolb.2020.00083%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Molecular%2520Biosciences%26atitle%3DTheoretical%252BExploring%252BSelective-Binding%252BMechanisms%252Bof%252BJAK3%252Bby%252B3D-QSAR%25252C%252BMolecular%252BDynamics%252BSimulation%252Band%252BFree%252BEnergy%252BCalculation%26aulast%3DZhu%26aufirst%3DJingyu%26date%3D2020%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xinying  Cheng</span>, <span class="hlFld-ContribAuthor ">Qiuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112155. <a href="https://doi.org/10.1016/j.ejmech.2020.112155" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112155%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJanus%252Bkinases%252B%252528JAKs%252529%25253A%252BThe%252Befficient%252Btherapeutic%252Btargets%252Bfor%252Bautoimmune%252Bdiseases%252Band%252Bmyeloproliferative%252Bdisorders%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2020%26volume%3D192%26spage%3D112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J.W.  Wieringa</span>, <span class="hlFld-ContribAuthor ">C.J.  van der Woude</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. </span><span class="cited-content_cbyCitation_journal-name">Best Practice & Research Clinical Gastroenterology</span><span> <strong>2020,</strong> <em>44-45 </em>, 101665. <a href="https://doi.org/10.1016/j.bpg.2019.101665" title="DOI URL">https://doi.org/10.1016/j.bpg.2019.101665</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bpg.2019.101665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bpg.2019.101665%26sid%3Dliteratum%253Aachs%26jtitle%3DBest%2520Practice%2520%2526%2520Research%2520Clinical%2520Gastroenterology%26atitle%3DEffect%252Bof%252Bbiologicals%252Band%252BJAK%252Binhibitors%252Bduring%252Bpregnancy%252Bon%252Bhealth-related%252Boutcomes%252Bin%252Bchildren%252Bof%252Bwomen%252Bwith%252Binflammatory%252Bbowel%252Bdisease%26aulast%3DWieringa%26aufirst%3DJ.W.%26date%3D2020%26volume%3D44-45%26spage%3D101665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhengtong  Mao</span>, <span class="hlFld-ContribAuthor ">Haokun  Pan</span>, <span class="hlFld-ContribAuthor ">Xingxian  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Pd-Catalyzed highly selective and direct
              ortho
              CâH arylation of pyrrolo[2,3-
              d
              ]pyrimidine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2020,</strong> <em>7 </em>
                                    (2)
                                     , 324-328. <a href="https://doi.org/10.1039/C9QO01312A" title="DOI URL">https://doi.org/10.1039/C9QO01312A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO01312A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO01312A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DPd-Catalyzed%252Bhighly%252Bselective%252Band%252Bdirect%252Bortho%252BC%2525E2%252580%252593H%252Barylation%252Bof%252Bpyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidine%252Bderivatives%26aulast%3DZhou%26aufirst%3DJing%26date%3D2020%26date%3D2020%26volume%3D7%26issue%3D2%26spage%3D324%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edoardo  Troncone</span>, <span class="hlFld-ContribAuthor ">Irene  Marafini</span>, <span class="hlFld-ContribAuthor ">Giovanna  Del Vecchio Blanco</span>, <span class="hlFld-ContribAuthor ">Antonio  Di Grazia</span>, <span class="hlFld-ContribAuthor ">Giovanni  Monteleone</span>. </span><span class="cited-content_cbyCitation_article-title"><p>Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK)Â Inhibitors</p>. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Experimental Gastroenterology</span><span> <strong>2020,</strong> <em>Volume 13 </em>, 131-139. <a href="https://doi.org/10.2147/CEG.S208020" title="DOI URL">https://doi.org/10.2147/CEG.S208020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/CEG.S208020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FCEG.S208020%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Experimental%2520Gastroenterology%26atitle%3D%25253Cp%25253ENovel%252BTherapeutic%252BOptions%252Bfor%252BPeople%252Bwith%252BUlcerative%252BColitis%25253A%252BAn%252BUpdate%252Bon%252BRecent%252BDevelopments%252Bwith%252BJanus%252BKinase%252B%252528JAK%252529%2525C2%2525A0Inhibitors%25253C%25252Fp%25253E%26aulast%3DTroncone%26aufirst%3DEdoardo%26date%3D2020%26date%3D2020%26volume%3DVolume%252013%26spage%3D131%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanchita  Raychaudhuri</span>, <span class="hlFld-ContribAuthor ">Christine  Abria</span>, <span class="hlFld-ContribAuthor ">Zachary T.  Harmany</span>, <span class="hlFld-ContribAuthor ">Charles M.  Smith</span>, <span class="hlFld-ContribAuthor ">Smriti  KunduâRaychaudhuri</span>, <span class="hlFld-ContribAuthor ">Siba P.  Raychaudhuri</span>, <span class="hlFld-ContribAuthor ">Abhijit J.  Chaudhari</span>. </span><span class="cited-content_cbyCitation_article-title">Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo
              18
              FâFDG PET. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Rheumatic Diseases</span><span> <strong>2019,</strong> <em>22 </em>
                                    (12)
                                     , 2165-2169. <a href="https://doi.org/10.1111/1756-185X.13732" title="DOI URL">https://doi.org/10.1111/1756-185X.13732</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/1756-185X.13732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2F1756-185X.13732%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Rheumatic%2520Diseases%26atitle%3DQuantitative%252Btracking%252Bof%252Binflammatory%252Bactivity%252Bat%252Bthe%252Bpeak%252Band%252Btrough%252Bplasma%252Blevels%252Bof%252Btofacitinib%25252C%252Ba%252BJanus%252Bkinase%252Binhibitor%25252C%252Bvia%252Bin%252Bvivo%252B18%252BF%2525E2%252580%252590FDG%252BPET%26aulast%3DRaychaudhuri%26aufirst%3DSanchita%26date%3D2019%26date%3D2019%26volume%3D22%26issue%3D12%26spage%3D2165%26epage%3D2169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Dai</span>, <span class="hlFld-ContribAuthor ">LiXi  Yang</span>, <span class="hlFld-ContribAuthor ">Glynn  Addison</span>. </span><span class="cited-content_cbyCitation_article-title">Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Mini-Reviews in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (18)
                                     , 1531-1543. <a href="https://doi.org/10.2174/1389557519666190617152011" title="DOI URL">https://doi.org/10.2174/1389557519666190617152011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389557519666190617152011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389557519666190617152011%26sid%3Dliteratum%253Aachs%26jtitle%3DMini-Reviews%2520in%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252BStatus%252Bin%252Bthe%252BDiscovery%252Bof%252BCovalent%252BJanus%252BKinase%252B3%252B%252528JAK3%252529%252BInhibitors%26aulast%3DDai%26aufirst%3DJun%26date%3D2019%26volume%3D19%26issue%3D18%26spage%3D1531%26epage%3D1543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Hart S.  Dengler</span>, <span class="hlFld-ContribAuthor ">Naomi S.  Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (20)
                                     , 126658. <a href="https://doi.org/10.1016/j.bmcl.2019.126658" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126658%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInhaled%252BJanus%252BKinase%252B%252528JAK%252529%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Basthma%26aulast%3DZak%26aufirst%3DMark%26date%3D2019%26volume%3D29%26issue%3D20%26spage%3D126658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisabetta  Antonelli</span>, <span class="hlFld-ContribAuthor ">Gabriele  Torti</span>, <span class="hlFld-ContribAuthor ">Gabrio  Bassotti</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of the Janus Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Gastroenterology</span><span> <strong>2019,</strong> <em>53 </em>
                                    (9)
                                     , 635-640. <a href="https://doi.org/10.1097/MCG.0000000000001250" title="DOI URL">https://doi.org/10.1097/MCG.0000000000001250</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/MCG.0000000000001250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FMCG.0000000000001250%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Gastroenterology%26atitle%3DInhibitors%252Bof%252Bthe%252BJanus%252BKinases%26aulast%3DAntonelli%26aufirst%3DElisabetta%26date%3D2019%26volume%3D53%26issue%3D9%26spage%3D635%26epage%3D640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shengzheng  Wang</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Structural simplification: an efficient strategy in lead optimization. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2019,</strong> <em>9 </em>
                                    (5)
                                     , 880-901. <a href="https://doi.org/10.1016/j.apsb.2019.05.004" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DStructural%252Bsimplification%25253A%252Ban%252Befficient%252Bstrategy%252Bin%252Blead%252Boptimization%26aulast%3DWang%26aufirst%3DShengzheng%26date%3D2019%26volume%3D9%26issue%3D5%26spage%3D880%26epage%3D901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin S.  Currie</span>, <span class="hlFld-ContribAuthor ">Leena  Patel</span>, <span class="hlFld-ContribAuthor ">Kassandra F.  Sedillo</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule agents for the treatment of inflammatory bowel disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (16)
                                     , 2034-2041. <a href="https://doi.org/10.1016/j.bmcl.2019.06.042" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.06.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.06.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.06.042%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall-molecule%252Bagents%252Bfor%252Bthe%252Btreatment%252Bof%252Binflammatory%252Bbowel%252Bdisease%26aulast%3DCurrie%26aufirst%3DKevin%2BS.%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2034%26epage%3D2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marta  Calbet</span>, <span class="hlFld-ContribAuthor ">Isabel  Ramis</span>, <span class="hlFld-ContribAuthor ">Elena  Calama</span>, <span class="hlFld-ContribAuthor ">Cristina  CarreÃ±o</span>, <span class="hlFld-ContribAuthor ">Stephane  Paris</span>, <span class="hlFld-ContribAuthor ">Monica  Maldonado</span>, <span class="hlFld-ContribAuthor ">Adelina  Orellana</span>, <span class="hlFld-ContribAuthor ">Elena  Calaf</span>, <span class="hlFld-ContribAuthor ">Montse  Pauta</span>, <span class="hlFld-ContribAuthor ">Jorge  De Alba</span>, <span class="hlFld-ContribAuthor ">Jordi  Bach</span>, <span class="hlFld-ContribAuthor ">Montserrat  Miralpeix</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2019,</strong> <em>370 </em>
                                    (2)
                                     , 137-147. <a href="https://doi.org/10.1124/jpet.119.256263" title="DOI URL">https://doi.org/10.1124/jpet.119.256263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.119.256263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.119.256263%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DNovel%252BInhaled%252BPan-JAK%252BInhibitor%25252C%252BLAS194046%25252C%252BReduces%252BAllergen-Induced%252BAirway%252BInflammation%25252C%252BLate%252BAsthmatic%252BResponse%25252C%252Band%252BpSTAT%252BActivation%252Bin%252BBrown%252BNorway%252BRats%26aulast%3DCalbet%26aufirst%3DMarta%26date%3D2019%26date%3D2019%26volume%3D370%26issue%3D2%26spage%3D137%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian  Qiu</span>, <span class="hlFld-ContribAuthor ">Qilin  Feng</span>, <span class="hlFld-ContribAuthor ">Xueying  Tan</span>, <span class="hlFld-ContribAuthor ">Mingxing  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Clinical Pharmacology</span><span> <strong>2019,</strong> <em>12 </em>
                                    (6)
                                     , 547-554. <a href="https://doi.org/10.1080/17512433.2019.1615443" title="DOI URL">https://doi.org/10.1080/17512433.2019.1615443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17512433.2019.1615443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17512433.2019.1615443%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Clinical%2520Pharmacology%26atitle%3DJAK3-selective%252Binhibitor%252Bpeficitinib%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DQiu%26aufirst%3DQian%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D6%26spage%3D547%26epage%3D554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yazhou  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Pan  Chen</span>, <span class="hlFld-ContribAuthor ">Li  Gui</span>, <span class="hlFld-ContribAuthor ">Xinxin  Zhao</span>, <span class="hlFld-ContribAuthor ">Xinrong  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongpeng  Luo</span>, <span class="hlFld-ContribAuthor ">Xin  Cong</span>, <span class="hlFld-ContribAuthor ">Jia  Wang</span>, <span class="hlFld-ContribAuthor ">Fei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (12)
                                     , 2592-2597. <a href="https://doi.org/10.1016/j.bmc.2019.03.048" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.03.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.03.048%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Banti-inflammatory%252B4-%2525284%25252C5%25252C6%25252C7-tetrahydrofuro%25255B3%25252C2-c%25255Dpyridin-2-yl%252529%252Bpyrimidin-2-amines%252Bfor%252Buse%252Bas%252BJanus%252Bkinase%252Binhibitors%26aulast%3DWang%26aufirst%3DYazhou%26date%3D2019%26volume%3D27%26issue%3D12%26spage%3D2592%26epage%3D2597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Emily J.  Hanan</span>, <span class="hlFld-ContribAuthor ">Patrick  Lupardus</span>, <span class="hlFld-ContribAuthor ">David G.  Brown</span>, <span class="hlFld-ContribAuthor ">Colin  Robinson</span>, <span class="hlFld-ContribAuthor ">Michael  Siu</span>, <span class="hlFld-ContribAuthor ">Joseph P.  Lyssikatos</span>, <span class="hlFld-ContribAuthor ">F. Anthony  Romero</span>, <span class="hlFld-ContribAuthor ">Guiling  Zhao</span>, <span class="hlFld-ContribAuthor ">Terry  Kellar</span>, <span class="hlFld-ContribAuthor ">Rohan  Mendonca</span>, <span class="hlFld-ContribAuthor ">Nicholas C.  Ray</span>, <span class="hlFld-ContribAuthor ">Simon C.  Goodacre</span>, <span class="hlFld-ContribAuthor ">Peter H.  Crackett</span>, <span class="hlFld-ContribAuthor ">Neville  McLean</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Hurley</span>, <span class="hlFld-ContribAuthor ">Po-wai  Yuen</span>, <span class="hlFld-ContribAuthor ">Yun-Xing  Cheng</span>, <span class="hlFld-ContribAuthor ">Xiongcai  Liu</span>, <span class="hlFld-ContribAuthor ">Marya  Liimatta</span>, <span class="hlFld-ContribAuthor ">Pawan Bir  Kohli</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Gary  Salmon</span>, <span class="hlFld-ContribAuthor ">Gerry  Buckley</span>, <span class="hlFld-ContribAuthor ">Julia  Lloyd</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Adam  Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 1522-1531. <a href="https://doi.org/10.1016/j.bmcl.2019.04.008" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.04.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.04.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252Bclass%252Bof%252Bhighly%252Bpotent%252BJanus%252BKinase%252B1%25252F2%252B%252528JAK1%25252F2%252529%252Binhibitors%252Bdemonstrating%252Beffective%252Bcell-based%252Bblockade%252Bof%252BIL-13%252Bsignaling%26aulast%3DZak%26aufirst%3DMark%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D1522%26epage%3D1531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanqi  Wang</span>, <span class="hlFld-ContribAuthor ">Yanyan  Diao</span>, <span class="hlFld-ContribAuthor ">Wenjie  Li</span>, <span class="hlFld-ContribAuthor ">Yating  Luo</span>, <span class="hlFld-ContribAuthor ">Tingyuan  Yang</span>, <span class="hlFld-ContribAuthor ">Yuyu  Zhao</span>, <span class="hlFld-ContribAuthor ">TianTian  Qi</span>, <span class="hlFld-ContribAuthor ">Fangling  Xu</span>, <span class="hlFld-ContribAuthor ">Xiangyu  Ma</span>, <span class="hlFld-ContribAuthor ">Huan  Ge</span>, <span class="hlFld-ContribAuthor ">Yingfan  Liang</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Xin  Liang</span>, <span class="hlFld-ContribAuthor ">Rui  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 1507-1513. <a href="https://doi.org/10.1016/j.bmcl.2019.04.011" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.04.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.04.011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bstructure-activity%252Brelationship%252Bstudy%252Bof%252Baminopyridine%252Bderivatives%252Bas%252Bnovel%252Binhibitors%252Bof%252BJanus%252Bkinase%252B2%26aulast%3DWang%26aufirst%3DWanqi%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D1507%26epage%3D1513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stanislav  Andreev</span>, <span class="hlFld-ContribAuthor ">Tatu  Pantsar</span>, <span class="hlFld-ContribAuthor ">Francesco  Ansideri</span>, <span class="hlFld-ContribAuthor ">Mark  Kudolo</span>, <span class="hlFld-ContribAuthor ">Michael  Forster</span>, <span class="hlFld-ContribAuthor ">Dieter  Schollmeyer</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>, <span class="hlFld-ContribAuthor ">Pierre  Koch</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen Synthase Kinase-3Î² Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (12)
                                     , 2331. <a href="https://doi.org/10.3390/molecules24122331" title="DOI URL">https://doi.org/10.3390/molecules24122331</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24122331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24122331%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252B7-Chloro-9H-pyrimido%25255B4%25252C5-b%25255Dindole-based%252BGlycogen%252BSynthase%252BKinase-3%2525CE%2525B2%252BInhibitors%26aulast%3DAndreev%26aufirst%3DStanislav%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D12%26spage%3D2331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">AgnÃ¨s  FernÃ¡ndez-Clotet</span>, <span class="hlFld-ContribAuthor ">JesÃºs  Castro-Poceiro</span>, <span class="hlFld-ContribAuthor ">JuliÃ¡n  PanÃ©s</span>. </span><span class="cited-content_cbyCitation_article-title">JAK Inhibition: The Most Promising Agents in the IBD Pipeline?. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmaceutical Design</span><span> <strong>2019,</strong> <em>25 </em>
                                    (1)
                                     , 32-40. <a href="https://doi.org/10.2174/1381612825666190405141410" title="DOI URL">https://doi.org/10.2174/1381612825666190405141410</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1381612825666190405141410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1381612825666190405141410%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmaceutical%2520Design%26atitle%3DJAK%252BInhibition%25253A%252BThe%252BMost%252BPromising%252BAgents%252Bin%252Bthe%252BIBD%252BPipeline%25253F%26aulast%3DFern%25C3%25A1ndez-Clotet%26aufirst%3DAgn%25C3%25A8s%26date%3D2019%26volume%3D25%26issue%3D1%26spage%3D32%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Su</span>, <span class="hlFld-ContribAuthor ">Yu-Qiao  Gao</span>, <span class="hlFld-ContribAuthor ">Yong-Jie  Deng</span>, <span class="hlFld-ContribAuthor ">Han-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">You-Ru  Wu</span>, <span class="hlFld-ContribAuthor ">Ying  Hu</span>, <span class="hlFld-ContribAuthor ">Quan-Xi  Mei</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Chinese Herbal Compounds with Potential as JAK3 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Evidence-Based Complementary and Alternative Medicine</span><span> <strong>2019,</strong> <em>2019 </em>, 1-11. <a href="https://doi.org/10.1155/2019/4982062" title="DOI URL">https://doi.org/10.1155/2019/4982062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2019/4982062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2019%2F4982062%26sid%3Dliteratum%253Aachs%26jtitle%3DEvidence-Based%2520Complementary%2520and%2520Alternative%2520Medicine%26atitle%3DIdentification%252Bof%252BChinese%252BHerbal%252BCompounds%252Bwith%252BPotential%252Bas%252BJAK3%252BInhibitors%26aulast%3DSu%26aufirst%3DDan%26date%3D2019%26volume%3D2019%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Attila  Egyed</span>, <span class="hlFld-ContribAuthor ">DÃ¡vid  Bajusz</span>, <span class="hlFld-ContribAuthor ">GyÃ¶rgy M.  KeserÅ±</span>. </span><span class="cited-content_cbyCitation_article-title">The impact of binding site waters on the activity/selectivity trade-off of Janus kinase 2 (JAK2) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (8)
                                     , 1497-1508. <a href="https://doi.org/10.1016/j.bmc.2019.02.029" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.02.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.02.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bimpact%252Bof%252Bbinding%252Bsite%252Bwaters%252Bon%252Bthe%252Bactivity%25252Fselectivity%252Btrade-off%252Bof%252BJanus%252Bkinase%252B2%252B%252528JAK2%252529%252Binhibitors%26aulast%3DEgyed%26aufirst%3DAttila%26date%3D2019%26volume%3D27%26issue%3D8%26spage%3D1497%26epage%3D1508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ru-Nan  Yu</span>, <span class="hlFld-ContribAuthor ">Cheng-Juan  Chen</span>, <span class="hlFld-ContribAuthor ">Lei  Shu</span>, <span class="hlFld-ContribAuthor ">Yuan  Yin</span>, <span class="hlFld-ContribAuthor ">Zhi-Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Tian-Tai  Zhang</span>, <span class="hlFld-ContribAuthor ">Da-Yong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (8)
                                     , 1646-1657. <a href="https://doi.org/10.1016/j.bmc.2019.03.009" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.03.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.03.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Band%252Bsynthesis%252Bof%252Bpyrimidine-4%25252C6-diamine%252Bderivatives%252Bas%252BJanus%252Bkinase%252B3%252Binhibitors%26aulast%3DYu%26aufirst%3DRu-Nan%26date%3D2019%26volume%3D27%26issue%3D8%26spage%3D1646%26epage%3D1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florence  Ecoeur</span>, <span class="hlFld-ContribAuthor ">Jessica  Weiss</span>, <span class="hlFld-ContribAuthor ">Klemens  Kaupmann</span>, <span class="hlFld-ContribAuthor ">Samuel  Hintermann</span>, <span class="hlFld-ContribAuthor ">David  Orain</span>, <span class="hlFld-ContribAuthor ">Christine  Guntermann</span>. </span><span class="cited-content_cbyCitation_article-title">Antagonizing Retinoic Acid-Related-Orphan Receptor Gamma Activity Blocks the T Helper 17/Interleukin-17 Pathway Leading to Attenuated Pro-inflammatory Human Keratinocyte and Skin Responses. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2019,</strong> <em>10 </em><a href="https://doi.org/10.3389/fimmu.2019.00577" title="DOI URL">https://doi.org/10.3389/fimmu.2019.00577</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2019.00577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2019.00577%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DAntagonizing%252BRetinoic%252BAcid-Related-Orphan%252BReceptor%252BGamma%252BActivity%252BBlocks%252Bthe%252BT%252BHelper%252B17%25252FInterleukin-17%252BPathway%252BLeading%252Bto%252BAttenuated%252BPro-inflammatory%252BHuman%252BKeratinocyte%252Band%252BSkin%252BResponses%26aulast%3DEcoeur%26aufirst%3DFlorence%26date%3D2019%26date%3D2019%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Annie  Mayence</span>, <span class="hlFld-ContribAuthor ">Jean  Vanden Eynde</span>. </span><span class="cited-content_cbyCitation_article-title">Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2019,</strong> <em>12 </em>
                                    (1)
                                     , 37. <a href="https://doi.org/10.3390/ph12010037" title="DOI URL">https://doi.org/10.3390/ph12010037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph12010037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph12010037%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DBaricitinib%25253A%252BA%252B2018%252BNovel%252BFDA-Approved%252BSmall%252BMolecule%252BInhibiting%252BJanus%252BKinases%26aulast%3DMayence%26aufirst%3DAnnie%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D1%26spage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">LuÃ­sa C. R.  Carvalho</span>, <span class="hlFld-ContribAuthor ">Ana  LourenÃ§o</span>, <span class="hlFld-ContribAuthor ">LuÃ­sa Maria  Ferreira</span>, <span class="hlFld-ContribAuthor ">Paula SÃ©rio  Branco</span>. </span><span class="cited-content_cbyCitation_article-title">Tofacitinib Synthesis - An Asymmetric Challenge. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (4)
                                     , 615-624. <a href="https://doi.org/10.1002/ejoc.201801180" title="DOI URL">https://doi.org/10.1002/ejoc.201801180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201801180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201801180%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTofacitinib%252BSynthesis%252B-%252BAn%252BAsymmetric%252BChallenge%26aulast%3DCarvalho%26aufirst%3DLu%25C3%25ADsa%2BC.%2BR.%26date%3D2019%26date%3D2018%26volume%3D2019%26issue%3D4%26spage%3D615%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoshiya  Tanaka</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecules. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 629-637. <a href="https://doi.org/10.1016/B978-0-12-814307-0.00059-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-814307-0.00059-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-814307-0.00059-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-814307-0.00059-1%26sid%3Dliteratum%253Aachs%26atitle%3DSmall%252BMolecules%26aulast%3DTanaka%26aufirst%3DYoshiya%26date%3D2019%26spage%3D629%26epage%3D637%26pub%3DElsevier%26atitle%3DMosaic%252Bof%252BAutoimmunity%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenfei  Wang</span>, <span class="hlFld-ContribAuthor ">Noa Krugliak  Cleveland</span>, <span class="hlFld-ContribAuthor ">Jacob  Ollech</span>, <span class="hlFld-ContribAuthor ">David T.  Rubin</span>. </span><span class="cited-content_cbyCitation_article-title">Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis. </span><span class="cited-content_cbyCitation_journal-name">ACG Case Reports Journal</span><span> <strong>2019,</strong> <em>6 </em>
                                    (9)
                                     , e00226. <a href="https://doi.org/10.14309/crj.0000000000000226" title="DOI URL">https://doi.org/10.14309/crj.0000000000000226</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.14309/crj.0000000000000226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.14309%2Fcrj.0000000000000226%26sid%3Dliteratum%253Aachs%26jtitle%3DACG%2520Case%2520Reports%2520Journal%26atitle%3DUse%252Bof%252BTofacitinib%252Bfor%252Bthe%252BTreatment%252Bof%252BArthritis%252BAssociated%252BWith%252BUlcerative%252BColitis%26aulast%3DWang%26aufirst%3DWenfei%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D9%26spage%3De00226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisabetta  Antonelli</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Villanacci</span>, <span class="hlFld-ContribAuthor ">Gabrio  Bassotti</span>. </span><span class="cited-content_cbyCitation_article-title">Novel oral-targeted therapies for mucosal healing in ulcerative colitis. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Gastroenterology</span><span> <strong>2018,</strong> <em>24 </em>
                                    (47)
                                     , 5322-5330. <a href="https://doi.org/10.3748/wjg.v24.i47.5322" title="DOI URL">https://doi.org/10.3748/wjg.v24.i47.5322</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3748/wjg.v24.i47.5322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3748%2Fwjg.v24.i47.5322%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Gastroenterology%26atitle%3DNovel%252Boral-targeted%252Btherapies%252Bfor%252Bmucosal%252Bhealing%252Bin%252Bulcerative%252Bcolitis%26aulast%3DAntonelli%26aufirst%3DElisabetta%26date%3D2018%26volume%3D24%26issue%3D47%26spage%3D5322%26epage%3D5330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alison  OâMahony</span>, <span class="hlFld-ContribAuthor ">Markus R.  John</span>, <span class="hlFld-ContribAuthor ">Hannah  Cho</span>, <span class="hlFld-ContribAuthor ">Misato  Hashizume</span>, <span class="hlFld-ContribAuthor ">Ernest H.  Choy</span>. </span><span class="cited-content_cbyCitation_article-title">Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. </span><span class="cited-content_cbyCitation_journal-name">Journal of Translational Medicine</span><span> <strong>2018,</strong> <em>16 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12967-018-1532-5" title="DOI URL">https://doi.org/10.1186/s12967-018-1532-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12967-018-1532-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12967-018-1532-5%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Translational%2520Medicine%26atitle%3DDiscriminating%252Bphenotypic%252Bsignatures%252Bidentified%252Bfor%252Btocilizumab%25252C%252Badalimumab%25252C%252Band%252Btofacitinib%252Bmonotherapy%252Band%252Btheir%252Bcombinations%252Bwith%252Bmethotrexate%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DAlison%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Makiko Yashiro  Furuya</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Asano</span>, <span class="hlFld-ContribAuthor ">Yuya  Sumichika</span>, <span class="hlFld-ContribAuthor ">Shuzo  Sato</span>, <span class="hlFld-ContribAuthor ">Hiroko  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Watanabe</span>, <span class="hlFld-ContribAuthor ">Eiji  Suzuki</span>, <span class="hlFld-ContribAuthor ">Hideko  Kozuru</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Yatsuhashi</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Koga</span>, <span class="hlFld-ContribAuthor ">Hiromasa  Ohira</span>, <span class="hlFld-ContribAuthor ">Hideharu  Sekine</span>, <span class="hlFld-ContribAuthor ">Atsushi  Kawakami</span>, <span class="hlFld-ContribAuthor ">Kiyoshi  Migita</span>. </span><span class="cited-content_cbyCitation_article-title">Tofacitinib inhibits granulocyteâmacrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils. </span><span class="cited-content_cbyCitation_journal-name">Arthritis Research & Therapy</span><span> <strong>2018,</strong> <em>20 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13075-018-1685-x" title="DOI URL">https://doi.org/10.1186/s13075-018-1685-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13075-018-1685-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13075-018-1685-x%26sid%3Dliteratum%253Aachs%26jtitle%3DArthritis%2520Research%2520%2526%2520Therapy%26atitle%3DTofacitinib%252Binhibits%252Bgranulocyte%2525E2%252580%252593macrophage%252Bcolony-stimulating%252Bfactor-induced%252BNLRP3%252Binflammasome%252Bactivation%252Bin%252Bhuman%252Bneutrophils%26aulast%3DFuruya%26aufirst%3DMakiko%2BYashiro%26date%3D2018%26date%3D2018%26volume%3D20%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">AgnÃ¨s  FernÃ¡ndez-Clotet</span>, <span class="hlFld-ContribAuthor ">JesÃºs  Castro-Poceiro</span>, <span class="hlFld-ContribAuthor ">JuliÃ¡n  PanÃ©s</span>. </span><span class="cited-content_cbyCitation_article-title">Tofacitinib for the treatment of ulcerative colitis. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Clinical Immunology</span><span> <strong>2018,</strong> <em>14 </em>
                                    (11)
                                     , 881-892. <a href="https://doi.org/10.1080/1744666X.2018.1532291" title="DOI URL">https://doi.org/10.1080/1744666X.2018.1532291</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1744666X.2018.1532291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1744666X.2018.1532291%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Clinical%2520Immunology%26atitle%3DTofacitinib%252Bfor%252Bthe%252Btreatment%252Bof%252Bulcerative%252Bcolitis%26aulast%3DFern%25C3%25A1ndez-Clotet%26aufirst%3DAgn%25C3%25A8s%26date%3D2018%26date%3D2018%26volume%3D14%26issue%3D11%26spage%3D881%26epage%3D892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roni  Weisshof</span>, <span class="hlFld-ContribAuthor ">Katia  El Jurdi</span>, <span class="hlFld-ContribAuthor ">Nada  Zmeter</span>, <span class="hlFld-ContribAuthor ">David T.  Rubin</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Therapies for Inflammatory Bowel Disease. </span><span class="cited-content_cbyCitation_journal-name">Advances in Therapy</span><span> <strong>2018,</strong> <em>35 </em>
                                    (11)
                                     , 1746-1762. <a href="https://doi.org/10.1007/s12325-018-0795-9" title="DOI URL">https://doi.org/10.1007/s12325-018-0795-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12325-018-0795-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12325-018-0795-9%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvances%2520in%2520Therapy%26atitle%3DEmerging%252BTherapies%252Bfor%252BInflammatory%252BBowel%252BDisease%26aulast%3DWeisshof%26aufirst%3DRoni%26date%3D2018%26date%3D2018%26volume%3D35%26issue%3D11%26spage%3D1746%26epage%3D1762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Allison  Greenplate</span>, <span class="hlFld-ContribAuthor ">Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Rati M.  Tripathi</span>, <span class="hlFld-ContribAuthor ">Norma  Palma</span>, <span class="hlFld-ContribAuthor ">Siraj M.  Ali</span>, <span class="hlFld-ContribAuthor ">Phil J.  Stephens</span>, <span class="hlFld-ContribAuthor ">Vincent A.  Miller</span>, <span class="hlFld-ContribAuthor ">Yu  Shyr</span>, <span class="hlFld-ContribAuthor ">Yan  Guo</span>, <span class="hlFld-ContribAuthor ">Nishitha M.  Reddy</span>, <span class="hlFld-ContribAuthor ">Lina  Kozhaya</span>, <span class="hlFld-ContribAuthor ">Derya  Unutmaz</span>, <span class="hlFld-ContribAuthor ">Xueyan  Chen</span>, <span class="hlFld-ContribAuthor ">Jonathan M.  Irish</span>, <span class="hlFld-ContribAuthor ">Utpal P.  DavÃ©</span>. </span><span class="cited-content_cbyCitation_article-title">Genomic Profiling of T-Cell Neoplasms Reveals Frequent
              JAK1
              and
              JAK3
              Mutations With Clonal Evasion From Targeted Therapies. </span><span class="cited-content_cbyCitation_journal-name">JCO Precision Oncology</span><span> <strong>2018,</strong> <em> </em>
                                    (2)
                                     , 1-16. <a href="https://doi.org/10.1200/PO.17.00019" title="DOI URL">https://doi.org/10.1200/PO.17.00019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/PO.17.00019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FPO.17.00019%26sid%3Dliteratum%253Aachs%26jtitle%3DJCO%2520Precision%2520Oncology%26atitle%3DGenomic%252BProfiling%252Bof%252BT-Cell%252BNeoplasms%252BReveals%252BFrequent%252BJAK1%252Band%252BJAK3%252BMutations%252BWith%252BClonal%252BEvasion%252BFrom%252BTargeted%252BTherapies%26aulast%3DGreenplate%26aufirst%3DAllison%26date%3D2018%26issue%3D2%26spage%3D1%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hisao  Hamaguchi</span>, <span class="hlFld-ContribAuthor ">Yasushi  Amano</span>, <span class="hlFld-ContribAuthor ">Ayako  Moritomo</span>, <span class="hlFld-ContribAuthor ">Shohei  Shirakami</span>, <span class="hlFld-ContribAuthor ">Yutaka  Nakajima</span>, <span class="hlFld-ContribAuthor ">Kazuo  Nakai</span>, <span class="hlFld-ContribAuthor ">Naoko  Nomura</span>, <span class="hlFld-ContribAuthor ">Misato  Ito</span>, <span class="hlFld-ContribAuthor ">Yasuyuki  Higashi</span>, <span class="hlFld-ContribAuthor ">Takayuki  Inoue</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (18)
                                     , 4971-4983. <a href="https://doi.org/10.1016/j.bmc.2018.08.005" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.08.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.08.005%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bstructural%252Bcharacterization%252Bof%252Bpeficitinib%252B%252528ASP015K%252529%252Bas%252Ba%252Bnovel%252Band%252Bpotent%252BJAK%252Binhibitor%26aulast%3DHamaguchi%26aufirst%3DHisao%26date%3D2018%26volume%3D26%26issue%3D18%26spage%3D4971%26epage%3D4983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Yin</span>, <span class="hlFld-ContribAuthor ">Cheng-Juan  Chen</span>, <span class="hlFld-ContribAuthor ">Ru-Nan  Yu</span>, <span class="hlFld-ContribAuthor ">Zhi-Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Tian-Tai  Zhang</span>, <span class="hlFld-ContribAuthor ">Da-Yong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (17)
                                     , 4774-4786. <a href="https://doi.org/10.1016/j.bmc.2018.04.005" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.04.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.04.005%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Band%252Bsynthesis%252Bof%252B1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-4-amino%252Bderivatives%252Bas%252BJanus%252Bkinase%252B3%252Binhibitors%26aulast%3DYin%26aufirst%3DYuan%26date%3D2018%26volume%3D26%26issue%3D17%26spage%3D4774%26epage%3D4786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monira  Hoque</span>, <span class="hlFld-ContribAuthor ">Ramzi H.  Abbassi</span>, <span class="hlFld-ContribAuthor ">Danielle  Froio</span>, <span class="hlFld-ContribAuthor ">Jennifer  Man</span>, <span class="hlFld-ContribAuthor ">Terrance G.  Johns</span>, <span class="hlFld-ContribAuthor ">Brett W.  Stringer</span>, <span class="hlFld-ContribAuthor ">Bryan W.  Day</span>, <span class="hlFld-ContribAuthor ">Marina  Pajic</span>, <span class="hlFld-ContribAuthor ">Michael  Kassiou</span>, <span class="hlFld-ContribAuthor ">Lenka  Munoz</span>. </span><span class="cited-content_cbyCitation_article-title">Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2018,</strong> <em>134 </em>, 166-178. <a href="https://doi.org/10.1016/j.phrs.2018.06.023" title="DOI URL">https://doi.org/10.1016/j.phrs.2018.06.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2018.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2018.06.023%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DChanges%252Bin%252Bcell%252Bmorphology%252Bguide%252Bidentification%252Bof%252Btubulin%252Bas%252Bthe%252Boff-target%252Bfor%252Bprotein%252Bkinase%252Binhibitors%26aulast%3DHoque%26aufirst%3DMonira%26date%3D2018%26volume%3D134%26spage%3D166%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yael  Renert-Yuval</span>, <span class="hlFld-ContribAuthor ">Emma  Guttman-Yassky</span>. </span><span class="cited-content_cbyCitation_article-title">Monoclonal antibodies for the treatment of atopic dermatitis. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Allergy & Clinical Immunology</span><span> <strong>2018,</strong> <em>18 </em>
                                    (4)
                                     , 356-364. <a href="https://doi.org/10.1097/ACI.0000000000000455" title="DOI URL">https://doi.org/10.1097/ACI.0000000000000455</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/ACI.0000000000000455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FACI.0000000000000455%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Allergy%2520%2526%2520Clinical%2520Immunology%26atitle%3DMonoclonal%252Bantibodies%252Bfor%252Bthe%252Btreatment%252Bof%252Batopic%252Bdermatitis%26aulast%3DRenert-Yuval%26aufirst%3DYael%26date%3D2018%26volume%3D18%26issue%3D4%26spage%3D356%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arnab  Mukherjee</span>, <span class="hlFld-ContribAuthor ">Anasuya  Hazra</span>, <span class="hlFld-ContribAuthor ">Mike K.  Smith</span>, <span class="hlFld-ContribAuthor ">Steven W.  Martin</span>, <span class="hlFld-ContribAuthor ">Diane R.  Mould</span>, <span class="hlFld-ContribAuthor ">Chinyu  Su</span>, <span class="hlFld-ContribAuthor ">Wojciech  Niezychowski</span>. </span><span class="cited-content_cbyCitation_article-title">Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Clinical Pharmacology</span><span> <strong>2018,</strong> <em>84 </em>
                                    (6)
                                     , 1136-1145. <a href="https://doi.org/10.1111/bcp.13523" title="DOI URL">https://doi.org/10.1111/bcp.13523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcp.13523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcp.13523%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DExposure-response%252Bcharacterization%252Bof%252Btofacitinib%252Befficacy%252Bin%252Bmoderate%252Bto%252Bsevere%252Bulcerative%252Bcolitis%25253A%252BResults%252Bfrom%252Ba%252Bdose-ranging%252Bphase%252B2%252Btrial%26aulast%3DMukherjee%26aufirst%3DArnab%26date%3D2018%26date%3D2018%26volume%3D84%26issue%3D6%26spage%3D1136%26epage%3D1145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ernest S.  Han</span>, <span class="hlFld-ContribAuthor ">Wei  Wen</span>, <span class="hlFld-ContribAuthor ">Thanh H.  Dellinger</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Selena A.  Lu</span>, <span class="hlFld-ContribAuthor ">Richard  Jove</span>, <span class="hlFld-ContribAuthor ">John H.  Yim</span>. </span><span class="cited-content_cbyCitation_article-title">Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (36)
                                     , 24304-24319. <a href="https://doi.org/10.18632/oncotarget.24368" title="DOI URL">https://doi.org/10.18632/oncotarget.24368</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.24368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.24368%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DRuxolitinib%252Bsynergistically%252Benhances%252Bthe%252Banti-tumor%252Bactivity%252Bof%252Bpaclitaxel%252Bin%252Bhuman%252Bovarian%252Bcancer%26aulast%3DHan%26aufirst%3DErnest%2BS.%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D36%26spage%3D24304%26epage%3D24319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linhong  He</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Shao</span>, <span class="hlFld-ContribAuthor ">Taijin  Wang</span>, <span class="hlFld-ContribAuthor ">Tingxuan  Lan</span>, <span class="hlFld-ContribAuthor ">Chufeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2018,</strong> <em>22 </em>
                                    (2)
                                     , 343-358. <a href="https://doi.org/10.1007/s11030-017-9803-2" title="DOI URL">https://doi.org/10.1007/s11030-017-9803-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-017-9803-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-017-9803-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252BSAR%252Bstudy%252Bof%252Bhighly%252Bpotent%25252C%252Bselective%25252C%252Birreversible%252Bcovalent%252BJAK3%252Binhibitors%26aulast%3DHe%26aufirst%3DLinhong%26date%3D2018%26date%3D2018%26volume%3D22%26issue%3D2%26spage%3D343%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">, , , . </span><span class="cited-content_cbyCitation_article-title">Regulation of T-Cell Signaling by Post-Translational Modifications in Autoimmune Disease. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (3)
                                     , 819. <a href="https://doi.org/10.3390/ijms19030819" title="DOI URL">https://doi.org/10.3390/ijms19030819</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19030819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19030819%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DRegulation%252Bof%252BT-Cell%252BSignaling%252Bby%252BPost-Translational%252BModifications%252Bin%252BAutoimmune%252BDisease%26aulast%3D%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D3%26spage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brent M  Kuenzi</span>, <span class="hlFld-ContribAuthor ">Lily L  Remsing Rix</span>, <span class="hlFld-ContribAuthor ">Paul A  Stewart</span>, <span class="hlFld-ContribAuthor ">Bin  Fang</span>, <span class="hlFld-ContribAuthor ">Fumi  Kinose</span>, <span class="hlFld-ContribAuthor ">Annamarie T  Bryant</span>, <span class="hlFld-ContribAuthor ">Theresa A  Boyle</span>, <span class="hlFld-ContribAuthor ">John M  Koomen</span>, <span class="hlFld-ContribAuthor ">Eric B  Haura</span>, <span class="hlFld-ContribAuthor ">Uwe  Rix</span>. </span><span class="cited-content_cbyCitation_article-title">Polypharmacology-based ceritinib repurposing using integrated functional proteomics. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2017,</strong> <em>13 </em>
                                    (12)
                                     , 1222-1231. <a href="https://doi.org/10.1038/nchembio.2489" title="DOI URL">https://doi.org/10.1038/nchembio.2489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nchembio.2489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnchembio.2489%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DPolypharmacology-based%252Bceritinib%252Brepurposing%252Busing%252Bintegrated%252Bfunctional%252Bproteomics%26aulast%3DKuenzi%26aufirst%3DBrent%2BM%26date%3D2017%26date%3D2017%26volume%3D13%26issue%3D12%26spage%3D1222%26epage%3D1231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linhong  He</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Tingxuan  Lan</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Chufeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2017,</strong> <em>350 </em>
                                    (11)
                                     , 1700194. <a href="https://doi.org/10.1002/ardp.201700194" title="DOI URL">https://doi.org/10.1002/ardp.201700194</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201700194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201700194%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252Ba%252BHighly%252BSelective%252BJAK3%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DHe%26aufirst%3DLinhong%26date%3D2017%26date%3D2017%26volume%3D350%26issue%3D11%26spage%3D1700194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiroaki  Yamagishi</span>, <span class="hlFld-ContribAuthor ">Takayuki  Inoue</span>, <span class="hlFld-ContribAuthor ">Yutaka  Nakajima</span>, <span class="hlFld-ContribAuthor ">Jun  Maeda</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Tominaga</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Usuda</span>, <span class="hlFld-ContribAuthor ">Takeshi  Hondo</span>, <span class="hlFld-ContribAuthor ">Ayako  Moritomo</span>, <span class="hlFld-ContribAuthor ">Fumihiro  Nakamori</span>, <span class="hlFld-ContribAuthor ">Misato  Ito</span>, <span class="hlFld-ContribAuthor ">Koji  Nakamura</span>, <span class="hlFld-ContribAuthor ">Hiroki  Morio</span>, <span class="hlFld-ContribAuthor ">Yasuyuki  Higashi</span>, <span class="hlFld-ContribAuthor ">Masamichi  Inami</span>, <span class="hlFld-ContribAuthor ">Shohei  Shirakami</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of tricyclic dipyrrolopyridine derivatives as novel JAK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (20)
                                     , 5311-5326. <a href="https://doi.org/10.1016/j.bmc.2017.07.043" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.07.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.07.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.07.043%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Btricyclic%252Bdipyrrolopyridine%252Bderivatives%252Bas%252Bnovel%252BJAK%252Binhibitors%26aulast%3DYamagishi%26aufirst%3DHiroaki%26date%3D2017%26volume%3D25%26issue%3D20%26spage%3D5311%26epage%3D5326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James  Kempson</span>, <span class="hlFld-ContribAuthor ">Damaso  Ovalle</span>, <span class="hlFld-ContribAuthor ">Junqing  Guo</span>, <span class="hlFld-ContribAuthor ">Stephen T.  Wrobleski</span>, <span class="hlFld-ContribAuthor ">Shuqun  Lin</span>, <span class="hlFld-ContribAuthor ">Steven H.  Spergel</span>, <span class="hlFld-ContribAuthor ">James J.-W.  Duan</span>, <span class="hlFld-ContribAuthor ">Bin  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhonghui  Lu</span>, <span class="hlFld-ContribAuthor ">Jagabandhu  Das</span>, <span class="hlFld-ContribAuthor ">Bingwei V.  Yang</span>, <span class="hlFld-ContribAuthor ">John  Hynes</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">John  Tokarski</span>, <span class="hlFld-ContribAuthor ">John S.  Sack</span>, <span class="hlFld-ContribAuthor ">Javed  Khan</span>, <span class="hlFld-ContribAuthor ">Gary  Schieven</span>, <span class="hlFld-ContribAuthor ">Yuval  Blatt</span>, <span class="hlFld-ContribAuthor ">Charu  Chaudhry</span>, <span class="hlFld-ContribAuthor ">Luisa M.  Salter-Cid</span>, <span class="hlFld-ContribAuthor ">Aberra  Fura</span>, <span class="hlFld-ContribAuthor ">Joel C.  Barrish</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">William J.  Pitts</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of highly potent, selective, covalent inhibitors of JAK3. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (20)
                                     , 4622-4625. <a href="https://doi.org/10.1016/j.bmcl.2017.09.023" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.09.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.09.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bhighly%252Bpotent%25252C%252Bselective%25252C%252Bcovalent%252Binhibitors%252Bof%252BJAK3%26aulast%3DKempson%26aufirst%3DJames%26date%3D2017%26volume%3D27%26issue%3D20%26spage%3D4622%26epage%3D4625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao  Wu</span>, <span class="hlFld-ContribAuthor ">Xuefang  Zeng</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Taijun  Hang</span>, <span class="hlFld-ContribAuthor ">Min  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of related substances in tofacitinib citrate by LC-MS techniques for synthetic process optimization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2017,</strong> <em>143 </em>, 17-25. <a href="https://doi.org/10.1016/j.jpba.2017.05.012" title="DOI URL">https://doi.org/10.1016/j.jpba.2017.05.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2017.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2017.05.012%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DIdentification%252Bof%252Brelated%252Bsubstances%252Bin%252Btofacitinib%252Bcitrate%252Bby%252BLC-MS%252Btechniques%252Bfor%252Bsynthetic%252Bprocess%252Boptimization%26aulast%3DWu%26aufirst%3DXiao%26date%3D2017%26volume%3D143%26spage%3D17%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm1004286&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm1004286%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-24&amp;citedByCount=211&amp;pagesCount=3&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="âtrueâ" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Overview of cytokine signaling through the JAK/STAT pathway. Reprinted by permission from Macmillan Publishers Ltd.: <i>Nat. Rev. Immunol</i>. <b>2003</b>, <i>3</i>, 900â911, copyright 2003.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of <b>1</b> and HTS lead <b>2a</b> (CP-352,664).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Expansion of structureâactivity relationships using high-speed analoging around the <i>N</i>-methyl-cycloalkyl headgroup motif leading to compounds <b>6a</b>â<b>h</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0013.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Generation of carvone-derived analogues resulting in the identification of milestone compound <b>12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/medium/jm-2010-004286_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0014.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Preparation of both enantiomers of <b>1</b> from intermediates <b>19a</b> and <b>19b</b>, separated by chiral HPLC. Single crystal X-ray structure of urea analogue <b>20</b>, prepared from <b>19a</b>, provided unambiguous confirmation of the 3<i>R</i>,4<i>R</i> stereochemical configuration for <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm1004286/production/images/large/jm-2010-004286_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1004286&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i79">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38041" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38041" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 43 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Stock, P. G.</span><span> </span><span class="NLM_article-title">The year in reviewâATC 2002</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1034%2Fj.1600-6143.2003.00115.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=12694058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A280%3ADC%252BD3s7nsF2itg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=373-380&author=P.+G.+Stock&title=The+year+in+review%E2%80%94ATC+2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The year in review--ATC 2002</span></div><div class="casAuthors">Stock Peter G</div><div class="citationInfo"><span class="NLM_cas:title">American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">373-80</span>
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    </div><div class="casAbstract">Strategies for dealing with the exponential growth of the waiting lists for solid organ transplants were the hottest clinical topics in 2002, and dominated the abstracts presented at ATC 2002.  Other clinical topics that were prominent in the 2002 literature and received the highest scores at ATC 2002 included: the development of immunosuppressive regimens minimizing calcineurin inhibitors and eliminating steroids; the increasing frequency and severity of hepatitis C recurrence following transplantation; the safety and efficacy of solid organ transplantation in HIV-positive recipients; the induction of tolerance with donor stem cell infusion and recipient preconditioning; the increasing incidence of BK virus; and beta-cell replacement for the treatment of diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_Sgaeh-ct3HELvajU9pjPfW6udTcc2eZRP0hd6oUCDLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s7nsF2itg%253D%253D&md5=ee89bf62336cc19d3bca793efc48419a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-6143.2003.00115.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-6143.2003.00115.x%26sid%3Dliteratum%253Aachs%26aulast%3DStock%26aufirst%3DP.%2BG.%26atitle%3DThe%2520year%2520in%2520review%25E2%2580%2594ATC%25202002%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2003%26volume%3D3%26spage%3D373%26epage%3D380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hong, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahan, B. D.</span><span> </span><span class="NLM_article-title">Immunosuppressive agents in organ transplantation: past, present, and future</span> <span class="citation_source-journal">Semin. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">â</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=10746855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD3cXit12qtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=108-125&author=J.+C.+Hongauthor=B.+D.+Kahan&title=Immunosuppressive+agents+in+organ+transplantation%3A+past%2C+present%2C+and+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Immunosuppressive agents in organ transplantation: past, present, and future</span></div><div class="casAuthors">Hong, Johnny C.; Kahan, Barry D.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Nephrology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">108-125</span>CODEN:
                <span class="NLM_cas:coden">SNEPDJ</span>;
        ISSN:<span class="NLM_cas:issn">0270-9295</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review with 174 refs.  The development of immunosuppressive agents reflects the progress in understanding the cellular and mol. mechanisms which mediate allograft rejection.  Six paradigms represent the evolution of immunosuppressive strategies for organ transplantation.  The proliferation paradigm advances agents which interrupt lymphocyte cell division (azathioprine, cyclophosphamide, mycophenolic acid).  The depletion paradigm conscripts drugs that bind to lymphocyte cell surface markers, thereby producing cell lysis and/or inactivation (polyclonal ATGAM and thymoglobulin, and monoclonal OKT3 antilymphocyte antibodies).  The cytokine paradigm uses agents that interrupt lymphocyte maturational events; eg, synthesis (calcineurin inhibitors: cyclosporine/tacrolimus), binding to surface receptors (anti-CD25 mAbs), or signal transduction phases of cytokine stimulation (sirolimus).  The introduction of calcineurin inhibitors markedly reduces the rate of acute rejection episodes and increases short-term graft survival rates; nephrotoxicity and chronic allograft attrition remain as unanswered challenges.  The cyclosporine A (CsA) sparing property of sirolimus permits the use of lower exposure to calcineurin agents, allows for early withdrawal of steroid therapy, and may delay allograft senescence.  Furthermore, the combination of SRL with anti-IL-2R mAbs proffers an induction approach which allows prolonged periods of holiday from calcineurin inhibitors.  To address the tissue nonselectivity of the calcineurin and mTOR inhibitors, which presumably causes the drug toxicities, new agents are being developed to selectively inhibit the T cell target Janus Kinase 3.  In the costimulation paradigm, the accessory signals generated by antigen-presenting cells are interrupted by distinct agents: the receptor conjugate CTLA4-Ig and anti-B7 or anti-CD40 ligand mAbs.  Another set of drugs (selectin blocking agents, anti-ICAM-1 antisense deoxy oligonucleotides, and the lymphocyte homing inhibitor FTY720) seeks to modulate the ischemia-reperfusion injury, which exacerbates cytokine-mediated events in the donor and the subsequent procurement injury and may also accelerate the progression of transplant senescence.  Finally, the transplantation tolerance paradigm is based on the development of strategies which distort alloimmune recognition by antigen reactive cells (MHC peptides or proteins), produce anergy (costimulation blockers), functional inactivation, or deletion of antigen-reactive cells (donor bone marrow infusions and gene therapy).  Presently, the optimal immunosuppressive strategy uses combinations of agents that act in synergistic fashion to provide the potency, freedom from toxic reactions, convenience of administration, and cost appropriate for the individual patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfmCERP9sM_rVg90H21EOLACvtfcHk0lguroNA-adl-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXit12qtLs%253D&md5=1ded3f89d274691cd914f80acf7da368</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DJ.%2BC.%26aulast%3DKahan%26aufirst%3DB.%2BD.%26atitle%3DImmunosuppressive%2520agents%2520in%2520organ%2520transplantation%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DSemin.%2520Nephrol.%26date%3D2000%26volume%3D20%26spage%3D108%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Darnell, J. E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, G. R.</span><span> </span><span class="NLM_article-title">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">â</span> <span class="NLM_lpage">1421</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1126%2Fscience.8197455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=8197455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1994&pages=1415-1421&author=J.+E.+J.+Darnellauthor=I.+M.+Kerrauthor=G.+R.+Stark&title=Jak-STAT+pathways+and+transcriptional+activation+in+response+to+IFNs+and+other+extracellular+signaling+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span></div><div class="casAuthors">Darnell, James E., Jr.; Kerr, Ian M.; Stark, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">5164</span>),
    <span class="NLM_cas:pages">1415-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with 97 refs.  Through the study of transcriptional activation in response to interferon Î± (IFN-Î±) and interferon Î³ (IFN-Î³), a previously unrecognized direct signal transduction pathway to the nucleus has been uncovered: IFN-receptor interaction at the cell surface leads to the activation of kinases of the Jak family that then phosphorylate substrate proteins called STATs (signal transducers and activators of transcription).  The phosphorylated STAT proteins move to the nucleus, bind specific DNA elements, and direct transcription.  Recognition of the mols. involved in the IFN-Î± and IFN-Î³ pathway has led to discoveries that a no. of STAT family members exist and that other polypeptide ligands also use the Jak-STAT mols. in signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo64rvN_qWlmLVg90H21EOLACvtfcHk0lguroNA-adl-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D&md5=f63d2c7bb3c1aeca6f36fef38aff713c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.8197455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8197455%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DKerr%26aufirst%3DI.%2BM.%26aulast%3DStark%26aufirst%3DG.%2BR.%26atitle%3DJak-STAT%2520pathways%2520and%2520transcriptional%2520activation%2520in%2520response%2520to%2520IFNs%2520and%2520other%2520extracellular%2520signaling%2520proteins%26jtitle%3DScience%26date%3D1994%26volume%3D264%26spage%3D1415%26epage%3D1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">â</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1038%2Fni.1701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19295632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=356-360&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Selectivity+and+therapeutic+inhibition+of+kinases%3A+to+be+or+not+to+be%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">356-360</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases, which serve crit. functions in signaling pathways in all cells, are popular therapeutic targets.  At present, eight kinase inhibitors have been approved in the United States, each of which shows nanomolar potency.  Although the initial goal was to generate inhibitors with a high degree of selectivity, recent experience has revealed that many of these approved compds. target more than one kinase.  Surprisingly, this promiscuity is less problematic than one would have imagined; indeed, it opens new therapeutic opportunities.  In this Perspective, we discuss the present status of Janus kinase inhibitors-a new class of immunosuppressive drugs-and the advantages and disadvantages of selectively inhibiting this class of kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU0w6t4jgqirVg90H21EOLACvtfcHk0liRipfbsALFhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D&md5=64dd47e897181d00e5dce6be3bc5db6e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fni.1701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1701%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSelectivity%2520and%2520therapeutic%2520inhibition%2520of%2520kinases%253A%2520to%2520be%2520or%2520not%2520to%2520be%253F%26jtitle%3DNat.%2520Immunol.%26date%3D2009%26volume%3D10%26spage%3D356%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">â</span> <span class="NLM_lpage">287</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0liRipfbsALFhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by IL-2 and related cytokines: JAKs, STATs and relationship to immunodeficiency</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=8864127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1996&pages=441-452&author=J.+A.+Johnstonauthor=C.+M.+Baconauthor=M.+C.+Riedyauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+IL-2+and+related+cytokines%3A+JAKs%2C+STATs+and+relationship+to+immunodeficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span></div><div class="casAuthors">Johnston, James A.; Bacon, Chris M.; Riedy, M. C.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 153 refs.  Cytokines that bind to the interleukin-2 (IL-2) receptor common gamma chain (Î³c), including IL-2, IL-4, IL-7, IL-9, and IL-15, are important for the growth and differentiation of T and B lymphocytes, natural killer cells, macrophages, and monocytes.  These cytokines have overlapping biol. effects that in part result from the use of the shared receptor subunit Î³c.  Recently it has become clear that these cytokines activate a no. of important intracellular signaling mols., including the Janus kinases JAK1 and JAK3 and members of the transcription factor family of signal transducers and activators of transcription (STATs).  The discovery of these signaling pathways has led to important new insights into their role of lymphocyte maturation, as it has emerged that mutations in the genes encoding both Î³c and JAK3 result in similar forms of severe combined immunodeficiency (SCID).  In this review we examine the structure and function of cytokine receptors and the signaling pathways involved in their regulation of gene expression.  Furthermore, we discuss recent advances that have led to a better understanding of how cytokines elicit intracellular responses, as well as their role in normal lymphoid development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBS-4Fw4Io7Vg90H21EOLACvtfcHk0liRipfbsALFhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D&md5=6ccea65ed0126878728f639506a565ac</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DBacon%26aufirst%3DC.%2BM.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520IL-2%2520and%2520related%2520cytokines%253A%2520JAKs%252C%2520STATs%2520and%2520relationship%2520to%2520immunodeficiency%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D1996%26volume%3D60%26spage%3D441%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Oakes, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henninghausen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaese, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">â</span> <span class="NLM_lpage">615</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1996&pages=605-615&author=S.+A.+Oakesauthor=F.+Candottiauthor=J.+A.+Johnstonauthor=Y.+Q.+Chenauthor=J.+J.+Ryanauthor=N.+Taylorauthor=X.+Liuauthor=L.+Henninghausenauthor=L.+D.+Notarangeloauthor=W.+E.+Paulauthor=R.+M.+Blaeseauthor=J.+J.+O%E2%80%99Shea&title=Signaling+via+IL-2+and+IL-4+in+JAK3-deficient+severe+combined+immunodeficiency+lymphocytes%3A+JAK3-dependent+and+independent+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOakes%26aufirst%3DS.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DRyan%26aufirst%3DJ.%2BJ.%26aulast%3DTaylor%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHenninghausen%26aufirst%3DL.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26aulast%3DPaul%26aufirst%3DW.%2BE.%26aulast%3DBlaese%26aufirst%3DR.%2BM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520via%2520IL-2%2520and%2520IL-4%2520in%2520JAK3-deficient%2520severe%2520combined%2520immunodeficiency%2520lymphocytes%253A%2520JAK3-dependent%2520and%2520independent%2520pathways%26jtitle%3DImmunity%26date%3D1996%26volume%3D5%26spage%3D605%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">6910</span><span class="NLM_x">â</span> <span class="NLM_lpage">6915</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=6910-6915&author=M.+Chenauthor=A.+Chengauthor=Y.+Q.+Chenauthor=A.+Hymelauthor=E.+P.+Hansonauthor=L.+Kimmelauthor=Y.+Minamiauthor=T.+Taniguchiauthor=P.+S.+Changelianauthor=J.+J.+O%E2%80%99Shea&title=The+amino+terminus+of+JAK3+is+necessary+and+sufficient+for+binding+to+the+common+gamma+chain+and+confers+the+ability+to+transmit+interleukin+2-mediated+signals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DHymel%26aufirst%3DA.%26aulast%3DHanson%26aufirst%3DE.%2BP.%26aulast%3DKimmel%26aufirst%3DL.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520amino%2520terminus%2520of%2520JAK3%2520is%2520necessary%2520and%2520sufficient%2520for%2520binding%2520to%2520the%2520common%2520gamma%2520chain%2520and%2520confers%2520the%2520ability%2520to%2520transmit%2520interleukin%25202-mediated%2520signals%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1997%26volume%3D94%26spage%3D6910%26epage%3D6915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Cytokines and their role in lymphoid development, differentiation and homeostasis</span> <span class="citation_source-journal">Curr. Opin. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">â</span> <span class="NLM_lpage">506</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1097%2F00130832-200212000-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=14752332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=495-506&author=S.+R.+Hofmannauthor=R.+Ettingerauthor=Y.+J.+Zhouauthor=M.+Gadinaauthor=P.+Lipskyauthor=R.+Siegelauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Shea&title=Cytokines+and+their+role+in+lymphoid+development%2C+differentiation+and+homeostasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines and their role in lymphoid development, differentiation and homeostasis</span></div><div class="casAuthors">Hofmann Sigrun R; Ettinger Rachel; Zhou Yong-Jie; Gadina Massimo; Lipsky Peter; Siegel Richard; Candotti Fabio; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-506</span>
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The development of lymphoid tissues as well as the ultimate differentiation of naive and memory T cells are dependent on cytokines.  In this review, we will focus on recent advances in the understanding of molecular mechanisms that regulate lymphoid development, homeostasis and tolerance.  RECENT FINDINGS:  Cytokines play a critical role in the development and differentiation of lymphoid cells.  In addition, newer data indicate important roles of interleukin-7 and interleukin-15 in lymphoid homeostasis and memory.  Furthermore, a new family of heterodimeric cytokines comprising interleukin-12, interleukin-23 and -27 is important for differentiation of helper T cells and cell-mediated immunity.  Finally the importance of tumor necrosis factor superfamily members in the development of lymphoid organs has recently been elucidated and will be discussed in detail.  SUMMARY:  New cytokines and receptors continue to be identified.  The discovery and characterization of cytokines, their receptors and signaling molecules will provide a more complete understanding of normal lymphoid development, differentiation and function.  In addition, this knowledge should improve our understanding of the pathogenesis of immunological diseases and hopefully will provide new treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTci7HKMzLxgUNHe_gFldTbfW6udTcc2eY26YPSSFKQLLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D&md5=9480ae8620e9053745c038149a08a607</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2F00130832-200212000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200212000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DEttinger%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DCytokines%2520and%2520their%2520role%2520in%2520lymphoid%2520development%252C%2520differentiation%2520and%2520homeostasis%26jtitle%3DCurr.%2520Opin.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2002%26volume%3D2%26spage%3D495%26epage%3D506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Macchi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giliani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacco, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frattini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugazio, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">â</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1038%2F377065a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=7659163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1995&pages=65-68&author=P.+Macchiauthor=A.+Villaauthor=S.+Gilianiauthor=M.+G.+Saccoauthor=A.+Frattiniauthor=F.+Portaauthor=A.+G.+Ugazioauthor=J.+A.+Johnstonauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Shea&title=Mutations+of+Jak-3+gene+in+patients+with+autosomal+severe+combined+immune+deficiency+%28SCID%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span></div><div class="casAuthors">Macchi, Paolo; Villa, Anna; Giliani, Silvia; Sacco, Maria G.; Frattini, Annalisa; Porta, Fulvio; Ugazio, Alberto G.; Johnston, James A.; Candotti, Fabio; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6544</span>),
    <span class="NLM_cas:pages">65-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Severe combined immune deficiency (SCID) represents a heterogeneous group of hereditary diseases.  Mutations in the common Î³-chain (Î³c), which is part of several cytokine receptors including those for interleukin (IL)-2, IL-4, IL-7, IL-9 and IL-15, are responsible for X-linked SCID, which is usually assocd. with a lack of circulating T cells and the presence of B lymphocytes (T- B+ SCID).  The gene(s) responsible for autosomal recessive T- B+ SCID is still unknown.  The Jak-3 protein kinase has been found to assoc. with the Î³c-chain-contg. cytokine receptors.  Therefore Jak-3 or other STAT proteins with which it interacts are candidate genes for autosomal recessive T- B+ SCID.  Here the authors investigate two unrelated T- B+ SCID patients (both from consanguineous parents) who have homozygous mutations in the gene for Jak-3.  One patient carries a mutation (Tyr100âCys) in a conserved tyrosine residue in the JH7 domain of Jak-3 which is absent in more than 150 investigated chromosomes.  The other patient carries a homozygous 151-base-pair deletion in the kinase-like domain, leading to a frameshift and premature termination.  Both mutations resulted in markedly reduced levels of Jak-3.  These findings show that abnormalities in the Jak/STAT signaling pathway can account for SCID in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJWFs-Wbegq7Vg90H21EOLACvtfcHk0ljQEK0Nj6rM9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D&md5=ac5a7064e6c3361c8906813770e1b6d9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2F377065a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F377065a0%26sid%3Dliteratum%253Aachs%26aulast%3DMacchi%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DGiliani%26aufirst%3DS.%26aulast%3DSacco%26aufirst%3DM.%2BG.%26aulast%3DFrattini%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DUgazio%26aufirst%3DA.%2BG.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DMutations%2520of%2520Jak-3%2520gene%2520in%2520patients%2520with%2520autosomal%2520severe%2520combined%2520immune%2520deficiency%2520%2528SCID%2529%26jtitle%3DNature%26date%3D1995%26volume%3D377%26spage%3D65%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovich, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">â</span> <span class="NLM_lpage">157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=147-157&author=M.+Noguchiauthor=H.+M.+Rosenblattauthor=A.+H.+Filipovichauthor=S.+Adelsteinauthor=W.+S.+Modiauthor=O.+W.+McBrideauthor=W.+J.+Leonard&title=Interleukin-2+receptor+gamma+chain+mutation+results+in+X-linked+severe+combined+immunodeficiency+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DRosenblatt%26aufirst%3DH.%2BM.%26aulast%3DFilipovich%26aufirst%3DA.%2BH.%26aulast%3DAdelstein%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DW.%2BS.%26aulast%3DMcBride%26aufirst%3DO.%2BW.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DInterleukin-2%2520receptor%2520gamma%2520chain%2520mutation%2520results%2520in%2520X-linked%2520severe%2520combined%2520immunodeficiency%2520in%2520humans%26jtitle%3DCell%26date%3D1993%26volume%3D73%26spage%3D147%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Russell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tayebi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migone, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">â</span> <span class="NLM_lpage">800</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=797-800&author=S.+M.+Russellauthor=N.+Tayebiauthor=H.+Nakajimaauthor=M.+C.+Riedyauthor=J.+L.+Robertsauthor=M.+J.+Amanauthor=T.+S.+Migoneauthor=M.+Noguchiauthor=M.+L.+Markertauthor=R.+H.+Buckleyauthor=J.+J.+O%E2%80%99Sheaauthor=W.+J.+Leonard&title=Mutation+of+Jak3+in+a+patient+with+SCID%3A+essential+role+of+Jak3+in+lymphoid+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DS.%2BM.%26aulast%3DTayebi%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DAman%26aufirst%3DM.%2BJ.%26aulast%3DMigone%26aufirst%3DT.%2BS.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMarkert%26aufirst%3DM.%2BL.%26aulast%3DBuckley%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DMutation%2520of%2520Jak3%2520in%2520a%2520patient%2520with%2520SCID%253A%2520essential%2520role%2520of%2520Jak3%2520in%2520lymphoid%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D797%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">203</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1111%2Fj.0105-2896.2005.00220.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=15661026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2005&pages=127-142&author=M.+Pesuauthor=F.+Candottiauthor=M.+Husaauthor=S.+R.+Hofmannauthor=L.+D.+Notarangeloauthor=J.+J.+O%E2%80%99Shea&title=Jak3%2C+severe+combined+immunodeficiency%2C+and+a+new+class+of+immunosuppressive+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs</span></div><div class="casAuthors">Pesu, Marko; Candotti, Fabio; Husa, Matthew; Hofmann, Sigrun R.; Notarangelo, Luigi D.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The recent elucidation of the multiple mol. mechanisms underlying severe combined immunodeficiency (SCID) is an impressive example of the power of mol. medicine.  Anal. of patients and the concomitant generation of animal models mimicking these disorders have quickly provided great insights into the pathophysiol. of these potentially devastating illnesses.  Here, the authors summarize the discoveries that led to the understanding of the role of cytokine receptors and a specific tyrosine kinase, Janus kinase 3 (Jak3), in the pathogenesis of SCID.  The authors discuss how the identification of mutations of Jak3 in autosomal recessive SCID has facilitated the diagnosis of these disorders, offered new insights into the biol. of this kinase, permitted new avenues for therapy, and provided the rationale for a generation of a new class of immunosuppressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYir7OTbMwFbVg90H21EOLACvtfcHk0lhVUZ-xBpORaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7o%253D&md5=038b25b97798eda4b6aa1818238e45ba</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.0105-2896.2005.00220.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0105-2896.2005.00220.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DHusa%26aufirst%3DM.%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJak3%252C%2520severe%2520combined%2520immunodeficiency%252C%2520and%2520a%2520new%2520class%2520of%2520immunosuppressive%2520drugs%26jtitle%3DImmunol.%2520Rev.%26date%3D2005%26volume%3D203%26spage%3D127%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzuti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koslov, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckius, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beals, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagouras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magna, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltarelli, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelms, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Des Etages, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finco-Kent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paniagua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">â</span> <span class="NLM_lpage">878</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=C.+Shang-Poaauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=S.+G.+Des+Etagesauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.+S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.+J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0lhVUZ-xBpORaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%2BEtages%26aufirst%3DS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">West, K.</span><span> </span><span class="NLM_article-title">CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">491</span><span class="NLM_x">â</span> <span class="NLM_lpage">504</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=491-504&author=K.+West&title=CP-690550%2C+a+JAK3+inhibitor+as+an+immunosuppressant+for+the+treatment+of+rheumatoid+arthritis%2C+transplant+rejection%2C+psoriasis+and+other+immune-mediated+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DK.%26atitle%3DCP-690550%252C%2520a%2520JAK3%2520inhibitor%2520as%2520an%2520immunosuppressant%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%252C%2520transplant%2520rejection%252C%2520psoriasis%2520and%2520other%2520immune-mediated%2520disorders%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D10%26spage%3D491%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Sorbera, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serradell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bozzo, J.</span><span> </span><span class="NLM_article-title">CP-690,550</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">674</span><span class="NLM_x">â</span> <span class="NLM_lpage">680</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1358%2Fdof.2007.032.08.1125174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yktL7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=674-680&author=L.+A.+Sorberaauthor=N.+Serradellauthor=J.+Bolosauthor=E.+Rosaauthor=J.+Bozzo&title=CP-690%2C550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">CP-690550 JAK3 inhibitor immunosuppressant treatment of rheumatoid arthritis treatment of transplant rejection</span></div><div class="casAuthors">Sorbera, L. A.; Serradell, N.; Bolos, J.; Rosa, E.; Bozzo, J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">674-680</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Std. immunosuppressive agents used in the clinic for the prevention of organ transplant rejection and autoimmune diseases, although generally effective, target ubiquitously expressed mols. and are assocd. with significant adverse events.  Identification of potential targets selectively expressed by immune cells has become a research priority in order to develop immunosuppressants devoid of the toxicities obsd. with current therapies.  In this regard, targeting of Janus kinase 3 (JAK3) represents a potentially effective immunosuppressive strategy since expression of this signaling mol. is relatively restricted to immune cells and it is only used by cytokine receptors contg. the Î³-chain (Î³c).  CP-690550 is a novel JAK3 inhibitor that has exhibited potent immunosuppressive effects in preclin. transplantation and arthritis models and has been shown to be clin. safe and effective in preventing transplant rejection and improving symptoms of rheumatoid arthritis and psoriasis.  CP-690550 continues to undergo phase II development as an immunosuppressive agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRtqSvl2_tJrVg90H21EOLACvtfcHk0liBErLO_Kpvzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yktL7E&md5=91e10457b300bc2cb43e3c5c8f385c3d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1358%2Fdof.2007.032.08.1125174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2007.032.08.1125174%26sid%3Dliteratum%253Aachs%26aulast%3DSorbera%26aufirst%3DL.%2BA.%26aulast%3DSerradell%26aufirst%3DN.%26aulast%3DBolos%26aufirst%3DJ.%26aulast%3DRosa%26aufirst%3DE.%26aulast%3DBozzo%26aufirst%3DJ.%26atitle%3DCP-690%252C550%26jtitle%3DDrugs%2520Future%26date%3D2007%26volume%3D32%26spage%3D674%26epage%3D680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wrobleski, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts, W. J.</span><span> </span><span class="NLM_article-title">Chapter 12 Advances in the discovery of small molecule JAK3 inhibitors</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">â</span> <span class="NLM_lpage">264</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=247-264&author=S.+T.+Wrobleskiauthor=W.+J.+Pitts&title=Chapter+12+Advances+in+the+discovery+of+small+molecule+JAK3+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26atitle%3DChapter%252012%2520Advances%2520in%2520the%2520discovery%2520of%2520small%2520molecule%2520JAK3%2520inhibitors%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D247%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kudlacz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P.</span><span> </span><span class="NLM_article-title">The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">â</span> <span class="NLM_lpage">57</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1046%2Fj.1600-6143.2003.00281.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=14678034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVCmtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=51-57&author=E.+Kudlaczauthor=B.+Perryauthor=P.+Sawyerauthor=M.+Conklynauthor=S.+McCurdyauthor=W.+Brissetteauthor=A.+Flanaganauthor=P.+Changelian&title=The+novel+JAK-3+inhibitor+CP-690550+is+a+potent+immunosuppressive+agent+in+various+murine+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models</span></div><div class="casAuthors">Kudlacz, Elizabeth; Perry, Bret; Sawyer, Perry; Conklyn, Maryrose; McCurdy, Sandra; Brissette, William; Flanagan, Mark; Changelian, Paul</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-57</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">JAK-3 kinase has been shown to play a key role in cytokine signaling via Î³c, e.g. IL-2, 4, 7, 9, 15, and 21.  The current study describes the immunosuppressive effects of CP-690550, a novel, small mol. inhibitor of JAK-3, in various murine models.  In vitro, CP-690550 effectively inhibited a murine mixed lymphocyte reaction (MLR).  Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrated dose- and time-dependent alterations in lymphocyte subsets when examd. by flow cytometry.  The most dramatic change obsd. was a 96% redn. in splenic NK1.1+TCRÎ²- cell nos. following 21 days of treatment.  Delayed-type hypersensitivity (DTH) responses in sensitized mice were reduced in a dose-dependent manner following treatment with the JAK-3 inhibitor (1.87-30 mg/kg, s.c.).  Extended survival of neonatal Balb/c hearts implanted into the ear pinna of MHC mismatched C3H/HEN mice was obsd. with CP-690550 monotherapy (10-30 mg/kg/day), but improved upon combination with cyclosporin (10 mg/kg/day).  These data support the participation of JAK-3 in various lymphocyte homeostatic functions in mature mice.  Furthermore, the ability of CP-690550 to extend cardiac allograft survival in murine models suggests it may afford a new treatment for prevention of transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJAFi7wg6_7Vg90H21EOLACvtfcHk0lh-4nv5DNvPhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVCmtbs%253D&md5=33f2f4c56b1463036d92943bddd4e0e6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1046%2Fj.1600-6143.2003.00281.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1600-6143.2003.00281.x%26sid%3Dliteratum%253Aachs%26aulast%3DKudlacz%26aufirst%3DE.%26aulast%3DPerry%26aufirst%3DB.%26aulast%3DSawyer%26aufirst%3DP.%26aulast%3DConklyn%26aufirst%3DM.%26aulast%3DMcCurdy%26aufirst%3DS.%26aulast%3DBrissette%26aufirst%3DW.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DChangelian%26aufirst%3DP.%26atitle%3DThe%2520novel%2520JAK-3%2520inhibitor%2520CP-690550%2520is%2520a%2520potent%2520immunosuppressive%2520agent%2520in%2520various%2520murine%2520models%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2004%26volume%3D4%26spage%3D51%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Meyer, D. M.; Jesson, M. I.; Li, W.; Elrick, M. M.; Funckes-Shippy, C. L.; Warner, J. D.; Gross, C. J.; Dowty, M. E.; Ramaiah, S. K.; Hirsch, J. L.; Saabye, M. J.; Barks, J. L.; Kishore, N.; Morris, D. L.</span><span> </span><span class="NLM_article-title">Anti-inflammatory activity and neutrophil reductions mediated by JAK1 and JAK3 inhibition in the rat AIA model</span>.  <span class="citation_source-journal">J. Inflammation (London)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=20701804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41&author=D.+M.+Meyer&author=M.+I.+Jesson&author=W.+Li&author=M.+M.+Elrick&author=C.+L.+Funckes-Shippy&author=J.+D.+Warner&author=C.+J.+Gross&author=M.+E.+Dowty&author=S.+K.+Ramaiah&author=J.+L.+Hirsch&author=M.+J.+Saabye&author=J.+L.+Barks&author=N.+Kishore&author=D.+L.+Morris&title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+JAK1+and+JAK3+inhibition+in+the+rat+AIA+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Meyer Debra M; Jesson Michael I; Li Xiong; Elrick Mollisa M; Funckes-Shippy Christie L; Warner James D; Gross Cindy J; Dowty Martin E; Ramaiah Shashi K; Hirsch Jeffrey L; Saabye Matthew J; Barks Jennifer L; Kishore Nandini; Morris Dale L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of inflammation (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors.  CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.  In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment.  These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment.  METHODS:  Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays.  The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays.  In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model.  RESULTS:  CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays.  Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment.  Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease.  At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels.  The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2.  CONCLUSION:  Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2.  In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550.  Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17.  Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2.  Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-l9vqy6452oNpW7w2tapOfW6udTcc2eajIHZpsUCebbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D&md5=1190d7c5509fde79a7b56024a3aec9d9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26atitle%3DAnti-inflammatory%2520activity%2520and%2520neutrophil%2520reductions%2520mediated%2520by%2520JAK1%2520and%2520JAK3%2520inhibition%2520in%2520the%2520rat%2520AIA%2520model%26jtitle%3DJ.%2520Inflammation%2520%2528London%2529%26date%3D2010%26volume%3D7%26spage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Simonsen, J.</span> <span class="citation_source-book">The Terpenes</span>; <span class="NLM_publisher-name">Cambridge University Press</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">1953</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">394</span>â <span class="NLM_lpage">408</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1953&pages=394-408&author=J.+Simonsen&title=The+Terpenes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSimonsen%26aufirst%3DJ.%26btitle%3DThe%2520Terpenes%26pub%3DCambridge%2520University%2520Press%26date%3D1953%26spage%3D394%26epage%3D408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Brown Ripin, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koecher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laue, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouwer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sha, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teixeira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vries, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcox, G.</span><span> </span><span class="NLM_article-title">Development of a scaleable route for the production of <i>cis</i>-<i>N</i>-benzyl-3-methylamino-4-methylpiperidine</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">â</span> <span class="NLM_lpage">120</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=115-120&author=D.+H.+Brown+Ripinauthor=S.+Abeleauthor=W.+Caiauthor=T.+Blumenkopfauthor=J.+M.+Casavantauthor=J.+L.+Dotyauthor=M.+Flanaganauthor=C.+Koecherauthor=K.+W.+Laueauthor=K.+McCarthyauthor=C.+Meltzauthor=M.+J.+Munchhofauthor=K.+Pouwerauthor=B.+Shaauthor=J.+Sunauthor=J.+Teixeiraauthor=T.+Vriesauthor=D.+A.+Whippleauthor=G.+Wilcox&title=Development+of+a+scaleable+route+for+the+production+of+cis-N-benzyl-3-methylamino-4-methylpiperidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%2BRipin%26aufirst%3DD.%2BH.%26aulast%3DAbele%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DW.%26aulast%3DBlumenkopf%26aufirst%3DT.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DFlanagan%26aufirst%3DM.%26aulast%3DKoecher%26aufirst%3DC.%26aulast%3DLaue%26aufirst%3DK.%2BW.%26aulast%3DMcCarthy%26aufirst%3DK.%26aulast%3DMeltz%26aufirst%3DC.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPouwer%26aufirst%3DK.%26aulast%3DSha%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DTeixeira%26aufirst%3DJ.%26aulast%3DVries%26aufirst%3DT.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DWilcox%26aufirst%3DG.%26atitle%3DDevelopment%2520of%2520a%2520scaleable%2520route%2520for%2520the%2520production%2520of%2520cis-N-benzyl-3-methylamino-4-methylpiperidine%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2003%26volume%3D7%26spage%3D115%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Jiang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deflorian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span> </span><span class="NLM_article-title">Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">8012</span><span class="NLM_x">â</span> <span class="NLM_lpage">8018</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801142b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8012-8018&author=J.+K.+Jiangauthor=K.+Ghoreschiauthor=F.+Deflorianauthor=Z.+Chenauthor=M.+Perreiraauthor=M.+Pesuauthor=J.+Smithauthor=D.+T.+Nguyenauthor=E.+H.+Liuauthor=W.+Leisterauthor=S.+Costanziauthor=J.+J.+O%E2%80%99Sheaauthor=C.+J.+Thomas&title=Examining+the+chirality%2C+conformation+and+selective+kinase+inhibition+of+3-%28%283R%2C4R%29-4-methyl-3-%28methyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%29piperidin-1-yl%29-3-oxopropanenitrile+%28CP-690%2C550%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm801142b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801142b%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPerreira%26aufirst%3DM.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DD.%2BT.%26aulast%3DLiu%26aufirst%3DE.%2BH.%26aulast%3DLeister%26aufirst%3DW.%26aulast%3DCostanzi%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26atitle%3DExamining%2520the%2520chirality%252C%2520conformation%2520and%2520selective%2520kinase%2520inhibition%2520of%25203-%2528%25283R%252C4R%2529-4-methyl-3-%2528methyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529piperidin-1-yl%2529-3-oxopropanenitrile%2520%2528CP-690%252C550%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8012%26epage%3D8018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0ljYOvJimQy9aw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Chrencik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gormley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommers, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenbrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, T. E.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">â</span> <span class="NLM_lpage">433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.+C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lgZJfq8QAUZJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span>World Intellectual Property Organization. (WO/2003/048162) Novel Crystalline Compound. <a href="http://www.wipo.int/pctdb/en/wo.jsp?wo=2003048162&amp;IA=IB2002004948&amp;DISPLAY=DOCS" class="extLink">http://www.wipo.int/pctdb/en/wo.jsp?wo=2003048162&IA=IB2002004948&DISPLAY=DOCS</a>. Accessed 3 August 2010.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Intellectual+Property+Organization.+%28WO%2F2003%2F048162%29+Novel+Crystalline+Compound.+http%3A%2F%2Fwww.wipo.int%2Fpctdb%2Fen%2Fwo.jsp%3Fwo%3D2003048162%26IA%3DIB2002004948%26DISPLAY%3DDOCS.+Accessed+3+August+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">van Gurp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimar, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pescovitz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Phase 1 dose-escalation study of CP-690-550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1711</span><span class="NLM_x">â</span> <span class="NLM_lpage">1718</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1111%2Fj.1600-6143.2008.02307.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=18557720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGhu7nJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1711-1718&author=E.+van+Gurpauthor=W.+Weimarauthor=R.+Gastonauthor=D.+Brennanauthor=R.+Mendezauthor=J.+Pruschauthor=S.+Swanauthor=M.+D.+Pescovitzauthor=G.+Niauthor=C.+Wangauthor=S.+Krishnaswamiauthor=V.+Chowauthor=G.+Chan&title=Phase+1+dose-escalation+study+of+CP-690-550+in+stable+renal+allograft+recipients%3A+preliminary+findings+of+safety%2C+tolerability%2C+effects+on+lymphocyte+subsets+and+pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics</span></div><div class="casAuthors">van Gurp, E.; Weimar, W.; Gaston, R.; Brennan, D.; Mendez, R.; Pirsch, J.; Swan, S.; Pescovitz, M. D.; Ni, G.; Wang, C.; Krishnaswami, S.; Chow, V.; Chan, G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1711-1718</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">CP-690 550 inhibits Janus kinase 3 with nanomolar potency.  In this dose-escalation study, we assessed the safety, tolerability, effects on lymphocyte subsets, and pharmacokinetics of CP-690 550 when coadministered with mycophenolate mofetil in stable renal allograft recipients for 28 days.  Twenty-eight patients were enrolled.  Six patients received CP-690 550 5 mg twice daily (BID), 6 patients received 15 mg BID, 10 patients received 30 mg BID, and 6 patients received placebo.  The most frequent adverse events were infections and gastrointestinal (abdominal pain, diarrhea, dyspepsia, and vomiting).  CP-690 550 15 mg BID and 30 mg BID were assocd. with a mean decrease in Hb from baseline of 11% and a mean decrease in abs. natural killer cell counts of 50%.  CP-690 550 30 mg BID was also assocd. with a mean increase in abs. CD19+ B-lymphocytes of 130%.  There were no changes in the no. of neutrophils, total lymphocytes, platelets, or CD4+ or CD8+ T cells; clin. chem.; vital signs; or electrocardiograms from the pretreatment baseline.  Administration of CP-690 550 without a concomitant calcineurin inhibitor resulted in CP-690 550 exposures consistent with previous studies in nontransplant subjects.  Addnl. dose-ranging studies are warranted to evaluate the safety and efficacy of CP-690 550 in renal transplant recipients over longer treatment duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo69SNdm7tfMrVg90H21EOLACvtfcHk0lgZJfq8QAUZJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGhu7nJ&md5=14582e231681d5cb704f11d1cdfd54d5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2008.02307.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2008.02307.x%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BGurp%26aufirst%3DE.%26aulast%3DWeimar%26aufirst%3DW.%26aulast%3DGaston%26aufirst%3DR.%26aulast%3DBrennan%26aufirst%3DD.%26aulast%3DMendez%26aufirst%3DR.%26aulast%3DPrusch%26aufirst%3DJ.%26aulast%3DSwan%26aufirst%3DS.%26aulast%3DPescovitz%26aufirst%3DM.%2BD.%26aulast%3DNi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DChow%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DPhase%25201%2520dose-escalation%2520study%2520of%2520CP-690-550%2520in%2520stable%2520renal%2520allograft%2520recipients%253A%2520preliminary%2520findings%2520of%2520safety%252C%2520tolerability%252C%2520effects%2520on%2520lymphocyte%2520subsets%2520and%2520pharmacokinetics%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2008%26volume%3D8%26spage%3D1711%26epage%3D1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Lawendy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">â</span> <span class="NLM_lpage">429</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1177%2F0091270008330982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19318693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFWls7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=423-429&author=N.+Lawendyauthor=S.+Krishnaswamiauthor=R.+Wangauthor=D.+Grubenauthor=C.+Cannonauthor=S.+Swanauthor=G.+Chan&title=Effect+of+CP-690%2C550%2C+an+orally+active+janus+kinase+inhibitor%2C+on+renal+function+in+healthy+adult+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of CP-690,550, an orally active Janus kinase inhibitor, on renal function in healthy adult volunteers</span></div><div class="casAuthors">Lawendy, Nervin; Krishnaswami, Sriram; Wang, Rong; Gruben, David; Cannon, Courtney; Swan, Suzanne; Chan, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">423-429</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">CP-690,550 is a Janus kinase inhibitor being developed to prevent allograft rejection and treat several autoimmune diseases.  This study examines the effect of multiple doses of CP-690,550 on renal function in healthy volunteers.  Thirty-four volunteers are randomized in a 2:1 ratio in a double-blinded manner to receive CP-690,550 15 mg twice daily or placebo twice daily for 14 days.  Volunteers are confined inhouse to receive a controlled regimen of water intake and sodium intake of 4 to 5 g/d.  The effect of CP-690,550 on glomerular filtration rate (GFR) is measured by iohexol serum clearance, effective renal plasma flow (ERPF) by para-aminohippuric acid (PAH) urinary clearance, and creatinine clearance by 24-h urine collection on day 1 (predose) and day 15.  Steady-state pharmacokinetics and tolerability are assessed.  Comparing the day 15 and day 1 (predose) values shows that geometric mean ratios for iohexol serum clearance, PAH urinary clearance, and creatinine clearance are 0.995, 0.925, and 0.948, resp.  When adjusted for the corresponding placebo day ratios, the geometric mean ratios are 1.09, 0.978, and 1.05, resp. CP-690,550 is well tolerated.  These findings indicate that CP-690,550 does not affect GFR, ERPF, or creatinine clearance in healthy volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrakPq3AS-HJLVg90H21EOLACvtfcHk0lj_YUl2j7GWxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFWls7s%253D&md5=906b01548522e36f4a8685b490015128</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1177%2F0091270008330982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270008330982%26sid%3Dliteratum%253Aachs%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DCannon%26aufirst%3DC.%26aulast%3DSwan%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DEffect%2520of%2520CP-690%252C550%252C%2520an%2520orally%2520active%2520janus%2520kinase%2520inhibitor%252C%2520on%2520renal%2520function%2520in%2520healthy%2520adult%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D423%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nedderman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span> </span><span class="NLM_article-title">Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">â</span> <span class="NLM_lpage">368</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx8004357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=357-368&author=D.+Dalvieauthor=R.+S.+Obachauthor=P.+Kangauthor=C.+Prakashauthor=C.+M.+Loiauthor=S.+Hurstauthor=A.+Neddermanauthor=L.+Gouletauthor=E.+Smithauthor=H.+Z.+Buauthor=D.+A.+Smith&title=Assessment+of+three+human+in+vitro+systems+in+the+generation+of+major+human+excretory+and+circulating+metabolites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Ftx8004357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx8004357%26sid%3Dliteratum%253Aachs%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKang%26aufirst%3DP.%26aulast%3DPrakash%26aufirst%3DC.%26aulast%3DLoi%26aufirst%3DC.%2BM.%26aulast%3DHurst%26aufirst%3DS.%26aulast%3DNedderman%26aufirst%3DA.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DBu%26aufirst%3DH.%2BZ.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26atitle%3DAssessment%2520of%2520three%2520human%2520in%2520vitro%2520systems%2520in%2520the%2520generation%2520of%2520major%2520human%2520excretory%2520and%2520circulating%2520metabolites%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D357%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flloyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A qualitive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Flloydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+qualitive+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFlloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520qualitive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_publisher-name">Pfizer Inc</span>. Data on file.<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Inc.+Data+on+file.+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26pub%3DPfizer%2520Inc%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Borie, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousvoal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates</span> <span class="citation_source-journal">Transplantation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">1756</span><span class="NLM_x">â</span> <span class="NLM_lpage">1764</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2005&pages=1756-1764&author=D.+C.+Borieauthor=M.+J.+Larsonauthor=M.+G.+Floresauthor=A.+Campbellauthor=G.+Rousvoalauthor=S.+Zhangauthor=J.+P.+Higginsauthor=D.+J.+Ballauthor=E.+M.+Kudlaczauthor=W.+H.+Brissetteauthor=E.+A.+Elliottauthor=B.+A.+Reitzauthor=P.+S.+Changelian&title=Combined+use+of+the+JAK3+inhibitor+CP-690%2C550+with+mycophenolate+mofetil+to+prevent+kidney+allograft+rejection+in+nonhuman+primates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBorie%26aufirst%3DD.%2BC.%26aulast%3DLarson%26aufirst%3DM.%2BJ.%26aulast%3DFlores%26aufirst%3DM.%2BG.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DRousvoal%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DJ.%2BP.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DReitz%26aufirst%3DB.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DCombined%2520use%2520of%2520the%2520JAK3%2520inhibitor%2520CP-690%252C550%2520with%2520mycophenolate%2520mofetil%2520to%2520prevent%2520kidney%2520allograft%2520rejection%2520in%2520nonhuman%2520primates%26jtitle%3DTransplantation%26date%3D2005%26volume%3D80%26spage%3D1756%26epage%3D1764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Rousvoal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy</span> <span class="citation_source-journal">Transplant Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1014</span><span class="NLM_x">â</span> <span class="NLM_lpage">1021</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1111%2Fj.1432-2277.2006.00387.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=17081232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGhsLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=1014-1021&author=G.+Rousvoalauthor=M.+S.+Siauthor=M.+Lauauthor=S.+Zhangauthor=G.+J.+Berryauthor=M.+G.+Floresauthor=P.+S.+Changelianauthor=B.+A.+Reitzauthor=D.+C.+Borie&title=Janus+kinase+3+inhibition+with+CP-690%2C550+prevents+allograft+vasculopathy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy</span></div><div class="casAuthors">Rousvoal, Geraldine; Si, Ming-Sing; Lau, Macy; Zhang, Sally; Berry, Gerald J.; Flores, Mona G.; Changelian, Paul S.; Reitz, Bruce A.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Transplant International</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1014-1021</span>CODEN:
                <span class="NLM_cas:coden">TRINE5</span>;
        ISSN:<span class="NLM_cas:issn">0934-0874</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Janus kinase 3 (JAK3) mediates signal transduction from cytokine receptors using the common Î³ chain.  The rationally designed inhibitor of JAK3, CP-690,550, prevents acute allograft rejection in rodents and in nonhuman primates.  Here we investigated the ability of CP-690,550, to prevent allograft vasculopathy in a rodent model of aorta transplantation.  Aortas from AxC Irish (RT1a) or Lewis (RT1l) rats were heterotopically transplanted into the infra-renal aorta of Lewis recipients and harvested at 28 or 56 days.  Treated recipients received CP-690,550 by osmotic pumps (mean drug exposure of 110 Â± 38 ng/mL).  Significant intimal hyperplasia was demonstrated in untreated allografts when compared with isografts at 28 days (2.08 Â± 0.85% vs. 0.43 Â± 0.2% luminal obliteration, resp., P = 0.001) and 56 days (5.3 Â± 2.4% vs. 0.38 Â± 0.3%, P = 0.002).  Treatment caused a 51% redn. in intimal hyperplasia at day 56.  CP-690,550-treated animals also had a significant redn. of donor-specific IgG prodn. and of the gene expression for suppressor of cytokine signaling-3 and with unchanged levels of expression of RANTES, IP-10 and transforming growth factor-Î²1.  These results are the first to show that JAK3 blockade by CP-690,550 effectively prevents allograft vasculopathy in this rat model of aorta transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL2Os-h6o7uLVg90H21EOLACvtfcHk0ljBTT5wWDMovA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGhsLbM&md5=59bc3ae042addab7c02f21555bc9e269</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-2277.2006.00387.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-2277.2006.00387.x%26sid%3Dliteratum%253Aachs%26aulast%3DRousvoal%26aufirst%3DG.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DLau%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DBerry%26aufirst%3DG.%2BJ.%26aulast%3DFlores%26aufirst%3DM.%2BG.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DReitz%26aufirst%3DB.%2BA.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DJanus%2520kinase%25203%2520inhibition%2520with%2520CP-690%252C550%2520prevents%2520allograft%2520vasculopathy%26jtitle%3DTransplant%2520Int.%26date%3D2006%26volume%3D19%26spage%3D1014%26epage%3D1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Busque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leventhal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klintmalm, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulgaonkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bromberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincenti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hariharan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slakey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peddi, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawendy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP690,550: a pilot study in de novo kidney allograft recipients</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1936</span><span class="NLM_x">â</span> <span class="NLM_lpage">1945</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1111%2Fj.1600-6143.2009.02720.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19660021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGrurrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1936-1945&author=S.+Busqueauthor=J.+Leventhalauthor=D.+Brennanauthor=S.+Steinbergauthor=G.+Klintmalmauthor=T.+Shahauthor=S.+Mulgaonkarauthor=J.+Brombergauthor=F.+Vincentiauthor=S.+Hariharanauthor=D.+Slakeyauthor=V.+R.+Peddiauthor=R.+A.+Fisherauthor=N.+Lawendyauthor=C.+Wangauthor=G.+Chan&title=Calcineurin-inhibitor-free+immunosuppression+based+on+the+JAK+inhibitor+CP690%2C550%3A+a+pilot+study+in+de+novo+kidney+allograft+recipients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in De novo kidney allograft recipients</span></div><div class="casAuthors">Busque, S.; Leventhal, J.; Brennan, D. C.; Steinberg, S.; Klintmalm, G.; Shah, T.; Mulgaonkar, S.; Bromberg, J. S.; Vincenti, F.; Hariharan, S.; Slakey, D.; Peddi, V. R.; Fisher, R. A.; Lawendy, N.; Wang, C.; Chan, G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1936-1945</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This randomized, pilot study compared the Janus kinase inhibitor CP-690,550 (15 mg BID [CP15] and 30 mg BID [CP30], n = 20 each) with tacrolimus (n = 21) in de novo kidney allograft recipients.  Patients received an IL-2 receptor antagonist, concomitant mycophenolate mofetil (MMF) and corticosteroids.  CP-690,550 doses were reduced after 6 mo.  Due to a high incidence of BK virus nephropathy (BKN) in CP30, MMF was discontinued in this group.  The 6-mo biopsy-proven acute rejection rates were 1 of 20, 4 of 20 and 1 of 21 for CP15, CP30 and tacrolimus groups, resp.  BKN developed in 4 of 20 patients in CP30 group.  The 6-mo rates of cytomegalovirus disease were 2 of 20, 4 of 20 and none of 21 for CP15, CP30 and tacrolimus groups, resp.  Estd. glomerular filtration rate was >70 mL/min at 6 and 12 mo (all groups).  NK cells were reduced by <77% in CP-690,550-treated patients.  In the CP-690,550 arms, there were modest lipid elevations and a trend toward more frequent anemia and neutropenia during the first 6 mo.  These data suggest that coadministration of CP-690,550 30 mg BID with MMF is assocd. with overimmunosuppression.  At 15 mg BID, the efficacy/safety profile was comparable to the tacrolimus control group, excepting a higher rate of viral infection.  Further dose-ranging evaluation of CP-690,550 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptskDnsVhSnrVg90H21EOLACvtfcHk0ljBTT5wWDMovA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGrurrP&md5=c63d35ad46e6041c3b63886aa75e424d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2009.02720.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2009.02720.x%26sid%3Dliteratum%253Aachs%26aulast%3DBusque%26aufirst%3DS.%26aulast%3DLeventhal%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DD.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DKlintmalm%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DT.%26aulast%3DMulgaonkar%26aufirst%3DS.%26aulast%3DBromberg%26aufirst%3DJ.%26aulast%3DVincenti%26aufirst%3DF.%26aulast%3DHariharan%26aufirst%3DS.%26aulast%3DSlakey%26aufirst%3DD.%26aulast%3DPeddi%26aufirst%3DV.%2BR.%26aulast%3DFisher%26aufirst%3DR.%2BA.%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DCalcineurin-inhibitor-free%2520immunosuppression%2520based%2520on%2520the%2520JAK%2520inhibitor%2520CP690%252C550%253A%2520a%2520pilot%2520study%2520in%2520de%2520novo%2520kidney%2520allograft%2520recipients%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2009%26volume%3D9%26spage%3D1936%26epage%3D1945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audoly, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P.</span><span> </span><span class="NLM_article-title">Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">R14</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=R14&author=A.+J.+Miliciauthor=E.+M.+Kudlaczauthor=L.+Audolyauthor=S.+Zwillichauthor=P.+Changelian&title=Cartilage+preservation+by+inhibition+of+Janus+kinase+3+in+two+rodent+models+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DAudoly%26aufirst%3DL.%26aulast%3DZwillich%26aufirst%3DS.%26aulast%3DChangelian%26aufirst%3DP.%26atitle%3DCartilage%2520preservation%2520by%2520inhibition%2520of%2520Janus%2520kinase%25203%2520in%2520two%2520rodent%2520models%2520of%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2008%26volume%3D10%26spage%3DR14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombs, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgos-Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C. A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dose levels of CP-690,550 versus placebo</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1895</span><span class="NLM_x">â</span> <span class="NLM_lpage">1905</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+F.+Zerbiniauthor=S.+H.+Zwillich&title=The+safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis%3A+results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dose+levels+of+CP-690%2C550+versus+placebo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0ljBTT5wWDMovA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%2BF.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dose%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez Reino, J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Ramos, V</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S.</span><span> </span><span class="NLM_article-title">The oral JAK inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) is efficacious, safe and well tolerated in patients with active rheumatoid arthritis (RA) with an inadequate response to methotrexate alone</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4030</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2008&pages=4030&author=J.+M.+Kremerauthor=S.+Cohenauthor=B.+Wilkinsonauthor=C+Connellauthor=J+Frenchauthor=J+Gomez+Reinoauthor=D.+Grubenauthor=K+Kanikauthor=S.+Krishnaswamiauthor=V+Pascual-Ramosauthor=G+Wallensteinauthor=S.+Zwillich&title=The+oral+JAK+inhibitor+CP-690%2C550+%28CP%29+in+combination+with+methotrexate+%28MTX%29+is+efficacious%2C+safe+and+well+tolerated+in+patients+with+active+rheumatoid+arthritis+%28RA%29+with+an+inadequate+response+to+methotrexate+alone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DConnell%26aufirst%3DC%26aulast%3DFrench%26aufirst%3DJ%26aulast%3DGomez%2BReino%26aufirst%3DJ%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKanik%26aufirst%3DK%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DPascual-Ramos%26aufirst%3DV%26aulast%3DWallenstein%26aufirst%3DG%26aulast%3DZwillich%26aufirst%3DS.%26atitle%3DThe%2520oral%2520JAK%2520inhibitor%2520CP-690%252C550%2520%2528CP%2529%2520in%2520combination%2520with%2520methotrexate%2520%2528MTX%2529%2520is%2520efficacious%252C%2520safe%2520and%2520well%2520tolerated%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520%2528RA%2529%2520with%2520an%2520inadequate%2520response%2520to%2520methotrexate%2520alone%26jtitle%3DArthritis%2520Rheum.%26date%3D2008%26volume%3D58%26spage%3D4030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">Safety and efficacy after 24 week (WK) dosing of the oral JAK inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) in patients (PTS) with active rheumatoid arthritis (RA)</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">S719</span><div class="note"><p class="first last">, 1925 (abstract)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=S719&issue=Suppl.+10&author=J.+M.+Kremerauthor=S.+Cohenauthor=B.+Wilkinsonauthor=D.+Grubenauthor=G+Wallensteinauthor=K+Kanikauthor=S.+H.+Zwillich&title=Safety+and+efficacy+after+24+week+%28WK%29+dosing+of+the+oral+JAK+inhibitor+CP-690%2C550+%28CP%29+in+combination+with+methotrexate+%28MTX%29+in+patients+%28PTS%29+with+active+rheumatoid+arthritis+%28RA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DWallenstein%26aufirst%3DG%26aulast%3DKanik%26aufirst%3DK%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DSafety%2520and%2520efficacy%2520after%252024%2520week%2520%2528WK%2529%2520dosing%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520CP-690%252C550%2520%2528CP%2529%2520in%2520combination%2520with%2520methotrexate%2520%2528MTX%2529%2520in%2520patients%2520%2528PTS%2529%2520with%2520active%2520rheumatoid%2520arthritis%2520%2528RA%2529%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26issue%3DSuppl.%252010%26spage%3DS719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Kanik, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S.</span><span> </span><span class="NLM_article-title">Phase 2b dose ranging monotherapy study of the oral JAK inhibitor CP-690,550 (CP) or adalimumab (ADA) vs placebo (PBO) in patients (pts) with active rheumatoid arthritis (RA) with an inadequate response to DMARDs</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">123</span><div class="note"><p class="first last">, OP-0159 (abstract)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2009&pages=123&issue=Suppl.+3&author=K.+Kanikauthor=R.+Fleischmannauthor=M.+Cutoloauthor=M.+Genoveseauthor=E.+Leeauthor=S.+Sadisauthor=C.+Connellauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=G.+Wallensteinauthor=B.+Wilkinsonauthor=S.+Zwillich&title=Phase+2b+dose+ranging+monotherapy+study+of+the+oral+JAK+inhibitor+CP-690%2C550+%28CP%29+or+adalimumab+%28ADA%29+vs+placebo+%28PBO%29+in+patients+%28pts%29+with+active+rheumatoid+arthritis+%28RA%29+with+an+inadequate+response+to+DMARDs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKanik%26aufirst%3DK.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCutolo%26aufirst%3DM.%26aulast%3DGenovese%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DSadis%26aufirst%3DS.%26aulast%3DConnell%26aufirst%3DC.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZwillich%26aufirst%3DS.%26atitle%3DPhase%25202b%2520dose%2520ranging%2520monotherapy%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520CP-690%252C550%2520%2528CP%2529%2520or%2520adalimumab%2520%2528ADA%2529%2520vs%2520placebo%2520%2528PBO%2529%2520in%2520patients%2520%2528pts%2529%2520with%2520active%2520rheumatoid%2520arthritis%2520%2528RA%2529%2520with%2520an%2520inadequate%2520response%2520to%2520DMARDs%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2009%26volume%3D68%26issue%3DSuppl.%25203%26spage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Fleischmann, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">Safety and efficacy after 24 week (wk) dosing of the oral JAK inhibitor CP-690,550 (CP) as monotherapy in patients (pts) with active rheumatoid arthritis (RA)</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">S718</span><div class="note"><p class="first last">, 1924 (abstract)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=S718&issue=Suppl.+10&author=R.+M.+Fleischmannauthor=M.+C.+Genoveseauthor=D.+Grubenauthor=K+Kanikauthor=G+Wallensteinauthor=B.+Wilkinsonauthor=S.+H.+Zwillich&title=Safety+and+efficacy+after+24+week+%28wk%29+dosing+of+the+oral+JAK+inhibitor+CP-690%2C550+%28CP%29+as+monotherapy+in+patients+%28pts%29+with+active+rheumatoid+arthritis+%28RA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%2BM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKanik%26aufirst%3DK%26aulast%3DWallenstein%26aufirst%3DG%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DSafety%2520and%2520efficacy%2520after%252024%2520week%2520%2528wk%2529%2520dosing%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520CP-690%252C550%2520%2528CP%2529%2520as%2520monotherapy%2520in%2520patients%2520%2528pts%2529%2520with%2520active%2520rheumatoid%2520arthritis%2520%2528RA%2529%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26issue%3DSuppl.%252010%26spage%3DS718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marfat, A.</span><span> </span><span class="NLM_article-title">Disposition of CP-671,305, a selective phosphodiesterase 4 inhibitor in preclinical species</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">â</span> <span class="NLM_lpage">770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2004&pages=755-770&author=A.+S.+Kalgutkarauthor=E.+Chooauthor=T.+J.+Taylorauthor=A.+Marfat&title=Disposition+of+CP-671%2C305%2C+a+selective+phosphodiesterase+4+inhibitor+in+preclinical+species"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DChoo%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DT.%2BJ.%26aulast%3DMarfat%26aufirst%3DA.%26atitle%3DDisposition%2520of%2520CP-671%252C305%252C%2520a%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520in%2520preclinical%2520species%26jtitle%3DXenobiotica%26date%3D2004%26volume%3D34%26spage%3D755%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Inhibition of human cytochrome P450 enzymes by constituents of St. Johnâs wort, an herbal preparation used in the treatment of depression</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">â</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=10871299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksFyht7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2000&pages=88-95&author=R.+S.+Obach&title=Inhibition+of+human+cytochrome+P450+enzymes+by+constituents+of+St.+John%E2%80%99s+wort%2C+an+herbal+preparation+used+in+the+treatment+of+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-95</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Com. available St. John's wort (Hypericum perforatum) exts., prepns. that are used in the treatment of depression, were examd. for the potential to inhibit human cytochrome P 450 (CYP) enzyme activities, specifically CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.  Crude exts. demonstrated inhibition of each of these five enzymes, with CYP2D6, CYP2C9, and CYP3A4 being more sensitive than CYP1A2 and CYP2C19.  Exts. were fractionated by HPLC, and each of the fractions was tested for inhibition of these five CYPs to identify individual constituents with inhibitory activity.  Several fractions were shown to possess inhibitory activity, including the fractions contg. hyperforin (the putative active antidepressant constituent), I3,II8-biapigenin, and hypericin.  Hyperforin and I3,II8-biapigenin were isolated from the ext., and inhibition consts. for the five CYP activities were measured.  In addn., three other constituents, hypericin, quercetin, and chlorogenic acid, were tested for inhibitory activity toward the CYP enzymes.  The flavonoid compd. I3,II8-biapigenin was shown to be a potent, competitive inhibitor of CYP3A4, CYP2C9, and CYP1A2 activities with Ki values of 0.038, 0.32, and 0.95 Î¼M, resp.  Hyperforin was a potent noncompetitive inhibitor of CYP2D6 activity (Ki = 1.5 Î¼M) and competitive inhibitor of CYP2C9 and CYP3A4 activities (Ki = 1.8 and 0.48 Î¼M, resp.).  Hypericin also demonstrated potent inhibition of several CYP activities.  These in vitro data indicate that St. John's wort prepns. contain constituents that can potently inhibit the activities of major human drug-metabolizing enzymes and suggest that these prepns. should be examd. for potential pharmacokinetic drug interactions in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3yqNwV8QP4bVg90H21EOLACvtfcHk0lhChWAxzcakYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksFyht7s%253D&md5=790574093452449f411ff2c79ac4348c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DInhibition%2520of%2520human%2520cytochrome%2520P450%2520enzymes%2520by%2520constituents%2520of%2520St.%2520John%25E2%2580%2599s%2520wort%252C%2520an%2520herbal%2520preparation%2520used%2520in%2520the%2520treatment%2520of%2520depression%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D294%26spage%3D88%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosea, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClure, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuperman, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombroski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes</span> <span class="citation_source-journal">Biopharm. Drug Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">â</span> <span class="NLM_lpage">386</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm1004286&amp;key=10.1002%2Fbdd.520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm1004286&amp;key=16944451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm1004286&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12htb7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=371-386&author=A.+S.+Kalgutkarauthor=H.+L.+Hatchauthor=F.+Koseaauthor=H.+T.+Nguyenauthor=E.+F.+Chooauthor=K.+F.+McClureauthor=T.+J.+Taylorauthor=K.+R.+Henneauthor=A.+V.+Kupermanauthor=M.+A.+Dombroskiauthor=M.+A.+Letavic&title=Preclinical+pharmacokinetics+and+metabolism+of+6-%284-%282%2C5-difluorophenyl%29oxazol-5-yl%29-3-isopropyl-%5B1%2C2%2C4%5D-triazolo%5B4%2C3-a%5Dpyridine%2C+a+novel+and+selective+p38alpha+inhibitor%3A+identification+of+an+active+metabolite+in+preclinical+species+and+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38Î± inhibitor: identification of an active metabolite in preclinical species and human liver microsomes</span></div><div class="casAuthors">Kalgutkar, Amit S.; Hatch, Heather L.; Kosea, Frederick; Nguyen, Hang T.; Choo, Edna F.; McClure, Kim F.; Taylor, Timothy J.; Henne, Kirk R.; Kuperman, Alexander V.; Dombroski, Mark A.; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">371-386</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The disposition of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine (1), a potent and selective inhibitor of mitogen activated protein (MAP) kinase p38Î±, was characterized in several animal species in support of its selection for preclin. safety studies and potential clin. development.  This p38Î± inhibitor demonstrated generally favorable pharmacokinetic properties in all species examd.  Following i.v. administration, 1 exhibited low vols. of distribution at steady state (Vdss) ranging from 0.4-1.3 l/kg (2.4-26 l/m2) in the rat, dog and monkey.  Systemic plasma clearance was low in cynomolgus monkeys (6.00 mL/min/kg, 72.0 mL/min/m2) and Sprague-Dawley rats (7.65 Â± 1.08 mL/min/kg, 45.9 Â± 6.48 mL/min/m2 in male rats and 3.15 Â± 0.27 mL/min/kg, 18.9 Â± 1.62 mL/min/m2 in female rats) and moderate in beagle dogs (12.3 Â± 5.1 mL/min/kg, 246 Â± 102 mL/min/m2) resulting in plasma half-lives ranging from 1-5 h in preclin. species.  Moderate to high bioavailability of 1 was obsd. in rats (30-65%), dogs (87%) and monkeys (40%) after oral (p.o.) dosing consistent with the in vitro absorption profile of 1 in the Caco-2 permeability assay.  In rats, the oral pharmacokinetics were dose dependent over the dose range studied (5, 50, and 100 mg/kg).  The principal route of clearance of 1 in rat, dog, monkey and human liver microsomes and in vivo in preclin. species involved oxidative metab. mediated by cytochrome P 450 enzymes.  The major metabolic fate of 1 in preclin. species and humans involved hydroxylation on the iso-Pr group to yield the tertiary alc. metabolite 2.  In human liver microsomes, this transformation was catalyzed by CYP3A4 as judged from reaction phenotyping anal. using isoenzyme-specific inhibitors and recombinant CYP enzymes.  Metabolite 2 was also shown to possess inhibitory potency against p38Î± in a variety of in vitro assays.  As well as the active metabolite 2 were moderately to highly bound to plasma proteins (fu â¼ 0.1-0.33) in rat, mouse, dog, monkey and human.  As well as the active metabolite 2 did not exhibit competitive inhibition of the five major cytochrome P 450 enzymes namely CYP1A2, 2C9, 2C19, 2D6 and 3A4 (IC50>50 Î¼M).  Overall, these results indicate that the absorption, distribution, metab. and excretion (ADME) profile of 1 is relatively consistent across preclin. species and predict potentially favorable pharmacokinetic properties in humans,.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYaH40KCab97Vg90H21EOLACvtfcHk0lhChWAxzcakYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12htb7L&md5=2ce867cf95aeb6f9aa4227a12ddc0749</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fbdd.520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.520%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DHatch%26aufirst%3DH.%2BL.%26aulast%3DKosea%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DH.%2BT.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DTaylor%26aufirst%3DT.%2BJ.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DKuperman%26aufirst%3DA.%2BV.%26aulast%3DDombroski%26aufirst%3DM.%2BA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520metabolism%2520of%25206-%25284-%25282%252C5-difluorophenyl%2529oxazol-5-yl%2529-3-isopropyl-%255B1%252C2%252C4%255D-triazolo%255B4%252C3-a%255Dpyridine%252C%2520a%2520novel%2520and%2520selective%2520p38alpha%2520inhibitor%253A%2520identification%2520of%2520an%2520active%2520metabolite%2520in%2520preclinical%2520species%2520and%2520human%2520liver%2520microsomes%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2006%26volume%3D27%26spage%3D371%26epage%3D386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Davoll, J.</span><span> </span><span class="NLM_article-title">Pyrrolo[2,3-d]pyrimidines</span> <span class="citation_source-journal">J. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1960</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">â</span> <span class="NLM_lpage">138</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1960&pages=131-138&author=J.+Davoll&title=Pyrrolo%5B2%2C3-d%5Dpyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavoll%26aufirst%3DJ.%26atitle%3DPyrrolo%255B2%252C3-d%255Dpyrimidines%26jtitle%3DJ.%2520Chem.%2520Soc.%26date%3D1960%26volume%3D82%26spage%3D131%26epage%3D138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i78"><a href="/doi/suppl/10.1021/jm1004286">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_55446"></div></div></div></div></div><hr /></hr><p class="last">Additional HSA compounds (<b>6c</b>, S1âS63), with initial JAK3% inhibition data. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm1004286/suppl_file/jm1004286_si_001.pdf">jm1004286_si_001.pdf (143.22 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm1004286&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm1004286%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-24" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm1004286" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797a244d21a336","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
